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Aneuploidy is a key process in tumorigenesis. Dysfunction of the mitotic spindle 
checkpoint proteins has been implicated as a cause of aneuploidy in cells. 
In this thesis, by applying high-throughput cDNA microarray technology, we 
discovered that FAT10, an ubiquitin-like modifier that is able to interact with spindle 
checkpoint protein MAD2, is upregulated in tumors of HCC patients. Northern blot 
analyses revealed upregulation of FAT10 expression in the tumors of 90% of HCC 
patients. In situ hybridization as well as immunohistochemistry utilizing anti-FAT10 
antibodies localized highest FAT10 expression in the nucleus of HCC hepatocytes 
rather than the surrounding immune and non-HCC cells. FAT10 expression was also 
found to be highly upregulated in other cancers of the gastrointestinal tract and female 
reproductive system. 
In characterizing functions of FAT10, we performed immunoprecipitation and 
immunofluorescence staining and found that FAT10 interacted with MAD2 during 
mitosis. Notably, we showed that localization of MAD2 at the kinetochore during the 
prometaphase stage of the cell cycle was greatly reduced in FAT10-overexpressing 
cells. Furthermore, compared with parental HCT116 cells, fewer mitotic cells were 
observed after double thymidine-synchronized FAT10-overexpressing cells were 
released into nocodazole for more than 4 hours. Nonetheless, when these double 
thymidine-treated cells were released into media, a similar number of G1 parental and 
FAT10-overexpressing HCT116 cells was observed throughout the 10-hour time 
course. Additionally, more nocodazole-treated FAT10-overexpressing cells escape 
mitotic controls and are multinucleate compared with parental cells. Significantly, we 
observed a higher degree of variability in chromosome number in cells 
overexpressing FAT10. Hence, our data suggest that high levels of FAT10 protein in 
 v
cells lead to increased mitotic nondisjunction and chromosome instability, and this 
effect is mediated by an abbreviated mitotic phase and the reduction in the 
kinetochore localization of MAD2 during the prometaphase stage of the cell cycle. 
To investigate pathological significance of overexpression of FAT10 in tumors, I 
characterized the regulation of FAT10 gene expression in various cell lines and found 
that endogenous FAT10 expression was induced by inflammatory cytokines tumor 
necrosis factor-alpha (TNF-α) through activated NF-κB pathway. Another cytokine 
interferon-gamma (IFN-γ) was able to greatly enhance the effect of TNF-α on FAT10 
expression. Interestingly, we observed that long term TNF-α/ IFN-γ treatment could 
induce similar aberrance of numerical chromosomal stability that occurred in FAT10 
overexpressing cells. As TNF-α/ NF-κB pathway plays critical functions to promote 
the development of chronic inflammation associated-cancers, so we will focus our 
future work on investigating whether FAT10 may play roles in the development of 
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Chapter 1 Introduction 
Cancer is the leading cause of death worldwide and this disease accounted for 
7.9 million deaths (or around 13% of all deaths worldwide) in 2007. 
(http://www.who.int/mediacentre/factsheets/fs297/en/index.html). On the contrary, 
cancer treatment is still far from satisfactory at present. 
(http://www.iht.com/articles/2007/12/02/europe/cancer.php?). Hence, intense research 
has been focused on understanding the mechanisms of carcinogenesis in order to 
improve the prevention and treatment of this serious disease. As a very malignant 
cancer, hepatocellular carcinoma (HCC) is currently under intense research interest, 
as evidenced by a proliferation of meetings and literature reviews on the subject 
(Seeff, 2004). 
1.1 Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is one of the most common cancers 
worldwide, with particularly high incidence in East and Southeast Asian countries, 
including Singapore (Figure 1.1). In 2005, there were 667,000 new cases reported 
worldwide (Rougier et al., 2007). Due to the difficulties in early diagnosis and the 
lack of efficacious treatment as well as poor prognosis (Schwartz et al., 2007), 5-year 
survival rates are only 5% worldwide (Parkin et al., 2005). Therefore HCC is also a 
highly lethal malignancy, accounting for nearly 650,000 deaths in 2005 (WTO, 
http://www.who.int/mediacentre/factsheets/fs297/en/index.html). Furthermore, the 
incidence of HCC has increased over the last 3 decades and is expected to escalate 
(Armstrong et al., 2000). Based on those facts, Kim et al. predicted that the high 






















































































































































economic burdens on the individuals as well as society in the near future (Kim et al., 
2005b). 
Currently, surgical treatment including partial liver resection and liver 
transplantation is considered the only curative approach to treat HCC (Schwartz et al., 
2007).  Other treatments such as percutaneous alcohol injection (PEI) (Burroughs and 
Samonakis, 2004), radiofrequency ablation (RFA) (Head and Dodd, 2004) and 
transarterial chemoembolization (TACE) (Vogl et al., 2007) are only considered  to be 
palliative in nature. Surgery is only applicable to 10-20% of patients due to the 
multiplicity of the lesions which often occur on a background of chronic liver disease 
(Johnson, 2002).   However, the recurrence rate after surgical operation is reported to 
be as high as 80% (Sasaki et al., 2006). Hence, it would appear that prevention would 
be a more practical and efficient approach. 
Understanding the molecular mechanism for HCC development may help us to 
control the occurrence of this disease. For example, based on the recognition of 
hepatitis B virus (HBV) infection as one of major risks for HCC development, HBV 
vaccination programs has been implemented worldwide since 1980s and this has 
greatly reduced the incidence of liver cancer (Chang et al., 1997). This fact indicates 
that further studies of the mechanisms underlying HCC tumourigenesis are vital in 
order to improve the management of this disease. 
Hepatocarcinogenesis can be caused by various risk factors (Table 1.1), among 
which hepatitis B virus (HBV) and hepatitis C virus (HCV) are found to be major risk 
factors which are associated with 75% to 80% of cases of HCC (Bosch et al., 2004). 
HCC development  is a long term, multi-stage process and is closely associated with 
chronic liver diseases (Thorgeirsson and Grisham, 2002) but not acute diseases such 
as those caused by hepatitis A virus (HAV) or hepatitis E virus (HEV) (Leong and 
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Leong, 2005). As chronic inflammation plays important roles in the progression of 
various chronic liver diseases, including alcohol liver disease, nonalcoholic 
steatohepatitis, viral hepatitis, biliary disorders and cirrhosis (Szabo et al., 2007), it 
has been suggested that chronic inflammation may play a very important role in 
promoting the development of HCC (Coussens and Werb, 2002). 
1.2 Chronic inflammation and cancer 
1.2.1 Chronic inflammation 
Inflammation is the complex biological response of vascular tissues to harmful 
stimuli, such as infectious agents, damaged cells, as well as chemical or physical 
irritants (Coussens and Werb, 2002; Schottenfeld and Beebe-Dimmer, 2006). It is a 
biologically protective response that the organism utilises to remove potentially 
harmful stimuli as well as initiate the healing process for the tissue. There are a 
number of built-in checkpoint controls that limit the duration and magnitude of 
inflammation (Lawrence and Gilroy, 2007). However, repeated or prolonged exposure 
to harmful stimuli will cause chronic inflammation associated diseases in the tissues 
(Aggarwal et al., 2006). For example, Hepatitis virus HBV or HCV is able to cause 
chronic inflammation in the liver of chronic hepatitis patients (Budhu and Wang, 
2006; Matsuzaki et al., 2007); ulcerative colitis (UC) may cause chronic inflammation 
in the lining of the rectum and colon (Baumgart and Carding, 2007); the gram-
negative bacterium Helicobacter pylori can induce a chronic, active inflammation in 
the mucosa of gastric (Makola et al., 2007); and it has been reported that tobacco 
smoke results in chronic inflammatory destruction of lung tissue, which is of 
pathogenic significance in the causal pathway of lung cancer, rather than any direct 























































































































































































































































































































































































































































































































































































































































































































































































































































 The correlation between chronic inflammation and cancer development has been 
noticed for long time (Maeda and Omata, 2008; Schafer and Werner, 2008).  At 
present, the significant role of chronic inflammation in promoting carcinogenesis has 
been widely accepted (Marx, 2004) based on the following evidence: 
1. Inflammatory diseases increase the risk of the development of many types 
of cancer. For example, HCC always develops from various chronic liver 
diseases that are accompanied by chronic inflammation, including alcohol 
liver disease, nonalcoholic steatohepatitis, viral hepatitis, biliary disorders 
and cirrhosis (Szabo et al., 2007). It has been estimated that hepatic 
preneoplasia usually takes more than 30 years after chronic infection with 
HBV or HCV is first diagnosed (Thorgeirsson and Grisham, 2002).  
Inflammatory bowel disease (IBD) has also been observed to promote the 
development of colorectal cancers (Itzkowitz and Yio, 2004; Lakatos and 
Lakatos, 2008). Extensive UC leads to a 19-fold increase in risk for colon 
cancer (Gillen et al., 1994). Moreover, Lutgens et al. reported that the risk 
of colorectal cancer in IBD patients increased with longer duration of 
disease. The incidence rate of colorectal cancers was 22% after 10 years 
and 28% after 20 years when IBD was first diagnosed in particular patients 
(Lutgens et al., 2008). 
In addition, chronic inflammation has also been found to correlate with the 
development of  gastric cancer (McNamara and El-Omar, 2008), lung 
cancer (Engels, 2008), breast cancer (Hojilla et al., 2008) and cervical 
cancer (Hiraku et al., 2007) et al. 
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2. Inflammatory cells, chemokines and cytokines are present in the 
microenvironment of all tumors in experimental animal models and 
humans from the earliest stages of development (Mantovani et al., 2008). 
For example, in 49 biopsies taken from patients with breast cancer, 43 
(88%) expressed tumor necrosis factor-α (TNF-α) mRNA and protein 
compared to 4/11 samples (36%) from patients with benign breast disease 
(Miles et al., 1994). Similarly, TNF-α has also been detected in other types 
of cancers such as ovarian cancer (Naylor et al., 1993), prostrate cancer 
(Nakashima et al., 1998) as well as haematological malignancies (Sati et 
al., 1999). 
3. Chronic inflammation may cause DNA damage in organisms, most 
possibly mediated by reactive oxygen species (ROS) (Meira et al., 2008) 
that is produced in cells under TNF-α stimulation (Ventura et al., 2004). 
4. Anti-inflammatory drugs can reduce the risk of developing certain cancers. 
For example, clinical research data showed that HCC development could 
be prevented or delayed in chronic hepatitis patients who were taking anti-
inflammation drugs (Arrieta et al., 2006; Kumada, 2002). 
The molecular mechanisms by which chronic inflammation promotes 
carcinogenesis is under intense investigation (Allavena et al., 2008). Cytokines are 
believed to play important roles in the process (Aggarwal et al., 2006). These small, 
short-lived proteins are produced and secreted by immune cells in respond to stimuli 
and can work in a network to initiate intracellular signalings in target cells by binding 
specific receptors (Lin and Karin, 2007). Among them, TNF-α has been demonstrated 
to be able to play critical roles in the development of cancer (Arnott et al., 2004; 
Moore et al., 1999). 
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1.2.2 TNF-α 
TNF-α belongs to the tumor necrosis factor (TNF) superfamily (Aggarwal, 
2003). This protein was first isolated in 1985 (Aggarwal et al., 1985) and its structure 
has been well characterized (Idriss and Naismith, 2000). TNF-α exerts its biological 
effects by binding to two receptors, TNF receptor I (TNFR1) and TNF receptor II 
(TNFR2) (Baker and Reddy, 1998; Chen and Goeddel, 2002). TNFR1 is expressed in 
all cell types whereas TNFR2 is mainly found in immune and endothelial cells 
(Aggarwal, 2003). 
TNF-α stimulation can activate opposite pathways in target cells (Figure 1.2) 
and the final cell fate is determined by the balance between death and life mediated by 
TNF-α (Aggarwal, 2003). On one hand, binding of TNF-α induces TNF receptors 
trimerization and conformational change. That results in the release of the inhibitory 
protein silencer of death domains (SODD) from the receptors’ intracellular death 
domains (DD). The resulting aggregated DDs are recognized and bound by the 
adaptor protein TNF receptor-associated death domains (TRADD), which then recruit 
additional adaptor proteins, such as receptor-interacting protein (RIP) (Yu et al., 
1999) and Fas-associated death domain (FADD) (Chinnaiyan et al., 1995). RIP and 
FADD may activate the apoptosis pathway by binding caspase-2 or caspase-8, 
respectively and lead to cell death (MacEwan, 2002). For this reason, TNF-α was 
originally identified as a factor that could cause rapid death of transplantable tumors  
in mice (Carswell et al., 1975) and transformed cell lines in vitro (Fransen et al., 
1986). This led to the interest on its application in cancer therapy. However systemic 
toxicity caused by TNF-α remains a major hindrance to its clinical applicability 
(Mocellin et al., 2007). 
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Figure 1.2 Schematic representation of the apoptotic and survival (NF-κB) signaling 
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 On the other hand, after TNF-α binding, TNF receptors can also interact with 
TNF receptor-associating factor 2 (TRAF2) (Wajant et al., 2001). TRFA2 is able to 
interact with downstream proteins and finally activate the c-Jun NH2-terminal kinase 
(JNK) as well as various transcription factors, such as c-Jun, AP-1 and Nuclear factor 
kappa B (NF-κB) (Baker and Reddy, 1998), which then induce anti-apoptotic effects 
or proliferation of cells (Lamb et al., 2003). For example, the activation of NF-κB has 
been strongly linked to the inhibition of apoptosis since three groups simultaneously 
reported that NF-κB helped cells to survive TNF-α stimulation (Beg and Baltimore, 
1996; Van Antwerp et al., 1996; Wang et al., 1996). In addition, Beg et al. reported 
that the disruption of RelA, a component of NF-κB, led to embryonic lethality at 15-
16 days of gestation in mouse (Beg et al., 1995). However, both TNFR1/RelA-
deficient mice (Alcamo et al., 2001) and TNF-α/RelA-deficient mice (Doi et al., 1999) 
were found not to be lethal. These data indicates that TNF-α stimulation not only 
activates the apoptotic pathway leading to cell death, but also induces anti-apoptotic, 
survival and proliferation effects through NF-κB pathway and these effects may 
promote carcinogenesis under certain conditions. 
To date, a number of studies have demonstrated the function of TNF-α in 
mediating cancer development. Moore et al. reported that fewer TNF-α-/- mice 
developed papillomatous tumors when they were treated with carcinogen 7,12-
dimethylbenz[a]-anthracene (DMBA) compared to wild type mice (6% vs 64%). In 
addition, tumors appeared much later in TNF-α-/- mice than those in wild type mice 
(18 weeks vs 11 weeks) (Moore et al., 1999). In the same year, another group reported 
similar results (Suganuma et al., 1999). Both of these data established the roles of 
TNF-α in the development of inflammation-associated cancers. 
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Knight et al. reported that TNF receptors also influenced the inflammation-
associated carcinogenesis. They found fewer liver tumors developed in TNFR1-/- mice 
than in wild type mice, even though the TNF-α level was equally induced in both 
mice by a carcinogenic choline-deficient, ethionine-supplemented diet (Knight et al., 
2000). In addition, Popivanova et al. (Popivanova et al., 2008) found that the 
incidence of colorectal carcinogenesis in TNFR1-/- mice was much less than that in 
wild type mice, when they were administrated with the carcinogen azoxymethane 
(AOM). Furthermore, they also found that administration of etanercept, a specific 
antagonist of TNF-α (Peppel et al., 1991) could also reduce the occurrence of 
colorectal cancer in mice with UC. This was consistent with the result reported by 
another group where they showed that treatment with TNF-α specific neutralizing 
antibody during the tumor promotion stage resulted in apoptosis of transformed 
hepatocytes and a failure to progress to HCC (Pikarsky et al., 2004). 
Intensive in vitro studies have also been done to unveil the molecular basis of 
the function of TNF-α in carcinogenesis. A number of cDNA microarray assays have 
been performed with various cell lines to analyze changes in the gene expression 
profile induced by TNF-α treatment. It has been demonstrated that TNF-α treatment 
could regulate the expression of a lot of genes involved in the immune response, cell 
cycle, apoptosis and cell adhesion (Banno et al., 2004; Murakami et al., 2000; 
Schwamborn et al., 2003). 
TNF-α treatment has been found to cause cytogenetic changes similar to that in 
cancer cells. It was demonstrated that long term treatment with TNF-α could cause 
telomere shortening, DNA breaks, DNA end-to-end fusions and abnormal karyotypes 
(Beyne-Rauzy et al., 2004). Consistently, Yan et al. reported that TNF-α treatment 
could cause DNA damage such as gene mutations, gene amplification and 
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micronuclei formation through cytotoxic ROS produced by the cells after TNF-α 
stimulation. The mutagenic effect of TNF-α was comparable to that of ionizing 
radiation (IR). TNF-α also induced oxidative stress and nucleotide damage in mouse 
tissue in vivo. TNF-α treatment alone led to increased malignant transformation of 
mouse embryo fibroblasts, which could be partially suppressed by antioxidants (Yan 
et al., 2006). 
Usually DNA damage may induce the apoptosis pathway and lead to cell death 
(Norbury and Zhivotovsky, 2004; Roos and Kaina, 2006), but as we have mentioned 
above, TNF-α stimulation can also activate protective pathways to help cells to 
survive (Aggarwal, 2003). Since the surviving cells still carry cytogenetic aberrations 
caused by DNA damage, it becomes apparent that carcinogenesis can occur under 
long term TNF-α exposure. Currently, the NF-κB pathway that can be activated by 
TNF-α stimulation is suggested as a crucial mediator of inflammation-induced tumour 
growth and progression, as well as an important modulator of tumour surveillance and 
rejection (Karin and Greten, 2005) because of its anti-apoptotic functions (Beg and 
Baltimore, 1996). 
1.2.3 NF-κB pathway 
NF-κB was first identified as a regulator of the expression of the kappa light-
chain gene in murine B-lymphocytes, but has subsequently been found in many 
different cells (Atchison and Perry, 1987). NF-κB transcription factors are assembled 
through the dimerization of five subunits: RelA (p65), c-Rel, RelB, p50/NF-κB1 and 
p52/NF-κB2 (Ghosh and Karin, 2002). In the absence of stimuli, most NF-κB dimers 
in the cytoplasm are bound to specific inhibitory proteins known as the inhibitors of 
NF-κB (IκBs). Under TNF-α stimulus, the TRAF2 protein is activated at TNF 
receptor and interacts with downstream signaling molecule NF-κB-inducing kinase 
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(NIK) (Baker and Reddy, 1998) (Figure 1.2). NIK then phosphorylates and activates 
its target, the inhibitor (IκB) kinase (IKK) complex, which is composed of two 
catalytic subunits (IKK-α and IKK-β) and a regulatory subunit (IKK-γ/NEMO) 
(Rothwarf and Karin, 1999). The activated IKK phosphorylates NF-κB bound IκB 
proteins and marks them for ubiquitination and subsequent degradation (Werner et al., 
2005). Freed NF-κB dimer then translocates to the nucleus where it activates the 
transcription of target genes (Figure1.2), including cytokines, chemokines, and 
antiapoptotic factors (Ghosh and Karin, 2002). 
The critical role of NF-κB in mediating inflammation-linked carcinogenesis has 
been very well established based on work with mouse models (Maeda and Omata, 
2008). Greten et al. blocked the NF-κB pathway in a colitis-associated cancer (CAC) 
mouse model by selectively inactivating the IKK-β gene within enterocytes. They 
found that although deletion of IKK-β in intestinal epithelial cells does not decrease 
inflammation, it led to a 80% decrease in tumor incidence. As tumour size was not 
affected, they concluded that IKK-β-dependent NF-κB in enterocytes contributes to 
tumour initiation or early tumour promotion, rather than tumour growth and 
progression (Greten et al., 2004). 
In another inflammation-driven cancer model, the multidrug resistance 2 
(MDR2)-knockout mouse, Pikarsky et al. switched off NF-κB activation using a 
hepatocyte specific IκB-super-repressor transgene and found that shutting down NF-
κB could also block tumor development in liver (Pikarsky et al., 2004). 
In the breast cancer model, the Neu/ErbB2-driven mouse, it was shown that 
genetic introduction of a nonactivatable IKK-α mutant significantly retarded breast 
tumor development (Cao et al., 2007). Of interest, inactivated IKK-α inhibited breast 
cancer development only in the ErbB2/Her2 model, but had no effect in a breast 
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cancer model driven by the Ha-Ras oncogene. This finding is important, as the onset 
of human breast cancers, which are estrogen receptor (ER)-negative, often depends on 
ErbB2/Her2 up-regulation, and was shown to be responsive to treatment with NF-κB 
inhibitors in vitro (Singh et al., 2007). Interestingly, the inactivation of IKK-α blocks 
the ability of Neu/ErbB2-induced tumors to generate secondary tumors upon 
orthotopic transplantation, as it inhibits the self-renewal capacity of breast cancer 
progenitors (Cao et al., 2007). 
The anti-apoptotic and cancer promoting functions of NF-κB was also verified 
in a number of in vitro experiments (Helbig et al., 2003; Mabuchi et al., 2004) and 
more than two hundred NF-κB target genes have been identified (Hinz et al., 2002; 
Pahl, 1999; Tian et al., 2005a). However, the downstream molecular mechanism by 
which NF-κB exerts its effect remains unclear. 
1.3 Aneuploidy and cancer 
1.3.1 Aneuploidy 
Aneuploidy refers to the abnormal chromosome number. It is caused by errors in 
chromosome segregation or the occurrence of pre-mature anaphase during cell 
division. 
The fact that long term TNF-α exposure could result in aberrant chromosome 
number (Beyne-Rauzy et al., 2004) provides evidence to support its function in 
promoting carcinogenesis, as aneuploidy is a hallmark of human cancers (Weaver and 
Cleveland, 2006). 
As shown in Figure 1.3, during mitosis, a group of so called spindle checkpoint 
proteins including Bub1, BubR1 (MAD3), Bub3, Mad1, and Mad2 can form a 
spindle-assembly checkpoint (SAC) to control Mitotic progression and sister-
chromatid segregation (Musacchio and Salmon, 2007). In normal cells, the SAC binds 
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to the kinetochore (Musacchio and Salmon, 2007) that lacks attachment or tension to 
generate a “stop anaphase” signal which is believed to consist of complexes of Bub3, 
BubR1, and Mad2. This signal diffuses into the mitotic cytosol, binds and inhibits the 
complex composed of ubiquitin ligase anaphase-promoting complex/cyclosome and 
its co-factor CDC20 (APC/CCdc20) (Sullivan and Morgan, 2007). As each pair of sister 
kinetochores attaches to microtubules and microtubule motors generate tension that 
stretches them, the production of the “stop anaphase” signals is halted and this 
triggers the release of inhibitory SAC from APC/CCdc20. The activated APC/CCdc20 
then mediates the destruction of cyclin B and securin and results in the release of 
separase, which in mammalian cells is inhibited through its association with securin 
and cyclin B/Cdk1-mediated phosphorylation. Separase subsequently triggers sister 
chromatid dysjunction by cleavage of the cohesin subunit Scc1. This allows cells to 
progress into anaphase and ensures sister chromosomes evenly segregated into 
daughter cells (Pines, 2006). If the function of mitotic checkpoint signaling is 
insufficient to control mitotic progression, anaphase will initiate before all 
chromosomes have established proper spindle attachments resulting in aneuploidy 
(Kops et al., 2005). It seems that the malfunction of mitotic checkpoint proteins is the 
main factor that causes aneuploidy in cancer cells because in addition to the 
observation of aneuploidy, deficiency of these proteins is always detected in human 
cancers (Weaver and Cleveland, 2006). In addition, it was reported that aneuploidy 
always occurred in mice that carried heterozygous deficient checkpoint proteins such 
as MAD2 (Michel et al., 2001), BubR1 (Baker et al., 2004) or Bub3 (Babu et al., 
2003).  
As we know, chromosomal structural instability such as mutation, insertion and 
deletion of DNA is always considered as the most popular cause of cancer (Hahn and 
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Weinberg, 2002), while the role of aneuploidy is neglected even thought its existence 
has been noticed for more than one hundred years (Weaver and Cleveland, 2006). 
However, currently gene mutation hypothesis still fails to answer a lot of questions for 
carcinogenesis. On the contrary, aneuploidy hypothesis seems to be able to explain 
cancer-specific phenotypes much better (Duesberg and Rasnick, 2000).  
To date, more and more evidence shows that aneuploidy may play critical roles 
in causing cancer. The major reason why aneuploidy has been proposed to initiate 
carcinogenesis is that it is a remarkably common characteristic of all cancers (Weaver 
and Cleveland, 2006). Moreover, aneuploidy has been detected in pre-cancerous 
lesions of the cervix (Duensing and Munger, 2004), head and neck (Ai et al., 2001), 
colon (Cardoso et al., 2006), oesophagus (Doak et al., 2004) and bone marrow (Amiel 
et al., 2005). Aneuploidy has also been found in premalignant breast (Medina, 2002) 
and skin (Dooley et al., 1993) lesions in experimental animals. In addition, it was 
found that transient megakaryoblastic leukaemia occured in 10% of newborns with 
Down syndrome, characterized by constitutional trisomy 21. Irreversible acute 
megakaryoblastic leukaemia develops in 20% of these individuals within 4 years 
(Hitzler and Zipursky, 2005). These data indicate that aneuploidy occurs at an early 
stage of cancer development and may precede transformation. In addition, in mouse 
aneuploidy models generated by introducing heterozygous deficiency of mitotic 
checkpoint proteins (Babu et al., 2003; Baker et al., 2004; Michel et al., 2001) or 
kinetochore component CENP-E (Weaver et al., 2007), tumorigenesis can be more 
readily induced compared to wildtype mice. 
How aneuploidy contributes to tumorigenesis is currently under investigation. It 
was reported that aneuploidy could deregulate gene expression profiles and lead to the 







































































































































































































































































































































































































growth control, which is necessary in tumorigenesis. In their experiment, Upender et 
al. generated artificial trisomies in a colorectal cancer cell line and normal human 
breast epithelial cells using microcell-mediated chromosome transfer and analyzed the 
global consequences on gene expression levels using cDNA microarray. They found 
that regardless of chromosome or cell types, chromosomal trisomies resulted in the 
misregulation of 100–200 genes, only 5–20% of which were contained on the trisomic 
chromosome (Upender et al., 2004). 
Based on observations in plants, Matzke et al. suggested that aneuploidy might 
signal the onset of tumor development by making the cells more vulnerable to 
structural alterations such as DNA damage or epigenetic modifications such as  DNA 
methylation (Matzke et al., 2003). This view is consistent with the two stage 
aneuploidy-cancer mechanism (Duesberg and Rasnick, 2000). 
1.3.2 MAD2 
MAD2 (mitotic arrest deficient 2) is one of the key mitotic spindle checkpoint 
proteins. Its primary role is to ensure that all the chromosomes are properly attached 
to the mitotic spindle before the onset of anaphase (Shah and Cleveland, 2000). 
During mitosis, MAD2 is activated at unattached kinetochore with the help of MAD1 
(Yu, 2006). The activated MAD2 then forms a complex with other checkpoint 
proteins BubR1 (MAD3) and Bub3 to bind to cdc20 and prevent the anaphase 
promoting complex (APC) from ubiquitylating securin (Figure 1.3). By doing this 
MAD2 can help to prevent anaphase initiation until all of the kinetochores have been 
attached by microtubules and the chromosomes are properly aligned along the 
kinetochore plate so that sister chromosomes can be evenly segregated into daughter 
cells (Sullivan and Morgan, 2007). MAD2 is an essential gene, and MAD2-/- mice die 
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in utero (Dobles et al., 2000). Loss of one allele of MAD2 has been reported to result 
in premature anaphase and aneuploidy in mammalian cells (Michel et al., 2001). 
Dysregulation of MAD2 has been implicated in various cancers. Reduced 
expression of MAD2 associated with loss of mitotic checkpoint control was observed 
in adult T-cell leukemia, ovarian cancer cells, breast cancer cells, liver cancer and 
nasopharyngeal carcinoma cells (Weaver and Cleveland, 2006). Interestingly, MAD2 
has been reported to be over-expressed in colorectal cancer (Li et al., 2003). 
Nonetheless, mutations of MAD2 are infrequently observed in bladder cancer, soft-
tissue carcinomas, hepatocellular carcinomas (Hernando et al., 2001), lung cancer, 
breast cancer (Gemma et al., 2001) and gastric cancer (Kim et al., 2005a). It was 
demonstrated that the deregulation of the Rb pathway leads to aberrant over-
expression of MAD2, which then contributes to mitotic alterations and chromosome 
instability (Hernando et al., 2004). 
Aberrant interaction of MAD2 with other proteins may also deregulate the 
checkpoint function of MAD2 and induce chromosomal instability. For example, 
over-expression of CMT2 (Caught by MAD2, also known as p31comet), which is 
capable of binding to MAD2, induces premature entry into anaphase without 
chromosome segregation (Habu et al., 2002; Yu, 2006). Our group also found that 
that overexpression of FAT10 (HLA-F associated transcript 10) (Fan et al., 1996) that 
could interact with MAD2 (Liu et al., 1999) resulted in abbreviation of mitosis and 
abnormal chromosome numbers in HCT116 cell line (Ren et al., 2006). 
In addition, Michel et al. reported that MAD2 haplo-insufficient mice not only 
have more aneuploid cells, but also developed lung tumors at high rates after long 
latencies compared to wild type mice (Michel et al., 2001). This data strongly 
supports the role of dysfunction of MAD2 in tumorigenesis. 
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1.4 Ubiquitin, ubiqutin like modifiers (UBL) and cancer 
As tumorigenesis often arises from dysregulated cell-cycle control or apoptosis 
and the ubiquitin plays instrumental roles in various cellular processes including cell-
cycle regulation (Nakayama and Nakayama, 2006) as well as cell death/apoptosis 
(Zhang et al., 2004) through the modification of target proteins, thus dysfunction of 
ubiquitination (or ubiquitylation) has been implicated to play critical roles in cancer 
development (Crosetto et al., 2006). Moreover, some ubiquitin like proteins such as 
SUMO (Dasso, 2008; Watts, 2007) have also been found to function during cell cycle 
progression. 
1.4.1 Ubiquitin 
Ubiquitin is a highly conserved 76 amino-acid polypeptide that was first purified 
from bovine thymus in 1975 (Vijay-Kumar et al., 1987). It functions by covalently 
attaching to the target proteins via an isopeptide bond between the C-terminal glycine 
of ubiquitin and the ε-amino group of a lysine in substrate proteins. This occurs 
through a cascade of events requiring participation of three enzymes. Firstly, ubiquitin 
is activated in an ATP-dependent manner by a ubiquitin-activating enzyme E1, then 
transferred to a ubiquitin-conjugating enzyme E2 via a thiol-ester bond, and finally 
conjugated to a target protein via ubiquitin-protein ligases E3 (Pickart, 2001). As a 
result, ubiquitination leads to different functional consequences to those target 
proteins: polyubiquitin-tagged proteins are targeted for degradation by the 26S 
proteasome (Herrmann et al., 2007), whereas monoubiquitination can regulate the 
function of the proteins (Hicke, 2001). Although only one E1 enzyme is known in 
human (Jin et al., 2007), approximately 60 E2 enzymes and 1000 E3 enzymes have 
been discovered thus far (Crosetto et al., 2006), making the number of possible 
combinations and substrate specificities very high. 
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There is accumulating evidence that mutations or altered expression of 
components in the ubiquitination pathway can influence various signaling processes, 
such as cell cycle control, DNA repair, the p53 pathway as well as the NF-κB 
pathway, and result in oncogenic alterations. Moreover, misregulated proteins 
involved in ubiquitination have been frequently discovered in various cancers (Dikic 
et al., 2006; Hoeller et al., 2006). For example, Adhikary et al. reported that ubiquitin 
ligase HectH9, which was highly expressed in multiple human tumors, was able to 
regulate transcriptional activation by Myc and was essential for tumor cell 
proliferation (Adhikary et al., 2005). 
1.4.2 Ubiquitin-like modifiers (UBL) 
Ubiquitin-like proteins refer to those proteins that contain ubiquitin like 
structures (Jentsch and Pyrowolakis, 2000). The roles of ubiquitin-like family 
members have been intensively investigated in recent decades (Welchman et al., 
2005). Two different families of ubiquitin-like proteins have been reported (Jentsch 
and Pyrowolakis, 2000). The ubiquitin-domain proteins (UDP), for example, RAD23, 
BAG1, Elongin B and Gdx, do not form conjugates with other proteins, although they 
contain embedded ubiquitin-like domains. Residues outside these domains do not bear 
similarities to each other or to ubiquitin. The UDPs are responsible for recruitment of 
ubiquitylated substrates to the proteasome and bind to the 26S proteasome in a UBL-
dependent manner and its dysfunction has been linked to human diseases including 
neurodegeneration and cancer (Madsen et al., 2007). 
The second family of ubiquitin-like proteins is known as the ubiquitin-like 
modifiers (UBL) and it is currently under more intensive study. To date, more than 10 
eukaryotic UBLs have been discovered (Kirkin and Dikic, 2007) (Table 1.2). 
Although the sequence identity of these UBLs to ubiquitin varies greatly from 10% to 
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60% (Herrmann et al., 2007), all of them share a similar ubiquitin-like 3D structure 
(Figure 1.4), called the ubiquitin fold, comprising of a four-stranded mixed β-sheet 
and an α-helix (Dye and Schulman, 2007). In addition, like ubiquitin, all the UBLs 
contain a C-terminal glycine doublet, whose carboxyl group is the site of attachment 
to the lysine residue of substrates via isopeptide bond formation (Jentsch and 
Pyrowolakis, 2000). The modification of proteins by UBLs uses a similar enzyme 
cascade to that used by ubiquitin (Herrmann et al., 2007) except that in some cases the 
E2s are often capable of interacting directly with substrate proteins (Welchman et al., 
2005). Although some UBLs such as NEDD8/RUB1 (Wu et al., 2005) can tag target 
proteins for degradation, most just modify proteins to regulate their functions (Kirkin 
and Dikic, 2007). For example, SUMO1 cannot form polySUMO-chains (Tatham et 
al., 2001) but it may sumoylate promyelocytic leukaemia proteins PML and Sp100 so 
that they localize them to PML bodies in the nucleus (Welchman et al., 2005). 
It was discovered that a specific protein or pathway could be modified by 
various UBLs. For example, p53 can be modified by sumoylation, ubiquitination 
(Hoeller et al., 2006) as well as neddylation (Xirodimas et al., 2004). Activity of NF-
κB signaling can also be regulated by both sumoylation and ubiquitination. More 
interestingly, sumoylation may oppose the function of the ubiquitylation on NF-κB 
because SUMO-1 and ubiquitin compete to modify the same site on IκB. The 
ubiquitylation of lysine 21 (K21) of IκB leads to its degradation, whereas K21 
sumoylation stabilizes IκΒ (Welchman et al., 2005). 
UBLs have also been associated with cell cycle-related processes and are 
implicated in cancer (Hoeller et al., 2006). SUMO, the most intensively studied UBL, 
has a lot of target substrates that function during mitosis, including condensin, 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































these proteins will thus influence the cell cycle process (Dasso, 2008). For example, 
sumoylation of Top2 is required to lower the affinity of topoisomerase for the 
chromatin or for the remodelling of topoisomerase on the chromosome during mitosis. 
Depletion of the SUMO ligase Ubc9 results in the prevention of the mobilisation of 
Top2 and under these conditions sister chromatid separation is defective (Watts, 
2007). In addition, Ledl et al. reported that the mutation of retinoblastoma (RB) 
protein, a major regulator of cell-cycle progression, led to the loss of modification by 
sumoylation that resulted in RB dysfunction, which is often observed in 
retinoblastoma tumours (Ledl et al., 2005). 
1.4.3 FAT10 
FAT10, also known as diubiquitin or ubiquitin D (UBD), is another UBL that 
may play a role in regulating the cell cycle process because it was reported to be able 
to interact with mitotic checkpoint protein MAD2 (Liu et al., 1999). FAT10 is a 18 
kDa protein comprising of 165 amino acid residues and contains two ubiquitin-like 
moieties fused in tandem (Jentsch and Pyrowolakis, 2000). It is 29% identical to 
ubiquitin at its N-terminus and 36% identical at the C-terminus. Like ubiquitin, it has 
the C-terminal Gly–Gly residues and a conserved Lys residue in each moiety of 
FAT10 analogous to Lys48 of ubiquitin, each of which may serve as a potential site 
for polyubiquitination (Raasi et al., 1999). Consistent to its ubiquitin-like structure, 
FAT10 was shown to be activated by E1-like protein E1-L2 which could also activate 
ubiquitin (Chiu et al., 2007) and interact with its target protein to form a 35-kDa 
protein conjugate (Raasi et al., 2001). FAT10 and its 35-kDa conjugate are short-lived 
proteins that are degraded by the 26S proteasome with the help of NEDD8-ultimate-
buster-1L (NUB1L) (Hipp et al., 2004). Moreover, it was suggested that FAT10-
mediated protein degradation by the proteasome is cytokine inducible and irreversible 
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(Hipp et al., 2005). It was suggested that FAT10 might contribute to maturation of 
human dendritic cells by mediating protein degradation (Ebstein et al., 2008). 
Recently, Kalveram et al. found that FAT10 can also interact with the cytoplasmic 
protein histone deacetylase 6 (HDAC6) so that under proteasome inhibition, it can 
help to transport target proteins to aggresomes (Kalveram et al., 2008).  
The function of FAT10 in cell proliferation is not clear. Raas et al. reported that 
FAT10 overexpression inhibited cell proliferation and induced apoptosis in a manner 
that is dependent on its C-terminal glycine residue (Raasi et al., 2001). But Canaan et 
al. found the cells without FAT10 were prone to spontaneous apoptotic death. In 
addition, they demonstrated that FAT10-/- mice demonstrated a high level of 
sensitivity toward endotoxin challenge. Based on their results, they proposed FAT10 
as a survival factor (Canaan et al., 2006). 
At present, more evidence has been reported to support the association between 
FAT10 and cancers. FAT10 overexpression has also been detected in primary non-
small cell lung cancer (Heighway et al., 2002), mantle cell lymphoma (Martinez et al., 
2003), as well as gastrointestinal and gynecological cancers (Lee et al., 2003). In 
addition, FAT10 overexpression is also reported in diseases associated with viral 
infection, such as Kaposi sarcoma-associated herpesvirus infected cells (Hong et al., 
2004) and human immunodeficiency virus (HIV) infected cells (Ross et al., 2006). In 
animal models, it was found that carcinogens can also induce FAT10 overexpression 
and FAT10 was one of the genes whose expression was upregulated during the early 
stages after carcinogen treatment (Yamashita et al., 2002). These results suggested 
that FAT10 overexpression occured at every stage of cancer development. 
Consistently, it has been reported that FAT10 is an epigenetic marker for liver 
preneoplasia in a drug-primed mouse model of tumorigenesis (Oliva et al., 2008). 
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FAT10 expression is also found to be cell cycle regulated (Lim et al., 2006) and 
can be suppressed by the tumor suppressor gene p53 (Zhang et al., 2006). More 
interestingly, the expression of FAT10 can be greatly induced by the cytokine TNF-α 
(Raasi et al., 1999).  TNF-α is always detected at a high level in the serum of cancer 
patients such as those with hepatocelluar carcinoma (Ataseven et al., 2006). 
Moreover, FAT10 overexpression in HCC and colon cancer was found to correlate 
with expression of the TNF-α and IFN-γ dependent proteasome subunit LMP2, 
suggesting that proinflammatory cytokines caused the joint overexpression of FAT10 
and LMP2 (Lukasiak et al., 2008). Hence, FAT10 may play a role in the development 
of inflammation-associated tumorigenesis. 
1.5 Objectives of this thesis 
In this thesis I intended to accomplish three objectives in order to elucidate the 
mechanism of cancer development (Table 1.3). 
Firstly, using cDNA microarrays, I screened for novel candidate cancer-
associated genes by analyzing altered gene expression profiles in HCCs. The 
ubiquitin-like gene FAT10, which was not previously reported to be associated with 
cancer and was overexpressed in HCC patients, was selected for further 
characterization. Northern blot results showed that FAT10 was not only 
overexpressed in HCC, but also in other cancers, especially gastrointestinal and 
gynecological cancers (Lee et al., 2003). 
Then I investigated the function of FAT10 and found that FAT10 interacted and 
co-localized with the mitotic checkpoint protein MAD2 during mitosis. 
Overexpressed FAT10 alters the subcellular localization of MAD2 during mitosis and 
caused premature anaphase. As a result, overexpressed FAT10 was able to induce 
chromosomal instability in mammalian cells (Ren et al., 2006). 
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Thirdly, I characterized the regulation of FAT10 gene expression in order to 
identify pathological conditions that might induce FAT10 overexpression. I found that 
endogenous FAT10 expression was induced by the inflammatory cytokine TNF-α, 
through the activated NF-κB pathway. These results suggest that FAT10 might play a 
role in the development of chronic inflammation associated cancers. 
1.6 Significance of this thesis 
In this thesis, I have observed that FAT10 is overexpressed in HCC as well as 
some other cancers. Our data represents the first report to correlate FAT10 expression 
with human cancers and made it meaningful to further elucidate the roles of FAT10 in 
tumorigenesis. 
I have also demonstrated that overexpressed FAT10 can influence mitosis 
through interaction with MAD2 and induce numerical chromosomal instability. These 
results highlight the important role that FAT10 plays, since deregulating its 
expression may lead to aneuploidy which is considered a hallmark and cause of 
cancers (Weaver and Cleveland, 2006). 
It is generally agreed that chronic inflammation is closely related to cancers 
(Mantovani et al., 2008) and TNF-α plays critical functions to promote the 
development of cancers through the activated NF-κB pathway (Karin and Greten, 
2005), possibly by inducing chromosomal instability in susceptible cells (Beyne-
Rauzy et al., 2004; Yan et al., 2006). However, downstream molecular mechanisms 
that link the TNF-α/NF-κB pathway and cancer are not well elucidated. In this thesis, 
I have shown that TNF-α is able to upregulate endogenous FAT10 expression through 
the NF-κB pathway, suggesting that FAT10 may be an important gene that mediates 




























































































































































































































































































































































































































































































































































 Chapter 2 Materials and methods 
2.1 Patients tissue samples and cell lines 
All HCC patient samples were obtained in accordance to the Institutional 
Review Board (IRB) Guidelines of the National Cancer Center, Singapore. Altogether 
23 HCC tumors paired with adjacent non-tumorous tissues were used in this thesis for 
the purpose of cDNA microarray assay, northern blot analysis, in situ hybridization as 
well as immunohistochemical staining. 
All the immortalized cell lines used in this thesis were purchased from 
American Type Culture Collection (ATCC, Manassas, VA). WRL68 (ATCC product 
CL-48) was grown in MEM medium (Gibco/Invitrogen, Carlsbad, CA). This cell line 
was originally regarded as human embryo liver cells but then found to be 
contaminated by Hela cells (ATCC product sheet). Mouse embryonic fibroblast cell 
line NIH3T3 (ATCC product CRL-1658) and human embryonic kidney (HEK) 293 
cells (ATCC product CRL-1573) were cultured with DMEM medium 
(Gibco/Invitrogen, Carlsbad, CA). Human colon cancer cell line HCT116 was grown 
in McCoy’s 5A medium (Sigma-Aldrich, St. Louis, MO). Human colon cancer cell 
line SW620 (ATCC product CCL-228) was grown in Leibovitz L-15 medium 
(Gibco/Invitrogen, Carlsbad, CA). SV40 large T antigen immortalized primary 
normal human liver cells THLE-3 (ATCC product CRL-11233) was grown in growth 
factors supplemented BEGM medium (Lonza, Allendale, NJ). 
Besides those commercial cell lines, we also isolated and cultured human T-cell 
from venous blood according to the method described by Berthold (Berthold, 1981). 
Briefly, 10ml of peripheral blood of healthy adult donors was overlaid carefully over 
3ml of Ficoll-Paque Plus reagent (Amersham Biosciences, Piscataway, NJ) and 
 30
centrifuged at 600g for 20 minutes without braking. The lymphocytes enriched layer 
(middle layer, about 2ml) was carefully transferred to a fresh tube and the cells were 
pelleted by centrifugation at 400g for 5 minutes. The cells were washed twice with 
PBS and grown in hTC culture medium (Amaxa, Gaithersburg, MD) supplemented 
with 2μg/ml phytohemagglutinin (PHA) (Gibco/Invitrogen, Carlsbad, CA) for three 
days. The lymphocytes were then cultured in 200IU/ml IL-2 (Chiron, Emeryville, 
CA) supplemented hTC culture medium until proliferation reached the exponential 
phase (usually 6-7 days after isolation). The cells are then ready to be used in 
experiments. 
2.2 RNA extraction 
Total RNA was extracted from HCC tissue samples with TRIzol reagent 
(Gibco/Invitrogen, Carlsbad, CA) following the protocols suggested in the product 
information sheet. Briefly, 0.2-0.4g frozen tissue was homogenized in 3ml of TRIzol 
reagent. Then 0.6ml chloroform was added to each tube and the mixture was shaken 
robustly for 15 seconds. The mixture was then centrifuged at 25000g for 15 minutes 
and top aqueous phase containing RNA (about 1.5ml) was transferred to a fresh tube. 
RNA was precipitated by adding 0.75ml Isopropanol and 0.75ml of high salt solution 
(0.8 M sodium citrate and 1.2 M NaCl) and spinning at 15000g for 10 minutes. 
Finally, the RNA pellet was dissolved in 100μl of 0.1% diethyl pyrocarbonate 
(DEPC) (Sigma-Aldrich, Inc. St. Louis, MO) treated water and RNA concentration 
was determined by measuring OD260nm. 
Poly-A RNA was extracted from 200 μg of total RNA via two-rounds of 
purification using Oligotex mRNA Mini Kit (Qiagen, Hilden, Germany) according to 
protocols suggested by the manufacturer. 
2.3 cDNA microarray analysis of HCC samples 
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cDNA generated from the Poly-A RNA was labeled with Cy3 or Cy5 and 
hybridized against the UniGem V2.0 microarray (IncyteGenomics, St. Louis, MO) on 
which 9128 genes could be analyzed. The generation and labeling of the cDNA, 
hybridization and scanning of the microarray were performed by IncyteGenomics (St. 
Louis, MO). The scanned array data was then analyzed. Gene expression in tumor and 
adjacent non-tumorous tissues was considered significantly different when the 
balanced differential expression was greater than 1.8-fold. A total of 4 pairs of HCC 
samples (Figure 3.1) were analyzed. 
2.4 Northern Blot analysis 
2.4.1 cDNA Probe preparation 
With reference to the sequence on UniGEM V2.0 (IncyteGenomics, St. Louis, 
MO), a unique FAT10 cDNA fragment was first prepared from RT-PCR of total RNA 
extracted from tissue samples. Briefly, 1ug of total RNA extracted from HCC tumor 
samples was used to perform reverse transcription with SuperScript II RNase H 
Reverse Transcriptase (Invitrogen, Carlsbad, CA) and oligo(dT)17-primers. The 
resultant cDNA was used to amplify a unique FAT10 fragment with FAT10 gene 
specific primers 5’-CGTTCCGAGGAATGGGATTT-3’ and 5’-
GACTCCACAAGAAACAAGGG-3’. 
The amplified 250bp fragments were sequenced to confirm its identity as 
FAT10 and then were used to prepare α-32P dCTP (Amersham Pharmacia Biotech 
Inc., Piscataway, NJ) labeled oligo probes using Rediprime labeling kit (Amersham 
Pharmacia Biotech Inc., Piscataway, NJ) according to the manufacturer’s instructions. 
2.4.2 Northern blot hybridization 
10-15μg of total RNA was lyophilized and resuspended in 12μl of northern 
buffer (appendix A). This was heated for 15 minutes at 65ºC and then cooled on ice 
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for 1 minute. 3μl of 5xNorthern dye (appendix A) was added and loaded onto a 1.5% 
denaturing formaldehyde agarose gel (appendix A). The gel was run at 5V/cm in 
1xMOPS (appendix A) for about 2 hours. A photograph of the gel was taken under 
UV light to check the quality of RNA by observing the 18S and 28S bands. The RNA 
was transferred to Hybond-N+ membrane (Amersham Pharmacia Biotech Inc., 
Piscataway, NJ) by capillary action in 10xSSC buffer (appendix A) for 16-18 hours 
and cross-linked to the membrane using the UV Stratalinker 2400 (Strategene, La 
Jolla, CA). The locations of 18S and 28S bands were marked on membrane under UV 
exposure. 
In hybridization, the membrane was shaken in boiled water for 5 minutes and 
pre-hybridized for 3-4 hours in 10 ml of hybridization solution (appendix A) in a glass 
hybridization tube at 55ºC. 10ul of α-32P dCTP labeled FAT10 cDNA probe was 
heated at 95ºC for 10 minutes and chilled in ice for 5 minutes and then added into the 
tube. Hybridization was continued at 55ºC for 14-16 hours. After hybridization, the 
membrane was washed twice in 2xSSC, 0.1% SDS at room temperature and twice in 
0.2xSSC, 0.5% SDS at 55°C. The membrane was then exposed to Biomax MS film 
(Kodak Inc., Rochester, NY) or Fuji imaging plate (Kanagawa, Japan) and quantitated 
using the FluorChemTM v2.0 (Alpha Innotech Corporation, San Leandro, CA) or the 
phosphorimager, BAS-2500 (Fujifilm, Kanagawa, Japan). 
2.5 In situ Hybridization 
2.5.1 Tissue sections 
Fresh HCC tissues and their adjacent non-tumorous tissues were immediately 
embedded in tissue freezing medium (Tissue-Tek® OCT compound, Sakura, Japan) 
in a cryomold (SIMPORT, Canada) in dry ice and stored at –70oC. Five-micron thick 
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sections of the tissues were then mounted onto poly-L-lysine-coated slides and fixed 
immediately in 4% paraformaldehyde-PBS for 15 min at room temperature. 
 
2.5.2 FAT10 probe preparation 
The unique sequence of the FAT10 cDNA was cloned into EcoRV site of the 
pBluescript II KS+ vector (Stratagene, La Jolla, CA). Two colonies, one containing 
insert in the forward and the other containing insert in the reverse orientation, were 
used for riboprobe generation as sense and antisense probes. For probe synthesis, the 
plasmid DNA from the 2 colonies was linearized with EcoRI and in vitro transcribed 
via the T3 promoter using T3 polymerase and DIG RNA labeling kit (Roche, Basel, 
Switzerland). Labeling efficiency was verified by electrophoretically separating the 
probe on a 1% denaturing agarose gel, transferring the gel onto a membrane and 
detecting the probe using anti-DIG alkaline phosphatase and NBT/BCIP. 
2.5.3 Hybridization 
In situ hybridization was then performed on the sectioned tissues with the 
respective probes using DAKO mRNA in situ Hybridization solution (DAKO, 
Glostrup, Denmark) following the method of Braissant and Wahli (Braissant and 
Wahli, 1998) with the following modifications. After incubation with the probes, the 
slides were washed at higher stringency conditions. These conditions include 30 
minutes in 5xSSC at room temperature, RNase treatment for 30 minutes at 37oC, 60 
minutes in 2xSSC at 65oC and 60 minutes in 0.1xSSC at 65oC. Sections were then 
incubated for 2 hours at room temperature with 1:1000 dilution of alkaline 
phosphatase-coupled sheep anti-DIG antibody (Roche, Basel, Switzerland) in 0.1M 
Tris, 0.15M NaCl, pH 7.5, 0.5% Blocking Reagent (Roche, Basel, Switzerland) and 
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2% normal sheep serum. Positive signals were visualized using NBT/BCIP substrate 
(Roche, Basel, Switzerland). 
 
2.6 Hybridization of cancer profiling array (CPA) and multiple tissue expression 
array (MTE) 
The expression levels of FAT10 in various other cancers were determined with 
the use of the Cancer Profiling Array (Clontech product 7841-1, Palo Alto, CA) 
containing paired normal/tumor tissues covering 12 different cancers from 241 
patients. In addition, FAT10 expression in various normal tissues and a number of 
transformed cell lines were determined using the Multiple Tissue Expression Array 
(Clontech product 7776-1, Palo Alto, CA) spotted with 76 different tissue types. Each 
spotted tissue-type was pooled from several individuals. 
For hybridization, the blot was put in boiling water for 5 minutes with 
continuous shaking. The blot was then preincubated in 10ml of Express Hyb 
hybridization solution (Clontech product 8015-2, Palo Alto, CA) supplemented with 
100ug/ml sonicated salmon sperm DNA (ssDNA) (Strategene, La Jolla, CA) at 65oC 
for 3 hours. 
Meanwhile, α-32P dCTP labeled oligo probes were prepared as described in 
2.4.1. The probes were then purified using Qiaquick nucleotide removal kit (Qiagen, 
Hilden, Germany). The purified oligos were used to prepare the probe mixture 
(Appendix B) and heated at 95oC for 10 minues then cooled down to 68oC and 
incubated at 68oC for 30 minutes. 
Probes were added to the blot and hybridization was continued at 65oC for 14-16 
hours. At the end of hybridization, the blot was washed with wash buffer I four times 
(15 minutes/per time) at 65oC, wash buffer II four times (15 minutes/per time) at 65oC 
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and wash buffer III once at room temperature (10 minutes). The probed blots were 
exposed to Biomax MS film (Kodak Inc., Rochester, NY) or Fuji imaging plate 
(Kanagawa, Japan).   
The blots were initially hybridized with FAT10 probes. The probes were then 
stripped by boiling in water for 10 minutes and re-hybridized against human ubiquitin 
probes provided with CPA and MTE to correct for minor variations of immobilized 
cDNA in the arrays. 
Samples with detectable signals were analyzed densitometrically. The intensity 
of each dot quantified with the FluorchemTM v2.0 (Alpha Innotech Corporation, San 
Leandro, CA) or the phosphorimager, BAS-2500 (Fujifilm, Kanagawa, Japan). For 
the Cancer Profiling Array, FAT10 was considered differentially expressed between 
non-tumor and tumor tissue if the intensity difference exceeded 1.5 times after 
normalization against signals obtained using the ubiquitin probe provided as a 
normalization control by Clontech. 
2.7 Generation of polyclonal FAT10 antibody 
The open reading frame of FAT10 containing the flanking regions of the attB1 
sequence and attB2 sequence compatible to the Gateway™ Cloning Technology 
(Invitrogen, Carlsbad, CA) was cloned into the Gateway™ donor vector, 
pDONR™201 to generate the entry clone, pENTR-FAT10. The expression clone, 
pEXPR17-FAT10, containing N-terminal 6X Histidine tagged to FAT10 was then 
generated in a BP reaction using pENTR-FAT10 and the Gateway™ entry vector 
pDEST™17. pEXPR17-FAT10 construct was transformed into BL21-SI E.coli cells 
(Invitrogen, Carlsbad, CA). Recombinant FAT10 protein expression in BL21-SI cells 
was induced by the addition of 0.3 M NaCl for 5h. 
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Recombinant FAT10 was purified using Ni-NTA resin (Qiagen, Hilden, 
Germany) according to manufacturer’s instructions with the following modifications. 
Briefly, 250 ml of induced BL21-SI cells were lysed in Buffer B (appendix C), and 
cleared lysate obtained by centrifugation at 10,000 x g for 20 minutes. One ml of 
equilibrated 50% Ni-NTA slurry was added to the cleared lysate and the mixture was 
incubated with shaking for 30 minutes at room temperature. The mixture was loaded 
onto a 1 ml polypropylene column (Qiagen, Hilden, Germany) and flowthrough was 
discarded. The column was then washed with 1ml Buffer B (appendix C) for four 
times and then 1ml Buffer C (appendix C) for four times. FAT10 protein was then 
eluted twice with Buffer E (appendix C). SDS-PAGE analysis was performed to 
determine the elution fractions that contain the highest level of His-FAT10 protein. 
These fractions were then pooled and diluted with 8 M Urea to a final protein 
concentration of 0.2mg/ml and dialysed in chilled milli-Q water with frequent change 
of water. The protein sample was then lyophilized with a Savant freeze drier (Thermo 
Scientific, Waltham, MA). 
Purified recombinant FAT10 protein were then used to generate antibodies in 
rabbits (BioGenes GmbH, Berlin, Germany) and polyclonal IgG was purified over a 
FAT10–Sepharose column. 
2.8 Immunostaining 
2.8.1 Immunohistochemical staining 
Thick sections (5μm) of frozen HCC tissue tissues were fixed in acetone for 10 
minutes at 41oC, washed briefly in water and treated with freshly prepared 3% 
hydrogen peroxide for 10 minutes to block endogenous peroxidases. The slides were 
then incubated with 2mg/ml of anti-FAT10 primary antibody for 30 minutes. A 
polymer-linked anti-rabbit secondary antibody was then applied using the DAKO 
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EnvisionTM AP KIT (Code K4016) (DAKO, Glostrup, Denmark) for another 30 
minutes. Freshly prepared chromogen solution (fast red) was then applied and the 
slides were counterstained with Harris Haematoxylin (Gill’s II Haematoxylin – 
Surgipath, Richmond, IL, USA). The slide preparations were observed under an 
Olympus BX51 microscope (Center Valley, PA). 
2.8.2 Immunofluorescent staining 
Cells were grown on coverslips and then fixed in 2% paraformaldehyde. The 
fixed cells were permeablized with 0.2% Triton X-100 for 10 minutes and blocked 
with 5% fetal calf serum (FCS) in phosphate-buffered saline (PBS) for 1 hour at room 
temperature. Then the cells were stained with primary antibody (for example, anti-
FAT10 antibody) diluted in 5% FCS (2µg/ml) for 1 hour at 37°C. After three washes 
in PBS, the coverslip was incubated with fluorescence conjugated secondary 
antibodies (Molecular Probes, Eugene, OR) (for example, Alexa Fluor® 647 chicken 
anti-rabbit IgG (H+L)) diluted in 5% FCS (1:300) for 1 hour at room temperature. 
The cells were then incubated in DAPI for 15 minutes and washed thrice in PBS and 
mounted onto glass slides using FluorSave Reagent (Calbiochem, San Diego, CA). 
The slides were observed with Zeiss LSM 510, laser scanning microscope 
(Heidelberg, Germany). 
2.9 Cloning of fluorescent fusion protein expressing plasmids 
To investigate the subcellular localization of FAT10 and MAD2, we constructed 
plasmids which expressed fluorescence fusion proteins (Figure 3.8A and 3.15A) using 
PCR-based technique described by Shevchuk et al. (Shevchuk et al., 2004). 
2.9.1 Generation of the FAT10- DsRed fusion construct 
In generating FAT10-DsRed fusion construct, the cytomegalovirus (CMV) 
promoter was introduced into pDsRed reporter gene (Clontech, Palo Alto, CA) at the 
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EcoRI and BamHI site within the multi-cloning region to produce a pCMVDsRed 
construct. The FAT10-DsRed fusion construct was generated via a 2-step Polymerase 
Chain Reaction (PCR) using primers as indicated in Figure 2.1A. In the first step, 
FAT10 and DsRed genes were amplified separately. FAT10 was amplified from 
human liver cDNA with primers C and D while DsRed was amplified from 
pCMVDsRed plasmid using primers A and B (Figure 2.1A).  The purified amplified 
FAT10 and DsRed PCR products were then mixed and another PCR reaction was 
performed using primers B and D to generate the fused FAT10-DsRed amplified 
product. The fused FAT10-DsRed amplified product was digested with BamHI and 
NotI restriction enzymes and cloned into pCMVDsRed at the BamHI/NotI site 
replacing the resident DsRed gene in the construct to generate pCMVFATDsRed. 
(Figure 3.8A). The identity of the fusion pCMVFATDsRed construct was confirmed 
by sequencing. 
pCMVFATDsRed or its parental pCMVDsRed constructs were introduced into 
the human liver cell line WRL68 (European Collection of Cell Cultures, Salisbury, 
UK), and plated on sterilized coverslips in 6-well plates via calcium phosphate co-
precipitation (Lee et al., 2000). Forty-eight hours after transfection, the cells were 
fixed in 2% paraformaldehyde and viewed under a fluorescence microscope. 
2.9.2 Generation of the MAD2-EGFP fusion construct 
A MAD2-EGFP fusion construct was also generated via a 2-step polymerase 
chain reaction (PCR) using the primers indicated in Figure 2.1B.  In the first step, 
MAD2 and EGFP genes were amplified separately. MAD2 was amplified from 
human liver cDNA with primers 3 and 4 while EGFP was amplified from pEGFP-1 
(Clontech, Palo Alto, CA) using primers 1 and 2. The purified amplified MAD2 and 
EGFP PCR products were then mixed and another PCR reaction was performed using 
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AB
Figure 2.1 Generation of fusion genes which encode fluorescence-tagged 
proteins. FAT10-DsRed (A) and MAD2-EGFP (B) fusion genes were generated by 
fusion PCR with individual primer sets and insert at BamHI/NotI sites after CMV 





























primers 2 and 4 to generate the fused MAD2-EGFP amplified product (Figure 2.1B). 
The fused MAD2-EGFP amplified product was then cloned into the BamHI/NotI site 
of the pCMVDsRed plasmid (see 2.9.1) replacing the resident DsRed gene in the 
construct to generate pMAD2EGFP (Figure 3.16A) and the identity of the fusion 
pMAD2EGFP construct was confirmed by sequencing. 
In this thesis, pMAD2EGFP was transfected into mammalian cells and MAD2 
aggregation at the kinetochores was quantitated by determining the intensity of the 
bright EGFP fluorescent signals normalized against similarly sized diffused 
fluorescent signals in other regions of the cells (Figure 3.17). 
2.10 Recombinant FAT10 Adenoviruses 
2.10.1 Generation of Recombinant FAT10 Adenoviruses 
Recombinant human FAT10 adenoviruses (AdFAT10) were generated as 
described (He et al., 1998). In this experiment, FAT10 cDNA was initially subcloned 
into the shuttle vector, pAdTrack-CMV; and the integrity of the FAT10 gene in this 
vector was sequence verified.  Another plasmid containing the adenoviral arms 
(pAdEasy-1) was co-transformed with either the PmeI linearized shuttle vector 
(pAdtract-CMV) or FAT10-containing shuttle vector (pAdTract-CMV-FAT10) into 
BJ5183 E.coli cells.  Recombinant control adenoviral (pAdControl) or recombinant 
FAT10-expressing adenoviral vectors (pAdFAT10) (Figure 3.9A) were then generated 
through homologous recombination of the AdEasy-1 and AdTract-CMV or AdTract-
CMV-FAT in the BJ5183 E. coli cells. Colonies obtained were screened for 
appropriate recombination events using EcoRV and PmeI restriction endonuclease 
analyses. 
pAdControl and pAdFAT10 vectors were then digested with PacI and 
transfected using Superfect™ Transfection Reagent (Qiagen, Hilden, Germany) into 
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the packaging cell-line HEK293 (ATCC product CRL-1573), which constitutively 
expresses the E1 gene product, to produce recombinant control adenoviruses 
(AdControl) and FAT10-expressing adenoviruses (AdFAT10). The titer of the viruses 
was assessed by monitoring the number of fluorescence cells after infection with 
serially diluted viral lysates and expressed as expression-forming units/per ml. 
2.10.2 Infection of cell lines with recombinant FAT10 Adenoviruses 
Cells were seeded at about 30% confluence and grown for 24 hours. AdControl 
or AdFAT10 adenoviruses were then added to the cells at a ratio of 20:1 (virus:cells) 
in less medium (2ml per T-25, for example) for 12 hours. Fresh media was then added 
and the cells were incubated for another 36 hours before they were harvested for 
further analysis. 
2.11 Generation and characterization of HCT116 cell-lines stably expressing 
FAT10 
2.11.1 Generation of stable FAT10 expressing HCT116 cell lines 
The Gateway Cloning Technology (Invitrogen, Carlsbad, CA) was utilized to 
clone the FAT10 cDNA downstream of the N-terminal 6XHis-tag peptide of the 
destination vectors pDEST26 (with CMV constitutive promoter) and pT-REx-
DEST31 (with Tet-inducible promoter) to generate pEXPR26-HisFAT10 and 
pTREXPR31-HisFAT10, respectively. 
HCT116 colon carcinoma cells were transfected with pEXPR26-HisFAT10 or 
co-transfected with pTREXPR31-HisFAT10 and pcDNA6/TR (containing the 
Tetracycline repressor (TetR) gene) using Superfect™ Transfection Reagent (Qiagen, 
Hilden, Germany) according to manufacturer’s instructions to generate cells 
expressing FAT10 constitutively or under tetracycline induction. Forty-eight hours 
post-transfection, a 1/100 dilution of cells was seeded into McCoy’s 5A medium 
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(Sigma-Aldrich, St. Louis, MO) containing 10% FCS and 0.7mg/mL G418-sulfate 
(Promega, Madison, WI). Additionally, 1μg/mL Blasticidin (Invitrogen, Carlsbad, 
CA) was added to cells cotransfected with pTREXPR31-HisFAT10 and pcDNA6/TR. 
Cells were then incubated at 37°C in 5% CO2 for approximately 10 days and several 
colonies were selected and analyzed for FAT10 expression by western blot analyses 
using anti-FAT10 antibody (see 2.7). For cells transfected with pTREXPR31-
HisFAT10 and pcDNA6/TR, expression of HisFAT10 was induced for 24 hours with 
2μg/mL tetracycline (Invitrogen, Carlsbad, CA) prior to harvesting for western 
analysis. One clone stably expressing FAT10 constitutively (FAT116) and 3 clones 
stably expressing FAT10 under tetracycline-induction (TetFAT116a, TetFAT116b, 
TetFAT116c) were selected for further analyses. 
2.11.2 Characterization of HCT116 stable cell lines 
The morphology of cells was examined under an Olympus Research Inverted 
microscope (IX51) and images were captured with a Qimaging Retiga 1300R digital 
imager (Qimaging, Tucson, AZ). The growth profile of these cells was determined by 
seeding these cells in 24-well plates.  At various time points as indicated, cells were 
harvested and only viable cells were counted using trypan blue exclusion and a 
hemocytometer. The cell cycle profile was examined by fixing the cells in 2% 
paraformaldehyde, staining them with propidium iodide solution and analyzing the 
stained cells using the FACScaliburTM instrument (BD Biosciences, Franklin Lakes, 
NJ). Apoptotic profile was examined using the Annexin V-PE kit (BD Biosciences, 




HCT 116 cells were infected with either control vector adenoviruses (control) or 
adenoviruses expressing the FAT10 gene (see 2.10). Forty-eight hours later, these 
cells were incubated in media with or without 300ng/ml nocodazole. Twenty hours 
later, the cells were trypsinized, detached and pelleted by centrifugation. 
Immunoprecipitation was performed with protein G-immunoprecipitation kit 
(Roche, Basel, Switzerland). Briefly, pelleted cells were resuspended in lysis buffer 
and lysed by 5 freeze/thaw cycles. Cell debris was removed through centrifugation 
and the protein concentration was determined with BCA protein assay kit 
(Pierce/Thermo Scientific, Rockford, IL) and adjusted to 3mg/ml with lysis buffer. 
600μg of the lysate was mixed with 2μg of either of the following antibodies: p16 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) which served as a non-specific 
rabbit IgG control; p53 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) which 
served as a non-specific mouse IgG control; monoclonal MAD2 antibody (BD 
Biosciences, Franklin Lakes, NJ) and rabbit FAT10 purified polyclonal antibodies 
(see 2.7). The mixture was incubated at 4°C for 5 hours. Then protein G-agarose 
beads were added and the mixture was incubated at 4°C for 15 hours. The 
immunoprecipitated proteins were electrophoresed in 18% SDS-PAGE gel and 
western blot analyses was performed (as described in 2.13) using either FAT10 or 
MAD2 antibodies. 
2.13 Western blot analysis 
The pelleted cells were lysed in PBS by sonication and the protein concentration 
was determined with a protein assay kit (BioRad, Hercules, CA). 20-30μg of protein 
was mixed with loading buffer (appendix D) and boiled for 15 minutes. Treated 
protein samples were electrophoresed in 13% SDS-PAGE gel and then transferred to 
PVDF membrane (BioRad, Hercules, CA). 
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The membrane was blocked for 1 hour at room temperature (block solution in 
appendix D) and then blotted to 0.1μg/ml primary antibody diluted with block 
solution for 1 hour at room temperature. After washing the blot twice with wash 
buffer (appendix D) at room temperature, the membrane was blotted to 1:30000 
diluted horseradish peroxidase (HRP) conjugated secondary antibody (Pierce, 
Rockford, IL) for another 1 hour at room temperature. The membrane was then 
washed for 5x15 minutes and visualized by applying Advanced ECL reagent (GE, 
Piscataway, NJ). The membrane is then exposed on a Kodak® BioMax™ MR film 
(Kodak Inc., Rochester, NY). 
The membrane can be used for the detection of other proteins, using specific 
antibodies after being stripped in strip buffer (appendix D) at 50°C for 15 minutes. 
2.14 Chromosome number analysis 
2.14.1 Cell preparation 
2.14.1.1 Long term growth of stable cells 
G-banded chromosome analysis was performed on HCT116 parental cells, 
FAT116, un-induced parental HCT116, TetFAT116a, TetFAT116b, TetFAT116c and 
tetracycline-induced parental HCT116, TetFAT116a, TetFAT116b and TetFAT116c. 
The parental HCT116 and FAT116 cells have been in continuous culture for 
approximately 11 months with approximately 80 subcultures (i.e. these cells have 
undergone approximately 250 cell doublings). Tetracycline-inducible TetFAT116a, 
TetFAT116b and TetFAT116c cells and parental HCT116 cells were grown in media 
with or without 3 μg/ml of tetracycline supplementation (Sigma-Aldrich, St. Louis, 
MO) for 33 subcultures (or approximately 100 doublings). These cells were re-
selected in 5μg/mL Blasticidin and 0.7 mg/mL G418 before karyotype determination. 
2.14.1.2 Long term TNF-α/IFN-γ treatments on HCT116 cells 
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HCT116 was grown in medium supplemented with (Treated cells) or without 
(control cells) 50ng/ml TNF-α (Invitrogen, Carlsbad, CA, USA) and 50 IU/ml IFN-γ 
(Roche, Indianapolis, IN) for 25 passages. In each passage, both of treated and control 
cells were seeded at 10% confluence and grown in normal medium. On the next day, 
TNF-α/IFN-γ was added to the flask and cells were cultured for 48 hours. The cells 
were then detached and counted and reseeded at 10% confluence for the next passage. 
2.14.2 Sample preparation for chromosome counting 
G-banded chromosome analysis was performed on above mentioned fixed cells. 
Briefly, cells were first synchronized for 17 hours in media containing 3 mM 
thymidine, replaced with fresh medium without thymidine for 7 hours, then treated 
with 0.1μg/ml of colcemid (Invitrogen Gibco, Carlsbad, CA) for 1.5 hours. Cells were 
detached in PBS containing 4mM EDTA and rinsed with PBS without EDTA, 
swelled in 0.06M KCl solution and fixed in a 3:1 methanol:glacial acetate acid mix. 
Fixed cells were dropped onto microscope slides, partially digested with trypsin and 
stained with Giemsa solution (Invitrogen Gibco, Carlsbad, CA). Chromosome 











Chapter 3 Results 
3.1 Candidate genes that may play roles in hepatocellular carcinogenesis 
3.1.1 Differential expression of genes in HCC 
The genome-wide expression profile of 9128 genes was analyzed in 4 paired 
samples of HCC patients using a cDNA microarray approach. Two of the HCC 
patients are chronic carriers of HBV (Figure 3.1B). Good quality RNA, as evaluated 
by clear 28S and 18S rRNA on agarose gel (Figure 3.1A), was extracted from these 
samples. 
The 9128 genes were first filtered to remove genes that had undetectable Cy3 or 
Cy5 signals (<25,000), and subsequently to remove genes that were not differentially 
expressed in all 4 HCC patients. The resulting data set comprised 1019 genes which 
were differentially expressed in at least one of the HCC patients, but only 351 genes 
were differentially expressed in at least 2 HCC patients, and 117 genes in at least 3 
HCC patients. Although each of the HCC patients exhibited 273 to 448 differentially 
expressed genes, only 20 genes were found to be commonly differentially expressed 
in all of the four HCC patients. 
3.1.2 Genes that were commonly underexpressed in HCCs 
In our cDNA microarray analysis, 14 genes were underexpressed in all of the 4 
HCCs (Table 3.1). Most of the 14 downregulated genes encode liver-specific proteins 
like hemopexin and complement component 6, or genes involved in detoxification 
like metallothionein, cytochrome p450 and alcohol dehydrogenase. Another down-
regulated gene, insulin-like growth factor-binding protein 4 (IGFBP-4), plays a 
functional role by interacting with the mitogenic insulin growth factors (IGFs), 
possibly repressing them. IGFs have been implicated in the neoplastic transformation 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































conceivably have tumorigenic consequences. The other two genes which were down-
regulated in our microarray analysis have also been previously linked to 
carcinogenesis. They are betaine-homocysteine methyltransferase which plays a role 
in methionine metabolism, and retinol-binding protein 4 which regulates the effects of 
retinoids on cell growth, differentiation and apoptosis (Avila et al., 2000; 
Kuppumbatti et al., 2000) (Table 3.1). 
3.1.3 Genes that were commonly overexpressed in HCCs 
The expressions of 6 genes were found to be up-regulated in all 4 HCC patients 
(Table 3.2). A number of these genes have been previously reported to play roles in 
carcinogenesis. The GSK-3 binding protein FRAT2, for example, is an upstream 
repressor of glycogen-synthase-kinase-3 (GSK-3) in the Wnt signaling pathway (Farr 
et al., 2000). GSK-3 in turn regulates β-catenin function. Hence deregulation of GSK-
3 may play a role in the tumorigenesis of many cancers. Consequently, FRAT2 up-
regulation in HCC patients could be involved in tumorigenesis by interfering with the 
function of β-catenin. Indeed, the up-regulation of another known GSK-3 inhibitor, 
GSK-3 binding protein (GBP), has been found to be oncogenic in Xenopus (Yost et 
al., 1998). Another up-regulated gene, chaperonin containing TCP1 (CCT), is a 
hetero-oligomeric complex involved in protein folding. The up-regulation of a 
functionally related protein, the 60kD heat-shock protein (HSP-60), has been 
previously identified as prognostic marker for ovarian carcinomas (Kimura et al., 
1993). 
There were a number of up-regulated genes that were less well understood with 
regards to their roles in tumorigenesis. For example, our microarray results show that 








































































































































































































































































































































































































































While this is in agreement with similar results previously reported (Honda et al., 
2001), other studies have contrastingly postulated that the loss of p16 function is an 
early event in tumor progression and is essential for tumor growth (Myohanen and 
Baylin, 2001). Another controversial observation is that glucocerebrosidase is down-
regulated in HCC. Some studies have reported the overexpression of 
glucocerebrosidase in liver cancer (Luft, 1998) but other conflicting reports have 
opined that the observed overexpression could in fact be due to the expression of 
several peudogenes with close homology to the functional glucocerebrosidase gene 
(Martinez-Arias et al., 2001). In addition, an un-identified cDNA fragment EST was 
also found upregulated in all 4 HCCs. Further work needs to be done to characterize 
this gene. 
Among the 20 genes whose expression were commonly deregulated in all of the 
4 HCCs, we found FAT10, which was overexpressed in HCCs (Table 3.2), to be of 
particular interest to us for further characterization for three reasons: Firstly, its 
physiological role in the cell was poorly characterized. Secondly, although no link 
was drawn between FAT10 and tumorigenesis at the time when we identified this 
gene, a tentative link to cell-cycle physiology was drawn by FAT10’s reported ability 
to bind the cell cycle checkpoint protein MAD2 (Liu et al., 1999) and thirdly, FAT10 
transcript level was greatly elevated in cell lines treated with cytokine TNF-α (Raasi 
et al., 1999). TNF-α was detected at high levels in the serum of liver disease patients 
(Chen et al., 2007; Gonzalez-Reimers et al., 2007; Kiki et al., 2006) and HCC patients 
(Nakazaki, 1992) which is suggestive of its potential role to promote chronic 




3.2 FAT10 is overexpressed in various cancers 
3.2.1 FAT10 is over-expressed in HCC tissue 
To validate the microarray data of FAT10 (Table 3.2), we performed Northern 
blot analysis on 23 pairs of tumor and adjacent non-tumorous samples from HCC 
patients, including the 4 pairs of HCC samples that were used in cDNA microarray 
analysis (patient A-D in Figure 3.2), to examine the levels of FAT10 gene expression 
in HCC. A 1 kb band representing FAT10 mRNA was detected in 21 of the 23 HCC 
samples. Nineteen of the 21 patients (90%) showed up-regulation of FAT10 
expression in tumor tissue (Figure 3.2). Notably, Northern blot results of samples 
from patients A to D were fully consistent with the microarray data.  
To examine the cell-type specificity of FAT10 expression in HCC liver tissue, in 
situ hybridization (Figure 3.3) using antisense FAT10 riboprobes as well as 
immunohistochemistry (Figure 3.4) utilizing anti-FAT10 antibodies that we generated 
was performed on cryo-sections of liver tissue from HCC patient #10 (Figure 3.2). As 
evident in Figure 3.3D, high levels of FAT10 transcript were detected primarily in 
hepatocellular carcinoma cells in tumors, with low and scattered signals in other cell-
types surrounding the HCC cells, including immune cells. 
Similarly, FAT10 protein was localized to the nuclei of HCC cells, and not other 
cell types around the HCC cells. Interestingly, high level of FAT10 protein was not 
detected in all HCC cells (Figure 3.4A). In the paired adjacent non-tumorous liver 
tissue from the same patient, FAT10 transcripts and protein were undetectable (Figure 
3.3H and Figure 3.4B). 
3.2.2 FAT10 is also over-expressed in other cancers 
To examine if FAT10 was also differentially expressed in cancers other than 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































representative paired tumor/normal tissues from several different cancers (Cancer 
Profiling Array, CPATM, Clontech). The expression levels of FAT10 were 
consistently low in non-tumorous tissues but were up-regulated in the majority of 
paired tumor samples (Figure 3.5A). Notably, FAT10 was consistently up-regulated 
in the tumors of the majority of patients with cancers of the gastrointestinal and 
female reproductive system (Figure 3.6). In addition, FAT10 was also up-regulated in 
the single cervical cancer, single pancreatic cancer, and two intestinal cancer samples 
represented on the array (Figure 3.5A). The other cancers represented on the array 
(e.g. kidney, thyroid, etc) did not show consistent up- or down-regulation of FAT10 
gene expression (Figure 3.5A, Figure 3.6). 
In contrast to the FAT10 findings, expression of ubiquitin was uniform across 
all normal and tumor types represented on the array (Figure 3.5B). 
3.2.3 Normal FAT10 expression is tissue specific 
To study the tissue-specific distribution of FAT10 in normal tissue, FAT10 
cDNA was labeled and hybridized to another array blot containing 76 different pooled 
normal tissue types (Multiple Tissue Array, MTETM, Clontech). FAT10 expression 
was detected in a number of different tissues including the gastrointestinal system, 
kidney, lung and prostate gland. In contrast, tissues from the brain and adrenal gland 
did not show any detectable signals (Figure 3.7). 
To examine the relation of FAT10 expression to tissue development, we 
classified the tissues in Figure 3.7 according to their embryonic origin (Table 3.3). 
Ectodermal-derived tissues like the brain did not show detectable expression of 
FAT10. However, FAT10 was consistently detected in tissues of endodermal origin, 
with expression levels highest in tissues of the reticuloendothelial system (e.g. 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Signal Intensity (arbitrary units)
D
60
Table 3.3  Tabular representation of the expression of FAT10 in the 
various tissues categorized by system as well as embryonic origin.








Heart (Atrium-right, ventricle-left & right, 
interventricular septum, apex of heart -
Heart (Atrium-left, aorta) +































(-) denotes that FAT10 expression is undetectable in the tissue.  (+) denotes that FAT10 is expressed at low levels in the tissue.  (++) 
denotes that FAT10 is expressed at moderate levels in the tissue.  (+++) denotes that FAT10 is expressed at high levels in the tissue. 
* Regions of brain that were tested include: cerebral cortex, frontal, parietal, occipital & temporal lobe, paracentral gyrus of
cerebral cortex, pons, cerebellum-left & right, corpus callosum, amygdala, caudate nucleus, hippocampus, medulla oblongata, 
putamen, substantia nigra, nucleus accumbens, thalamus
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 We further compared FAT10 expression levels in fetal and adult tissues (Figure 
3.7D). There was no difference between fetal and adult tissues of the 
reticuloendothelial system, and no detectable expression in both fetal and adult brain 
and heart.  Interestingly, a higher expression was observed in fetal compared to adult 
liver, while adult kidney showed higher expression compared with fetal kidney. 
These results suggest that normal FAT10 expression is both developmentally 
and tissue-specifically regulated. 
3.2.4 FAT10 protein is localized in the nucleus of cells 
To begin to understand the role of FAT10 in tumorigenesis, the subcellular 
localization of the FAT10 protein in cells was evaluated through different approaches. 
In the first approach, the subcellular localization of a chimeric FAT10-
fluorescent protein that was introduced into the cell was examined. FAT10–DsRed 
fusion construct (pCMVFATDsRed) or its parental construct (pCMVDsRed) was 
introduced into human liver cell line WRL68 (Figure 3.8). Cells transfected with 
pCMVDsRed (negative control) exhibited uniform fluorescence in the nucleus and 
cytoplasm, whereas cells transfected with pCMVFATDsRed fusion construct showed 
intense red fluorescence only in the nucleus, indicating FAT10 protein localization to 
the nucleus (Figure 3.8B). 
One criticism of the above approach is that since FAT10 is fused to another 
protein, the conformation of the FAT10 protein may change and the subcellular 
localization may be influenced by the other protein. Hence the subcellular localization 
of the FAT10 protein was also determined using exogenously introduced non-
chimeric FAT10.  Control adenoviruses or recombinant adenoviruses expressing 




























































































































































































































































































































































Phase Contrast Anti-FAT10 Ab
C
Figure 3.9 FAT10 is expressed in the nuclei of cells. (A) Maps of constructs used for the
generation of the recombinant adenoviruses (AdVector – vector control; AdFAT10 – FAT10-expressing 
adenoviral construct). (B) Western blot analyses of either uninfected NIH3T3 cells (uninfected control) or 
NIH3T3 cells infected with either the control adenoviruses (AdVector infected) or FAT10-expressing 
adenoviruses (AdFAT10 infected). Anti-FAT10 antibodies were used at a concentration of 0.1 mg/ml. (C) 
Immunofluorescence localization of FAT10 protein in NIH3T3 cells. NIH3T3 cells were infected with 
either AdVector (upper panels) or AdFAT10 (lower panels) adenoviruses. Left panels represent phase 
contrast depiction of NIH3T3 cells, while right panels represent either NIH3T3 infected with AdVector or 
AdFAT10 adenoviruses probed with anti-FAT10 antibodies.
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NIH3T3, and Western blot analyses and immunofluorescence analyses utilizing anti-
FAT10 antibodies were performed. Figure 3.9B confirms the expression of FAT10 
protein in NIH3T3 cells infected with AdFAT10 adenoviruses. As demonstrated in 
Figure 3.9C, the FAT10 protein was localized to the nucleus of cells infected with 
AdFAT10 adenoviruses.  The nuclear localization of FAT10 was further confirmed in 
HCT116 cells stably expressing the FAT10 gene (Figure 3.11B). 
The subcellular localization of endogenous FAT10 was then determined. The 
endogenous expression of FAT10 in non-tumorous (Figure 3.4B) or uninduced cells 
(Figure 3.10A) is very low.  Nonetheless, it was reported that FAT10 expression can 
be induced by TNF-α (Raasi et al., 1999).  When colon cancer SW620 cells were 
induced with 100 ng/ml of TNF-α, FAT10 expression was detected in Western blot 
analysis (Figure 3.10A) and FAT10 was found to be expressed in the nuclei of these 
cells (Figure 3.10B).  Finally, as shown earlier in Figure 3.4A, immunostaining of the 
tumor of HCC patient with FAT10 antibodies further confirm that FAT10 is 
expressed in the nucleus of HCC tumors but not the adjacent non-tumorous tissues. 
3.3 FAT10 plays a role in the regulation of chromosomal stability 
3.3.1 Cells stably over-expressing FAT10 have similar growth, cell-cycle and 
apoptotic profiles as parental cells 
We generated and characterized the HCT116 cell-line stably over-expressing 
FAT10 named FAT116. FAT116 cells were found to express high levels of the 
FAT10 protein as shown by Western blot analyses (Figure 3.11A). In addition, as 
mentioned in 3.2.4, the FAT10 protein was found to localize in the nucleus of these 
FAT116 cells through confocal microscopy (Figure 3.11B). 
Morphology (Figure 3.12A) and growth properties (Figure 3.12C) of FAT116 
















Figure 3.10 Endogenous FAT10 localizes in the nucleus. SW620 cells were 
grown in medium with or without 100ng/ml TNF-α for 15 hours and then fixed 
for immunofluorescence staining. (A) Western analysis showed FAT10 
expression was induced by TNF-α treatment. (B) The fixed cells were stained 
with primary anti-FAT10 and secondary Alexa Fluor® 488 Chicken Anti-rabbit 
























































































































































































































































































































































































































































































































































































































































































of FAT10 in FAT116 cells also did not alter the general cell-cycle (Figure 3.12B) or 
apoptotic (Figure 3.12D) profiles significantly. 
We also analyzed three different clones of HCT116 cells expressing FAT10 
under a tetracycline-inducible promoter (TetFAT116a, TetFAT116b, and 
TetFAT116c). Western result shows that upon tetracycline induction, FAT10 
expression is greatly increased (Figure 3.13). 
3.3.2 FAT10 interacts and localizes with MAD2 during mitosis 
We hypothesized that since FAT10 was reported to interact with MAD2 (Liu et 
al., 1999), it might play a role in the regulation of mitosis. We thus evaluated if there 
was interaction between FAT10 and MAD2 during mitosis using co-
immunoprecipitation assays. We were unable to detect the FAT10 protein in the anti-
MAD2 immunoprecipitate or vice versa in unsynchronized cells where majority of the 
cells are in the G1 phase (Figure 3.14, untreated). Notably, when these cells were 
arrested at mitosis with nocodazole, MAD2 was detected in the anti-FAT10 or anti-
MAD2 immunoprecipitate in FAT10-expressing HCT116 cells and in control cells, 
MAD2 was only detected in anti-MAD2 but not anti-FAT10 immunoprecipitate 
(Figure 3.14, nocodazole treated). Consistently, FAT10 was detected in anti-MAD2 or 
anti-FAT10 immunoprecipitate of only nocodazole-treated FAT10-expressing 
HCT116 cells (Figure 3.14, nocodazole treated). Neither FAT10 nor MAD2 was 
detected when cells were co-immunoprecipitated with non-specific control antibodies 
(Figure 3.14). These results confirm Liu’s observations (Liu et al., 1999) that MAD2 
and FAT10 are capable of interaction and we demonstrate that the interaction occurs 
during mitosis. 
Although FAT10-MAD2 interaction is detected during mitosis, MAD2 level is 

















































































































































































































































































































































































































































































































































































































FAT10 does not lead to MAD2 degradation even though it is reported to be activated 
by an E1-like protein which can also activate the ubiquitin pathway (Chiu et al., 
2007). 
3.3.3 FAT10 and MAD2 co-localize during mitosis 
To further understand why FAT10-MAD2 interaction is only detected during 
mitosis, we stained asynchronous FAT116 cells with DAPI to determine the cell-cycle 
stage of the cells, as well as with anti-FAT10 and anti-MAD2 antibodies to determine 
the localization of these two proteins in the same cells using confocal microscopy. As 
shown clearly in Figure 3.15, FAT10 localizes primarily to the nucleus while MAD2 
localizes to the cytoplasm during interphase (Figure 3.15, 1st column). During 
different stages of mitosis when the nuclear membrane breaks down, FAT10 and 
MAD2 co-localize around the condensed DNA (Figure 3.15, 2nd to 6th column). 
3.3.4 Localization of MAD2 at the kinetochore is greatly reduced in FAT10 over-
expressing cells 
To further determine the localization of MAD2 in FAT10 over-expressing cells, 
we generated a construct, pMAD2EGFP, whereby the MAD2 gene is fused with the 
enhanced green fluorescent protein (EGFP) gene (Figure 3.16A). We then transfected 
this construct as well as the vector control construct not containing MAD2, pEGFP, 
into either the parental HCT116 or the FAT116 cells and demonstrate through 
Western analyses that the EGFP and MAD2-EGFP fusion proteins could be expressed 
(Figure 3.16B). 
As shown in Figure3.17, in cells that did not receive the pEGFP or 
pMAD2EGFP construct, no fluorescence was observed (Figure 3.17A, 1st column of 








































































































































































































































































































































































































































































































































































































































































either the parental HCT116 or FAT116 cells, the EGFP fluorescence signal was 
diffused throughout the cell (Figure 3.17A, left two panels). When the construct, 
pMAD2EGFP, was transfected into the parental HCT116 cells, the MAD2-EGFP 
fusion protein seems to accumulate as strong punctate signals at the kinetochores 
during the prometaphase but not the metaphase stage of the cell-cycle (Figure 3.17A, 
top right panel). This observation is consistent with the reported localization of 
MAD2 during mitosis (Waters et al., 1998). Interestingly, in FAT10-overexpressing 
FAT116 cells, the MAD2-EGFP fusion protein appears diffuse whether the cells are 
in the prometaphase or metaphase stage of the cell-cycle (Figure 3.17A, bottom right 
panel). Statistically significant (P<0.01) reduction in the punctuate signals at the 
kinetochores were observed in the prometaphase stage in FAT10-expressing cells 
compared to parental HCT116 cells (Figure 3.17B). Taken together, these results 
suggest that MAD2 localization at the kinetochore is greatly reduced in FAT10 over-
expressing cells during the critical prometaphase stage of the cell-cycle. 
These observations are consistent with the results obtained when HCT116 and 
FAT116 cells were stained with anti-FAT10, anti-MAD2 antibodies and DAPI 
(Figure 3.18). As shown in Figure 3.18A, in parental HCT116 cells where FAT10 
expression is negligible, MAD2 aggregated at the kinetochores during the 
prometaphase stage of the cell-cycle. However, when the FAT10 gene was over-
expressed in FAT116 cells, MAD2 aggregation at the kinetochores was significantly 
reduced (p<0.01) (Figure 3.18B). 
Hence, FAT10 interaction with MAD2 during mitosis may decrease the 
efficiency of binding of MAD2 to the unattached kinetochore although it does not 































































































Figure 3.17 MAD2EGFP localization during prometaphase is altered in FAT10-overexpressing cells.
(A) EGFP or MAD2-EGFP fluorescence (row 1 of each panel) or fluorescence from cells stained with 
DAPI (row 2 of each panel) or composite of EGFP or MAD2-EGFP and DAPI fluorescence (row 3 of 
each panel). The first column of each panel shows the low magnification view, where transfected and 
untransfected cells are present. Untransfected cells were found not to be fluorescent. (B) Quantitation of 
punctuate signals in prometaphase I and II in HCT116 and FAT116 cells. n, the number of bright spots 
quantitated. **, statistical significance at p< 0.01.
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Figure 3.18 Localization of native MAD2 is altered during prometaphase in FAT10-
overexpressing cells. (A) Images showing immunofluorescence staining results of HCT116 or 
FAT116 cells with anti-FAT10 and anti-MAD2 antibodies. Prometaphase HCT116 (top panels) and 
FAT116 (bottom panels) cells were stained with DAPI (blue), anti-FAT10 (red), and anti-MAD2 
(green) antibodies. (B) Quantitation of punctuate signals in prometaphase HCT116 and FAT116 cells 
stained with anti-MAD2 antibodies. n, the number of bright spots quantitated. **, statistical 
significance at p< 0.01.
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insufficiency is sufficient to cause premature anaphase and chromosome instability 
(Michel et al., 2001), it will be interesting to investigate whether overexpressed 
FAT10 may be able to influence cell cycle progression, especially during mitosis. 
3.3.5 FAT10 over-expression results in an abbreviated mitotic phase 
Since FAT10 interacts and reduces the kinetochore localization of MAD2 
during mitosis, and since MAD2 is a mitotic checkpoint protein (Yu, 2006), we 
examined the effect of over-expression of FAT10 on cell-cycle regulation and 
especially on mitosis. 
First, we synchronized un-induced and induced HCT116 cells stably expressing 
FAT10 under tetracycline-inducible promoter (TetFAT116c) at G1/S phase using 
double-thymidine treatment. These cells were released into medium containing 
nocodazole so that they are arrested at mitosis (Figure 3.19A). At each time point 
after being released from thymidine treatment the cells were harvested and stained 
with mitosis-specific antibody MPM-2 (Upstate, Lake Placid, NY) (Figure 3.19B) to 
check the mitotic index. As shown in Figure 3.19C, more cells were arrested at 
mitosis as time progresses. Approximately 5% of both un-induced and tetracycline-
induced TetFAT116c cells entered mitosis at 4h after release from G1/S. However, at 
each time point after 4h, approximately 10% more un-induced cells (no FAT10) were 
arrested at mitosis than tetracycline-induced cells (FAT10 overexpressed) (Figure 
3.19D). These results suggest that there may be a delay in entrance into mitosis in 
FAT10-overexpressing cells. However, it is also possible that the observed reduction 
in mitotic FAT10-expressing cells may be a consequence of these cells escaping M-
phase and reverting to interphase with a tetraploid G1 DNA content. 
To exclude the second possibility, we performed another experiment to evaluate 




































































































































































































































































































































































































































































































































































experiment, thymidine synchronized cells were released to normal culture medium so 
that cell cycle might progress through G2 phase and mitosis and then enter next G1 
phase (Figure 3.20A, B). Figure 3.20C shows that re-entry of cells into G1 phase from 
their arrest at G1/S was similar between uninduced and tetracycline-induced 
TetFAT116c cells, despite the delayed entry into mitosis of FAT116 and tetracycline-
induced Tet-FAT116 cells (Figure 3.19D). 
When data from the two experiments were combined and analyzed together, we 
found that the difference between the uninduced and induced TetFAT116c cells in 
time of entry into mitosis is significantly greater (p<0.05) than their corresponding 
difference in time of reentry into G1 (Figure 3.21A). Taken together, these data 
suggest both a delayed and an abbreviated mitotic phase in cells over-expressing 
FAT10 (Figure 3.21B). 
The results were consistent when we repeated the experiments with HCT116 
parental cells, and FAT116 cells which stably express FAT10 constitutively (Figure 
3.22). 
3.3.6 FAT10 over-expression results in greater escape from mitotic arrest and 
more multinucleate cells 
To address the effect of FAT10 over-expression on mitosis, parental HCT116 
and FAT116 cells were treated with 200 ng/ml nocodazole for 8 h. Mitotic cells were 
then shaken off and replated in media containing 200 ng/ml nocodazole for another 15 
h. The doubling time for both HCT116 and FAT116 cells is approximately 15 h. We 
found more adherent FAT116 (>20%) than HCT116 (6.5%) cells (Figure 3.23A, B). 
This result suggested that more FAT116 cells either failed to arrest or escaped mitotic 
arrest and continued to cycle. To rule out the possibility that the observed increase in 



































Figure 3.20 FAT10 over-expression does not influence re-entry into G1 in G1/S 
synchronized TetFAT116 cells. (A) Schematic representation of experiment design. 
Cells were arrested at G1/S phase by double thymidine treatment and then were grown 
in normal medium. These cells were then harvested at the indicated time points and 
stained with propidium iodide for cell cycle profile determination. (B) Representative 
fluorescence-activated cell sorting profile of cell cycle stage determination showing 
DNA of HCT116 cells stained by propidium iodide. Control denotes unsynchronized 
cells. (C) A graph to show at each time point similar number of FAT10 overexpressing 
cells (Induced) enter G1 phase compared to control cells (uninduced). The cells were 







































































































































































































































































































































































































































































Time after release (hours)
HCT116
FAT116
Figure 3.22 FAT10 overexpression results in abbreviated mitosis in FAT116. Parental HCT116 and 
stable FAT116 cells were arrested at G1/S phase by double thymidine treatment and then released to 
medium with (A) or without (B) 300 ng/ml nocodazole. These cells were then harvested at the indicated 
time points for mitotic index (MPM2 staining, A) or cell cycle stage (propidium iodide staining, B) 
determination, respectively. (A) A graph to show at each time point fewer FAT116 cells enter mitosis 
compared to HCT116 cells. (B) At each time point similar number of FAT116 cells  enter G1 phase 
compared to HCT116 cells. (C) Difference in percentage of mitotic cells (open squares) and G1 phase 
cells (closed squares) between HCT116 cells and FAT116 cells. The values are shown as means  S.E. of 



























cells, the mitotic index of the reattached HCT116 and FAT116 cells after shake-off 
was determined. As shown in Figure 3.23C, greater than 95% of the reattached cells 
were mitotic cells, and the percentage of interphase cells was small and similar 
between the HCT116 and FAT116 cells. 
Upon prolonged exposure to nocodazole (54 h), most of the HCT116 and 
FAT116 cells died. Of the cells that reattached, more FAT116 cells (~40%) showed 
abnormal nuclear morphology and were multinucleated (Figure 3.24) compared with 
the attached parental HCT116 cells (~5%). 
Both of these results indicate that overexpression of FAT10 directly affects 
mitosis in cells and may cause dysfunction of mitotic checkpoint functions and result 
in occurrence of premature anaphase. 
3.3.7 FAT10 over-expression results in numerical chromosome instability 
We next examined if overexpression of FAT10 affects chromosome stability. 
Parental HCT116 cells were reported to have a relatively stable karyotype (45,X), 
with aneuploid cells occurring at only ~6.8% (Michel et al., 2001). HCT116 and 
FAT116 cells were grown in culture for about 11 months (~80 passages), which is 
equivalent to ~250 cell doublings, before they were harvested for chromosome 
analyses (Figure 3.25A). As shown in the Table in Figure 3.25B, the parental 
HCT116 cell-line is itself aneuploid, with a modal chromosome number of 45 and the 
overwhelming majority of cells (82%) having 40-49 chromosomes per cell. None of 
the parental HCT116 cells contain more than 100 chromosomes. On the other hand, 
the majority of FAT116 cells (70%) carry 80-89 chromosomes, with 5% of these cells 
having more than 100 chromosomes. Thus, constitutive FAT10 over-expression 
increases aneuploidy in HCT116 cells. It is possible that the increased chromosome 
































































































































































































































































































































































































































































































































































































































































































whereby in that particular clone, the pEXPR26-HisFAT10 plasmid was introduced 
into a HCT116 cell already containing 80-89 chromosomes, which is the case in 
~4.2% of parental cells. 
To rule out clonal artifact, we also analyzed the parental HCT116 as well as 3 
different clones of HCT116 cells expressing FAT10 under tetracycline-inducible 
promoter (TetFAT116a, TetFAT116b and TetFAT116c). Upon tetracycline induction, 
FAT10 expression is greatly increased in all three clones (Figure 3.13). Uninduced 
and tetracycline-induced parental HCT116 and TetFAT116a-c cells are grown for 
approximately 100 population doublings (33 passages) with media changes every 
three days, after which chromosomal analysis was performed. Approximately 84% of 
parental HCT116 cells contain relatively normal chromosome numbers of 40-49 
whether they were treated with tetracycline or not (Figure3.25B). In contrast, when 
cells were not treated with tetracycline, 87-96% of Tet116a-c cells were found to 
contain relatively normal chromosome numbers of 40-49 in all three clones. However, 
in the same 3 clones induced with tetracycline, only between 43-56% of cells carry 
40-49 chromosomes, with the remaining cells carrying either more or fewer 
chromosomes (Figure 3.25B). Notably, for all three clones, between 2.5 and 4% of 
tetracycline-induced cells were observed to contain more than 100 chromosomes. 
This was not observed in uninduced TetFAT116 cells, uninduced or tetracycline-
induced parental HCT116 cells (Figure 3.25B). 
Statistical analysis shows that chromosomal status in tetracycline-treated stable 
clones (FAT10 overexpressed) is significantly different from untreated clones (no 

































































































































































































































































































































































































































































































































































































































































































































































































































3.4 Endogenous FAT10 expression is induced through TNF-α/NF-kB pathway 
To further understand the upregulation of FAT10 gene in cancers, we 
investigated the possible mechanisms underlying the regulation of FAT10 expression. 
Pro-inflammatory TNF-α and IFN-γ have been reported to be able to elevate FAT10 
transcript levels in different cells (Raasi et al., 1999) and high levels of TNF-α are 
always observed in the serum of HCC patients (Ataseven et al., 2006; Wang et al., 
2003). In addition, TNF-α was suggested to promote inflammation-associated 
carcinogenesis by activating NF-κB pathway (Pikarsky et al., 2004). Thus we 
proceeded to investigate whether FAT10 protein expression can be increased in the 
presence of TNF-α, as well as whether the NF-κB pathway plays a role in regulating 
FAT10 expression. 
3.4.1 TNF-α induces endogenous FAT10 expression in various cell lines 
As shown in Figure 3.27, in the human colon cancer cell line SW620, FAT10 
expression was found to be significantly induced by recombinant human TNF-α 
treatment. Another cytokine human IFN-γ cannot induce FAT10 overexpression by 
itself but it can greatly enhance the effect of TNF-α in the regulation of FAT10 
expression (Figure 3.27A). The effect of TNF-α in combination with IFN-γ on FAT10 
expression can be detected in various cell lines including SV40 large T antigen 
immortalized primary normal liver cells THLE-3 (AATC product number CRL-
11233), but not in primary cultures of T-cells isolated from cord blood (Figure 
3.27B). In SW620 and the human kidney embryonic cell line 293, TNF-α alone can 
induce FAT10 protein expression but in THLE3 and the colon cancer cell line 




























Figure 3.27 TNF-α induces endogenous FAT10 expression in various cell lines. Cells 
were grown to about 60% confluece and then treated with TNF-α and/or IFN-γ at the 
indicated concentrations for 24 hours before being harvested for western analysis against 
anti-FAT10 antibody. (A) About 18kD FAT10 protein can be detected in TNF- α treated 
SW620 cells. (B) FAT10 expression in various cells under TNF-α and/or IFN-γ treatment.
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In addition, the effect of TNF-α and IFN-γ on FAT10 expression is dosage related, 
but beyond a certain concentration (10ng/ml TNF-α/20U/ml IFN-γ), a higher dose of 
the cytokines does not further affect FAT10 expression (Figure 3.28). 
We found that FAT10 protein level dramatically decreased 24 hours after the 
withdrawal of TNF-α, indicating that the effect of TNF-α on FAT10 is transient 
(Figure 3.29A). On the other hand, high level of FAT10 can be detected in cells as 
long as TNF-α is present in the medium (Figure 3.29B). The data suggests that high 
level of FAT10 expression in cells may only persist under constitutive TNF-α 
treatment. It also implies that the FAT10 protein is not stable and degrads rapidly. 
3.4.2 TNF-α up-regulates FAT10 expression through the NF-κB pathway 
To investigate whether NF-κB mediates TNF-α’s effect on FAT10 expression, 
we transfected siRNA to suppress NF-κB subunit p65 protein (also known as RelA) 
level (Figure 3.30). Figure 3.30B shows FAT10 expression can be induced by TNF-
α/IFN-γ treatment in control siRNA transfected THLE-3 cells. However, transfection 
of siRNA against FAT10 siRNAs dramatically suppresses FAT10 protein level. 
Transfection of siRNA against p65 can eliminate both of phosphorylated and native 
p65 proteins efficiently. Meanwhile, in p65 siRNA transfected cells, FAT10 
expression is not induced by TNF-α/IFN-γ stimulation (Figure 3.30B). The results 
obtained from HCT116 cells are consistent with that in THLE-3 cells (Figure 3.30C). 
These data indicates NF-κB plays important functions in the regulation of FAT10 












































































































































































Figure 3.29 Induction of endogenous FAT10 expression depends on continuous existence of 
TNF-α. (A) SW620 cells grown at ~50% confluence were treated with TNF-α with/without IFN-
γ for 15 hours. The cells were then grown in normal medium without cytokine supplements and 
harvested at the indicated timepoint for western blot analysis. Timing was started at the time when 
cytokines were withdrawn. (B) SW620 cells grown at ~50% confluence were grown in medium 
supplemented with 50ng/ml TNF-α for indicated time and harvested for western analysis. Timing 
was started at the time when TNF-α was added. “no TNF-α” refers to control cells which were 



































































































































































































































































































































































































































































































































































3.4.3 Prolonged TNF-α/IFN-γ treatment induces numerical chromosomal 
instability in HCT116 
Since it has been reported that long term TNF-α treatment could induce 
chromosomal instability (CIN) including numerical changes in human leukemic cells 
(Beyne-Rauzy et al., 2004), we next investigate whether TNF-α might also induce 
CIN in HCT116 cells. As endogenous FAT10 could only be detected in HCT116 cells 
treated with TNF-α/IFN-γ (Figure 3.27B), these cells were grown in TNF-α/IFN-γ 
supplemented medium for 25 passages and then harvested for chromosome number 
count. As shown in Figure 3.31, long-term treatment with TNF-α/IFN-γ was found to 
lead to chromosomal instability. The number of cells that still retain the modal 
number of about 45 as observed in untreated HCT116 is greatly reduced after TNF-
α/IFN-γ treatment. On the other hand, treated cells had a higher frequency of aberrant 
chromosome number (more than fifty or fewer than 40 chromosomes). Notably, about 
10% of TNF-α/IFN-γ treated cells have more than 100 chromosomes, which was not 
observed in untreated HCT116 cells (Figure 3.31). The chromosome number profile 
in long term TNF-α/IFN-γ treated HCT116 cells was similar to that in FAT10 



















































































































































































































Chapter 4 Discussion 
4.1 The identification of candidate genes that may play roles in tumorigenesis 
Tumorigenesis is a multistage process that involves a series of genetic and 
epigenetic alterations, such as the activation of dominantly acting oncogenes and     
inactivation of tumor-suppressor genes (Brumby and Richardson, 2005; Wu and 
Pandolfi, 2001). Identification of those genes whose expression is deregulated in 
tumors may greatly help in our understanding of the molecular mechanisms 
underlying the development of HCC. To accomplish this purpose, various methods 
such as northern blots (Alwine et al., 1977), S1 nuclease protection (Dimitrov, 1997), 
differential display (Liang and Pardee, 1992), sequencing of cDNA libraries (Okubo 
et al., 1992), serial analysis of gene expression (SAGE) (Velculescu et al., 1995) and 
subtractive hybridization (Blumberg and Belmonte, 1999) have been employed. The 
cDNA micaroarray technique which was first reported in 1995 (Schena et al., 1995), 
facilitates high-throughput simultaneous comparisons to obtain a global gene 
expression profile (Duggan et al., 1999). In recent years, the cDNA microarray 
technique has been commonly applied to broader areas of research, such as tumor 
classification and prediction of clinical outcomes, identification of genes involved in 
various diseases, cellular processes, or elucidation of biological pathways in response 
to external stimuli (Bucca et al., 2004; Mah et al., 2004). Currently more than 47400 
transcripts derived from 38500 human genes can be analyzed in a single array 
(Lemmer et al., 2006). 
In our experiment, we used IncyteGenomics UniGEM V2.0 microarray to 
analyze gene expression profiles in HCC. The expression patterns of certain 
commonly studied genes were found to be consistent with previous reports. For 
example, metallothionein and cytochrome p450 (Table 3.1) are also found to be 
 98
down-regulated in HCC in other microarray analyses (Okabe et al., 2001). Moreover, 
by doing real time RT-PCR or northern blotting we have confirmed the results from 
microarray analysis of many genes including FAT10 (Lee et al., 2003) and Cyr61 
(Wang et al., 2005). All these facts indicate that our microarray assay is replicable and 
consistent at some level and the data are valuable for the preliminary identification of 
candidate molecules for further investigation to elucidate the mechanisms of 
tumorigenesis. 
We analyzed the expression profile of 9128 genes in 4 paired samples of HCC 
patients. In each patient, we found that several hundred genes were deregulated in 
tumors (Figure 3.1). This result suggests that the alteration of gene expression in 
cancer is very complicated and it is a big challenge to identify critical molecules to 
elucidate mechanism in tumorigenesis from so many candidates. 
We have identified a total of 1019 genes (11.17% of genes on chip) that were 
differentially expressed in at least one of the 4 HCC samples, but only 20 of those 
genes were found to be differentially expressed in all 4 HCC patients (Table 3.1, 
Table 3.2). This large gap in numbers reflects the substantial variation in expression 
profiles between the different developmental modalities and stages of HCC (Okabe et 
al., 2001). These 20 genes are therefore significant for our understanding of common 
events in HCC tumorigenesis which are non-stage specific. Notably many of these 
genes are involved in carcinogenesis. For example, most of the 14 genes that were 
downregulated in the tumors of HCC patients encodes for hepatic-specific (i.e. 
hemopexin, complement component 6) or detoxification (metallothionein, cytochrom 
P450, alcohol dehydrogease etc) proteins (Table 3.1), indicating the de-differentiation 
of the liver cancer cells (Okabe et al., 2001). The down-regulation of proteins that 
mediate detoxification in the liver also suggests that the potential carcinogenic role of 
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alcohol and the DNA damaging effects of heavy metals such as chromium (Ashmarin 
et al., 2000; Bourdon and Blache, 2001; Sugden and Stearns, 2000). Downregulation 
of these genes may make cells more susceptible to carcinogenesis. 
In addition to the detoxification proteins, some other genes in Table 3.1 and Table 
3.2 are also well-known players in cancer development, such as insulin-like growth 
factor-binding protein 4 (IGFP) (Durai et al., 2007), betaine-homocysteine 
methyltransferase (Ji et al., 2007) and GSK-3 binding protein (Jin et al., 2008). We 
also encountered a class of genes whose participation in HCC tumorigenesis was less 
clear, if not unknown, for example, chaperonin containing TCP1 (CCT), β-
glucosidase, EST (BF131551) and FAT10. Further investigation into these genes may 
assist in our understanding of HCC development. 
In addition, the products of some genes in Table 3.1 and Table 3.2 are serum 
proteins, including complement component 6, insulin-like growth factor-binding 
protein 4, retinol-binding protein 4 and acid beta-glucosidase. These could represent 
potential serum biomarkers for the diagnosis and/or prognosis of HCC. 
The choice of candidate genes for further characterisation was based on a few 
criteria: Firstly, the expression of the candidate gene should be deregulated in all of 
the HCC patients examined in the microarray assay. Secondly, the physiological 
functions of the candidate gene in tumorigenesis should preferably not be well 
characterized. Thirdly, the candidate gene should have potential functions in 
tumorigenesis. Based on these 3 criteria, some genes in Table 3.1 and Table 3.2 do 
not seem to be good candidates for further investigation. For example, 
downregulation of alcohol dehydrogenase expression are possibly the consequence of 
carcinogenesis but not the cause. Some genes that may contribute to tumorigenesis 
have been already well studied, including insulin-like growth factor-binding protein 4 
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and GSK-3 binding protein FRAT2. We also ruled out some genes such as FLJ23602 
fis (EST) and CCT3 because there was very little information about their normal 
physiological functions which suggest that they could be involved in tumourigenesis 
in the literature. 
FAT10 seems to be an appropriate candidate as it was convincingly 
overexpressed in all the HCC patients examined in microarray assay. In addition, 
although no previous link has been drawn between FAT10 and tumorigenesis at the 
time when we obtained the microarray data, a tentative link to cell cycle physiology 
had been implicated by the observation that FAT10 binds cell cycle checkpoint 
protein MAD2 (Liu et al., 1999). Moreover, FAT10 transcript level was greatly 
elevated in cell lines when treated with cytokine TNF-α (Raasi et al., 1999) which is 
suggestive of its potential role in chronic inflammation-associated carcinogenesis 
(Szlosarek and Balkwill, 2003). By combining these fragmented evidences, we 
hypothesized that FAT10 might play an important role in inflammation-associated 
tumorigenesis through the deregulation of mitosis by interfering with the function of 
MAD2. 
4.2 FAT10 is overexpressed in various cancers 
FAT10 was initially identified as a candidate gene that may play a role in 
tumorigenesis through cDNA microarray analyses of the tumor and adjacent non-
tumorous tissues in 4 HCC patients.  Its up-regulation was then validated using 
Northern Blot in 23 HCC patients that also included the 4 patients that were 
previously tested by the microarray analysis. 
FAT10 transcripts were detected in 21 of 23 HCC samples. Upregulation of the 
FAT10 gene expression was observed in the tumors of 19 HCC patients.  Hence, 90% 
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of HCC tumors showed FAT10 overexpression (Figure 3.2), which is consistent with 
the microarray data. 
Furthermore, our in situ hybridization analyses of HCC tissue sections clearly 
showed that FAT10 transcript is localized primarily to HCC hepatocytes and not to 
other cells such as immune cells in the liver (Figure 3.3). 
As it is the protein that ultimately functions in tumourigenic pathways, we 
performed immunohistochemical stain to investigate whether FAT10 protein levels in 
HCC were consistent with an elevated mRNA level. Figure 3.4 showed that more 
FAT10 protein was detected in tumors compared to non-tumorous tissue. 
We also examined FAT10 expression in other cancers using a cancer profiling 
array spotted with cDNAs from 241 paired cancer/normal samples. Upregulation of 
FAT10 expression in the tumor tissues of several different types of cancers was 
observed (Figure 3.5, Figure 3.6), indicating FAT10 overexpression may be a 
common phenomenon in tumorigenesis and not merely restricted to HCC. This is 
consistent with recent reports in which FAT10 overexpression was detected in 
primary non-small cell lung cancer (Heighway et al., 2002), Mantle cell lymphoma 
(Martinez et al., 2003) as well as liver and colon cancers (Lukasiak et al., 2008). 
Based on these facts we suggest that FAT10 is a cancer-associated gene. 
Of note, FAT10 expression was upregulated in a higher proportion of cancers of 
the gastrointestinal tract (stomach, intestinal and colorectal) and the female 
reproductive system (uterine, cervical and ovarian) (Figure 3.6). In other cancer types 
such as thyroid, prostate and kidney, we did not detect any consistent up- or down-
regulation. This raises the question of FAT10’s physiological link to cancer, and 
whether this link is tissue specific. 
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4.3 Developmental and tissue-specific expression of FAT10 
We further analyzed the normal tissue distribution of FAT10 expression using a 
multiple tissue expression array (MTE) containing 76 different normal tissues. We 
found that FAT10 is highly expressed in tissues of the gastrointestinal and 
reticuloendothelial systems, while strikingly absent in brain, cardiovascular and 
reproductive tissues (Figure 3.7). Although FAT10 was found to be expressed in the 
normal liver tissue in the multiple tissue expression array (Figure 3.7), its expression 
was variable and mostly undetectable in Northern Blot analysis (Figure 3.2).  A 
possible reason could be that in the multiple tissue expression array, each spot 
represented pooled sample from several individuals, whereas in the Northern Blot, a 
single sample is shown in each lane and variable FAT10 expression in the normal 
liver was observed. 
When the tissues were grouped according to their embryonic origins, it was 
found that FAT10 expression was detected mostly in tissues originating from the 
mesoderm and endoderm, while ectodermal tissues did not have detectable levels of 
FAT10 (Table 3.3). Furthermore, FAT10 appears to be expressed mostly in tissues 
associated with the immunological system, such as the reticuloendothelial and 
mucosal-associated lymphoid tissues (MALT) systems (e.g. spleen, thymus and 
lungs). This is consistent with previous reports that FAT10 expression is inducible by 
Epstein Barr virus infection, growth factors such as IFN-γ and TNF-α (Raasi et al., 
1999) and is linked to the maturation state of B cells and the antigen presentation of 
dendritic cells (Bates et al., 1997). In contrast, FAT10 is conspicuously absent in both 
fetal and adult brain, an immunologically privileged organ. These data indicate that 
FAT10 expression is closely related to the changes of immune systems and FAT10 
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may play important functions under pathological conditions such as chronic 
inflammation. 
4.4 FAT10 is a nuclear protein 
Studying the subcellular localization of a protein may help to elucidate its 
functions. For example, in the cytoplasm, β-catenin interacts with E-cadherin and 
actin to help to maintain cytoskeleton structures. When it is translocated to the 
nucleus under certain stimuli, β-catenin functions as a transcription factor and 
regulates expression of downstream target genes including c-myc (Clapper et al., 
2004). Hence, we performed several experiments to determine the subcellular 
localization of FAT10 in order to find clues to facilitate the functional 
characterization of this protein. 
Five evidences have shown that FAT10 is a nuclear protein in interphase cells: 
Firstly, FAT10-DsRed-fusion protein accumulated in the nucleus of transfected 
WRL68 cells although DsRed fluorescent protein alone diffused throughout the whole 
cell (Figure 3.8). Secondly, exogenous FAT10 introduced by adenovirus vectors was 
detected in the nucleus of infected cells (Figure 3.9). Thirdly, in HCT116 cells stably 
expressing FAT10, FAT10 protein localized in nucleus (Figure 3.11). Notably, in 
TNF-α treated SW620 cells, endogenous FAT10 was also detected in the nucleus 
(Figure 3.10). Finally, FAT10 was observed in the nucleus of the tumor of a HCC 
patient but not in the adjacent non-tumorous liver tissues of the same patient (Figure 
3.4). 
Earlier reports have suggested that the FAT10 protein is localized to the 
cytoplasm of IFN-γ induced B lymphoblastoid (JY) cells based on Western blot 
analyses of fractionated cells (Liu et al., 1999), and to the cytoplasm of murine 
fibroblast cells via immunofluorescence of the HA in HA-tagged FAT10 protein 
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(Raasi et al., 2001). However, their results were not conclusive as it is not possible to 
rule out HA directed localization from the data of Raasi et al. (Raasi et al., 2001) 
since localization of HA-only negative (vector) control was not shown. Similarly, in 
the FAT10 protein localization study of Liu et al. (Liu et al., 1999), no proper 
subcellular markers were used as controls in their Western blots. They should have 
detected nuclear fraction markers such as lamin A/C to confirm that they had isolated 
the nuclear fraction successfully (de Graaf et al., 2002). Hence, our data has shown 
several lines of evidence to convince the nuclear localization of FAT10. 
Since FAT10 was reported to be able to interact with the mitotic-checkpoint 
protein MAD2 (Liu et al., 1999), we hypothesized that FAT10 might alter cell cycle 
progression by interfering with the functions of MAD2. But the nuclear localization 
of FAT10 makes it difficult to explain the physiological significance of FAT10-
MAD2 interaction because during interphase, MAD2 mainly localizes in cytoplasm 
and only in mitotic cells, MAD2 was found to aggregate at condensed chromatin 
region (Li and Benezra, 1996). It was thus pertinent to investigate when and where 
FAT10 interacts with MAD2 so that we can further study functions of FAT10. 
To further characterize the FAT10 gene in cells, HCT116 cells was selected due 
to the following reasons: Firstly, FAT10 expression is also upregulated in colon 
cancers. Secondly, the doubling time of HCT116 is reasonably short (~16hrs, Figure 
3.12) facilitating the synchronization of these cells for cell cycle study and 
chromosome number determination. Thirdly, the modal chromosome number in 
HCT116 cells is 45, which is most similar to the number of chromosome that should 
be found in a normal cell. Moreover, the HCT116 cell line is the preferred cell line for 
cytogenetic studies (Michel et al., 2001). 
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4.5 FAT10 interacts with MAD2 and reduced the kinetochore localization of 
MAD2 during the prometaphase of the cell cycle 
As mentioned above, to study FAT10’s potential functions in mitosis, we have 
to determine whether FAT10 interacts with MAD2 under native conditions and when 
and where the interaction occurs. 
Using co-immunoprecipitation assays, we found that the reported interaction of 
FAT10 with MAD2 occurred only during the mitotic phase of the cell cycle. We were 
unable to immunopreciptate FAT10 with anti-MAD2 antibodies or vice-versa using 
unsynchronized cells, which are primarily G1-phase cells. Nonetheless, we found that 
in mitotic cells, FAT10 can be immunoprecipitated with anti-MAD2 antibodies and 
vice versa (Figure 3.14). This result can be explained by the localization of FAT10 
and MAD2 during different cell cycle stages. Using FAT10-specific antibodies that 
we generated, we found that during interphase FAT10 expression is primarily nuclear 
in HCT116 cells stably expressing FAT10, while MAD2 is mainly detected in 
cytoplasm which is consistent with a previous report (Li and Benezra, 1996). 
Colocalization of FAT10 and MAD2 can only be observed during mitotic stages, 
when the nuclear membrane is broken down (Ellenberg et al., 1997) (Figure 3.15). 
Interestingly, using MAD2-EGFP fusion constructs, we found that whereas 
MAD2 localizes at the kinetochores in the parental HCT116 cells, in FAT10-
expressing HCT116 cells, MAD2 localization at the kinetochores is greatly reduced 
(Figure 3.17). Similar observations were made when HCT116 and FAT116 cells were 
stained with DAPI, anti-MAD2, and anti-FAT10 antibodies (Figure 3.18). This has 
important implications, since MAD2 is a spindle checkpoint protein that helps to 
ensure the fidelity of the mitotic process by delaying the onset of anaphase until all of 
the chromosomes are properly aligned at the spindle (Bharadwaj and Yu, 2004). 
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Normally, MAD2 localizes to unattached kinetochores during the prometaphase stage 
of mitosis (Figure 3.17A) (Chen et al., 1996; Li and Benezra, 1996). We thus 
hypothesized that the interaction of FAT10 with MAD2 decreases the ability of 
MAD2 to localize to unattached kinetochores. This is likely to disrupt the role of 
MAD2 as a checkpoint protein, resulting in dysregulated mitosis and aneuploidy. 
The mechanism by which FAT10 reduced the kinetochore localization of 
MAD2 during the prometaphase stage of the cell cycle remains unclear and awaits 
further investigation. Although as a ubiquitin-like modifier, FAT10 was reported to be 
able to lead target proteins for degradation (Hipp et al., 2004), it seems that 
overexpressed FAT10 does not change MAD2 levels (Figure 3.14, before IP). It may 
be because the interaction between FAT10 and MAD2 is noncovalent (Liu et al., 
1999) so FAT10 cannot “tag” MAD2 with polyubiquitin-like tails for degradation in 
the proteasome for degradation. It seems that FAT10 may influence the functions of 
its targets by modifying them in a nonproteolytic way like another ubiquitin-like 
modifier SUMO (Gill, 2004). As SUMO was also reported to function in the 
regulation mitotic progression (Dasso, 2008) and chromosome segregation (Watts, 
2007), these studies on SUMO may guide our understanding of how FAT10 carries 
out its role in deregulation of mitosis. 
4.6 FAT10 Overexpression Results in dysregulated mitosis and chromosome 
instability 
To understand the influence of interaction between FAT10 and MAD2 in cells, 
we proceeded to explore the effect that FAT10 overexpression has on HCT116 cells. 
As shown in Figure 3.21 and Figure 3.22, compared with parental or uninduced 
HCT116 cells, fewer mitotic cells were observed after double thymidine-synchronized 
FAT10-overexpressing cells were released into nocodazole for more than 4 h. This 
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may be due to a delay in the entrance into mitosis or an escape from mitotic arrest. 
Nonetheless, when these double thymidine-treated cells were released into media, 
similar numbers of G1 parental and FAT10-overexpressing HCT116 cells were 
observed throughout the 10-h time course. Taken together, these results suggested that 
FAT10-overexpressing cells experienced a delayed and abbreviated mitotic phase or 
an abbreviated mitotic arrest phase upon spindle damage. 
An abbreviated mitotic phase in FAT10-overexpressing cells could potentially 
have adverse consequences. For example, there may be insufficient time for proper 
alignment of the sister chromatids at the equator, leading to premature separation of 
these sister chromatids and an increased rate of chromosome missegregation. This 
possibility is pertinent, given the observation that dysfunctional MAD2 also causes 
premature sister chromatid separation and chromosome instability (Michel et al., 
2001). We therefore examined the effect of FAT10 overexpression on mitosis and 
chromosomal instability. 
Upon treatment with nocodazole, more FAT10-overexpressing cells either failed 
to arrest or escaped mitotic arrest (Figure 3.23). Prolonged exposure to nocodazole 
resulted in more FAT10-overexpressing cells exhibiting abnormal and multinuclear 
morphology than the parental controls (Figure 3.24). These results suggest a 
dysregulation of mitosis in FAT10-overexpressing cells and indicate that premature 
anaphase may occur in these cells. As early anaphase causes aneuploidy (Michel et 
al., 2001), thus we further investigate whether overexpressed FAT10 may influence 
the chromosomal stability cells. 
Significantly, we demonstrate using HCT116 cells stably expressing FAT10 
either constitutively or under a tetracycline-inducible promoter that more FAT10-
expressing cells have an abnormal chromosome number compared with the parental 
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or uninduced counterpart (Figure 3.25). These results strongly suggest that FAT10 
overexpression not only affects proper mitotic disjunction, but also results in 
aneuploidy and CIN. Based on this result we hypothesized that overexpression of 
FAT10 in various cancers might be closely associated with the frequently observed 
aneuploidy in cancers (Weaver and Cleveland, 2006) and it may promote cancer 
development by inducing aneuploidy (Duesberg and Rasnick, 2000). In order to test 
our hypothesis, we need to identify the crucial pathways in which FAT10 may play its 
roles to promote tumorigenesis under in vivo pathological conditions. Hence, 
characterization of the mechanisms that regulate FAT10 gene expression will 
significantly facilitate our understanding of the functions of FAT10 in tumorigenesis. 
We then sought to identify in vivo pathological conditions and pathways through 
which FAT10 expression may be deregulated. 
FAT10 expression has been reported to be regulated by various factors. Our lab 
has found that FAT10 expression is regulated during the cell cycle (Lim et al., 2006) 
and could be suppressed by tumor suppressor gene P53 (Zhang et al., 2006). Rassi et 
al reported that proinflammatory cytokines TNF-α and IFN-γ could induce FAT10 
expression in cell lines. Moreover, FAT10 overexpression is also reported in viral 
infected diseases, such as Kaposi sarcoma-associated herpesvirus infected cells (Hong 
et al., 2004) and HIV infected cells (Ross et al., 2006). In the stomach cancer model 
ACI rats, it was found that the carcinogen, N-Methyl-N'-nitro-N-nitrosoguanidine 
(MNNG), could also induce FAT10 gene expression within a week of exposure to the 
carcinogen (Yamashita et al., 2002). These evidences suggested that FAT10 
overexpression occured at every stage of cancer development. Consistently, it was 
reported that Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed 
mouse model of tumorigenesis (Oliva et al., 2008). 
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Amongst the factors that can regulate FAT10 expression, we were particularly 
interested in TNF-α because it was known to promote chronic inflammation-
associated tumorigenesis (Marx, 2004). In addition, high levels of TNF-α are always 
detected in the serum of patients with chronic inflammation disease such as hepatitis 
(Chen et al., 2007; Gonzalez-Reimers et al., 2007; Kiki et al., 2006), indicating that 
TNF-α may play critical roles in the initiation of carcinogenesis. Based on these 
evidences, we decided to perform experiments to elucidate the mechanisms by which 
FAT10 expression is regulated by TNF-α. 
4.7 FAT10 expression is up-regulated by TNF-α 
We have verified that FAT10 protein level could be increased in thecolon cancer 
cell line SW620 treated with recombinant TNF-α. But in SW620 treated with another 
cytokine, human IFN-γ, we could not detect FAT10 overexpression (Figure 3.27A). 
This result is different from the observation by Raasi et al who reported the FAT10 
expression was also induced by IFN-γ (Raasi et al., 1999). A possible reason is that 
different methods were used to detect FAT10 expression levels. Our study utilized 
western blot analysis to detect the FAT10 protein while the other group detected 
FAT10 transcripts employing simple, non-quantitative RT-PCR which is much more 
sensitive but is also prone to giving false positive results (Raasi et al., 1999). 
Nonetheless, we observed that IFN-γ was able to greatly enhance the effect of 
TNF-α in inducing FAT10 expression (Figure 3.27A), which is consistent with 
Rassi’s result. A possible pathway through which IFN-γ enhances TNF-induced 
FAT10 expression may be through the induction of the expression of TNF receptor 
TNFR2 (Kost et al., 1999; Wang et al., 2006). An alternative pathway is through the 
inhibition of the TNFR1/STAT-1α complex formation by IFN-γ which will enhance 
the TNF-α-dependent NF-kB activation (Wesemann and Benveniste, 2003). 
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Induction of FAT10 expression by TNF-α can be observed in various cell lines 
including SV40 large T antigen immortalized primary normal liver cell THLE3, but 
not in primarily cultured T-cell isolated from cord blood (Figure 3.27B). In SW620 
and human kidney embryonic cell line 293, TNF-α alone can induce FAT10 protein 
expression but in THLE3 and colon cancer cell line HCT116, FAT10 protein is only 
detectable after co-treatment with TNF-α and IFN-γ (Figure 3.27B). Another 
observation is that the effect of TNF-α and IFN-γ on FAT10 expression is dose-
related. But beyond the treatment with 10ng/ml TNF-α/20U/ml IFN-γ, higher doses of 
the cytokines will not further induce FAT10 expression (Figure 3.28). The difference 
in the response of different cells to TNF-α may be due to the difference in the 
distribution and expression level of TNF receptors (Aggarwal, 2003; Santis et al., 
1992). 
We also found that FAT10 protein expression dramatically decreased after the 
withdrawal of TNF-α. Under continuous TNF-α treatment, the induction of FAT10 
protein expression can be maintained (Figure 3.29). These results suggested that the 
effect of TNF-α on FAT10 expression may be transient and constitutive TNF-α 
treatment is necessary for maintaining FAT10 expression at a high level. It is possible 
that in patients with chronic disease such as liver cirrhosis (Ataseven et al., 2006), 
sustained high-levels of TNF-α in the serum results in sustained FAT10 
overexpression which may promote tumorigenesis. 
Since TNF-α stimulation can activate the NF-κB that can function as an anti-
apoptotic and survival factor, it may play important roles in promoting the 
development of inflammation-associated cancers (Pikarsky et al., 2004). It is thus 
interesting to investigate if TNF-α induction of FAT10 expression is through this NF-
κB pathway.  
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As shown in Figure 3.30, when we blocked the NF-κB pathway by inhibiting 
the expression of subunit p65, TNF-α could not induce FAT10 overexpression in both 
THLE-3 and HCT116 cells. This data suggests that TNF-α regulates the expression of 
FAT10 through the NF-κB pathway. 
We have also observed numerical chromosomal instability in long term TNF-α 
/IFN-γ treated HCT116 cells in which FAT10 expression was induced (Figure 3.31). 
This result is consistent with Beyne-Rauzy’s observation in human leukemic cells 
(Beyne-Rauzy et al., 2004). Notably the pattern of chromosome instability in long 
term TNF-α/IFN-γ treated HCT116 cells is similar to that observed in HCT116 cells 
stably expressing the FAT10 gene (Figure 3.26), implying FAT10 may be involved in 
the alteration of chromosomal status caused by TNF-α although further experiments 
need to be performed to validate this. 
Our future work will focus on confirming the hypothesis that FAT10 functions 
in TNF-α/NF-κB pathway associated carcinogenesis pathways. According to the two 
stage aneuploidy-cancer mechanism (Duesberg and Rasnick, 2000), aneuploidy plays 
key roles in the initiation of carcinogenesis in cells (Matzke et al., 2003) and FAT10 
may play this role by inducing aneuploidy. For example, TNF-α induces DNA 
damage which usually leads to cell death (Norbury and Zhivotovsky, 2004; Roos and 
Kaina, 2006) as well as aneuploidy (Beyne-Rauzy et al., 2004) which may occur 
through FAT10. The aneuploid cells are usually defective in surveillance 
mechanisms, allowing these cells to escape from apoptosis. 
To investigate our hypothesis, we will establish stable cell lines in which FAT10 
expression is knocked down either by shRNA stable transfection (Hannon and Rossi, 
2004) or recombinant gene deletion (Kohli et al., 2004). These cells will then be 
treated with TNF-α to investigate whether it can induce chromosomal instability in 
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the absence of overexpressed FAT10. Furthermore, rescue experiments in which 
FAT10 overexpression is introduced by transfection of plasmid will also be 
performed with the FAT10-deficient cells in order to investigate FAT10 functions. In 
addition, the successful generation of a Fat10 knockout mouse (Canaan et al., 2006) 
will make it possible to study FAT10 function in vivo. 
In conclusion, our work reveals that the expression of FAT10 is up-regulated in 
several cancers. Functional studies showed that cells overexpressing the FAT10 gene 
affect mitosis by deregulating the function of the checkpoint protein MAD2, resulting 
in numerical chromosomal instability, which was also observed in the same cells that 
were treated with the cytokine TNF-α. In addition, our results also show that 
endogenous FAT10 expression can be induced by TNF-α through the NF-κB 
pathway. The work in my thesis raised the interesting possibility that FAT10 may 
play an important role in inflammation-associated tumorigenesis through the TNF-
α/NF-κB pathway. 
Currently, it is clear that TNF-α/NF-κB pathway play a key role in mediating 
inflammation-associated tumorigenesis (Balkwill, 2009). However, downstream 
mechanisms beyond NF-κB of this pathway are less clear even though the expression 
of many genes have been reported to be regulated by activated NF-κB (Pahl, 1999; 
Tian et al., 2005b). Since FAT10 expression can be induced by TNF-α through 
activated NF-κB (Figure 3.30), in addition to the observation that both  TNF-α and 
overexpressed FAT10 can cause similar numerical chromosomal instability, (Figure 
3.26 and Figure 3.31), it would be interesting to determine whether FAT10 may 
mediated the effect of TNF-α in inducing aneuploidy. If this is true, we would like to 
propose FAT10 as an important factor that mediates the TNF-α/NF-κB pathway in 
 113
inflammation related tumourigenesis (Figure 4.1) as aneuploidy is the hallmark of 
almost all of cancers (Weaver and Cleveland, 2006). 
Previous reports suggested that interfering the TNF-α/NF-κB pathway may 
potentially block inflammation-associated tumorigenesis (Greten et al., 2004; Moore 
et al., 1999). TNF-α antagonists (Balkwill, 2009) and inhibitors of NF-κB activation 
(Baud and Karin, 2009) have been proposed as possible drug targets to block the link 
between inflammation and cancer development. However, since TNF-α and NF-κB 
also play important functions in host immune responses (Efimov et al., 2009; 
Vallabhapurapu and Karin, 2009; Wilson et al., 2009), complete inhibition of the 
TNF-α/NF-κB pathway may not seem so feasible as this could result in serious side 
effects. In contrast, FAT10 appears to have minimal function under normal 
physiological conditions based on the observation that FAT10 knockout mice can 
grow normally like the wild type mice (Canaan et al., 2006). Consequently, based on 
our findings, we propose that FAT10 gene may be a more suitable target for 













Figure 4.1 Potential functions of FAT10 in mediating tumorigenesis under chronic 
inflammation condition. Underchronic inflammation, high level TNF-α induces FAT10 
expression through activated NF-κB. Overexpressed FAT10 induces aneuploidy which is 
one of crucial factors in initiating cancer development.
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Appendix A: Reagents used in Northern Blot 
10xMOPS 
1. Dissolve 41.8g MOPS (3-[N-Morpholino] propanesulfonic acid, MW209) in 800ml 
of DEPC treated ddH2O. 
2. Add 16.6ml of 3M DEPC treated NaAc. 
3. Adjust pH to 7 with 10N NaOH. 
4. Add 20ml of DEPC treated 0.5M EDTA. 
5. Adjust volume to 1000ml with DEPC treated ddH2O. 
6. Store in dark at room temperature. 
Northern Buffer (250ul) 
125μl formamide 
60μl DEPC ddH2O 
40μl formaldehyde 
25μl 10XMOPS 
5X Northern dye  
1. Add the following to ddH2O: 
25% glycerol 
0.5mM EDTA (pH8.0) 
0.1% Bromophenol Blue 
0.1% Xylene Cyanole FF 
2. Treat the dye with DEPC and store at room temperature. Protect from light. 









100μg/ml sonicated salmon sperm DNA (ssDNA) (Strategene, La Jolla, CA) 
50% formamide 
 
Appendix B: Reagent used in hybridization of CPA and MTE 
Probe mixture (for two blots) 
3.5x107 cpm purified labeled oligo probe 
75μg human cot-I (Invitrogen, Carlsbad, CA) 
375μg ssdna (Strategene, La Jolla, CA) 
125μl 20xssc 
H2O top up to 450μl 
Wash buffer I 
2xSSC + 1% SDS 
Wash buffer II 
0.2xSSC + 0.5%SDS 
Wash buffer III 
2xSSC 
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Appendix C: Buffers for purification of his-tagged FAT10 under denature 
conditions 
Buffer B (lysis buffer) 
100 mM NaH2PO4, 10 mM Tris, 8M Urea; pH 8.0 
Buffer C (washing buffer) 
100 mM NaH2PO4, 10 mM Tris, 8M Urea; pH 6.3 
Buffer E (elution buffer) 
100 mM NaH2PO4, 10 mM Tris, 8M Urea; pH 4.5 
 
Appendix D: Reagents used in SDS-PAGE electrophoresis and western bloting 
2x SDS-PAGE loading buffer 
0.5M Tris-HCl, pH6.8                      2.4ml 
Glycerol                                               2ml 
10%  (w/v) SDS                                   4ml 
0.5% (w/v) Bromophenol Blue         0.1ml 
ddH2O                                               0.5ml 
β-Mercaptoethanol                               1ml 
SDS-PAGE running buffer 
25mM Tris, 250mM Glycine, o.1% SDS, pH8.3 
Transfer buffer 
25mM Tris, 250mM Glycine, o.1% SDS, 20% Methanol 
Wash buffer: Tris buffered saline with Tween-20 (TBST)  
10mM Tris-HCl, 125mM NaCl, 0.1% Tween-20, pH7.5 
Blocking solution 
2% of ECL Advance Blocking Reagent (GE, Piscataway, NJ) in TBST 
Strip buffer (for 50ml) 
10% SDS                     10ml 
1M Tris-HCl, pH6.5    3.15ml 
β-Mercaptoethanol      343μl 
H2O                             41.5ml 
 
Appendix E: Permission for the usage of figure from Annual Review 
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the Annual Review of Biophysics and Biomolecular Structure, Volume 36 ©2007 by 
Annual Reviews   www.annualreviews.org” 
  
This permission to reprint is for a one-time usage only and any subsequent use of this 
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Expression of the FAT10 gene is highly upregulated in hepatocellular
carcinoma and other gastrointestinal and gynecological cancers
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The ubiquitin-like modiﬁer (UBL) family has recently
generated much interest in the scientiﬁc community, as it
is implicated to play important regulatory roles via novel
protein–protein modiﬁcation. FAT10 (diubiquitin) belongs
to this family of proteins, comprising two ubiquitin-like
moieties fused in tandem, and has been implicated to be
involved in the maintenance of spindle integrity during
mitosis. As FAT10 may play a role in the regulation of
genomic stability, we examined if there is an association
between FAT10 expression and hepatocellular carcinoma
(HCC) or other cancers. Northern blot analyses revealed
upregulation of FAT10 expression in the tumors of 90%
of HCC patients. In situ hybridization as well as
immunohistochemistry utilizing anti-FAT10 antibodies
localized highest FAT10 expression in the nucleus of
HCC hepatocytes rather than the surrounding immune
and non-HCC cells. FAT10 expression was also found to
be highly upregulated in other cancers of the gastro-
intestinal tract and female reproductive system. In
conclusion, we demonstrated upregulation of FAT10
expression in various gastrointestinal and gynecological
cancers. Its overexpression is unrelated to the general
increase in protein synthesis or a general immune/
inﬂammatory response to cancer. Rather, FAT10 may
modulate tumorigenesis through its reported interaction
with the MAD2 spindle-assembly checkpoint protein.
Oncogene (2003) 22, 2592–2603. doi:10.1038/sj.onc.1206337
Keywords: diubiquitin; FAT10; ubiquitin-like modiﬁer
(UBL); hepatocellular carcinoma; gastrointestinal
cancers
Introduction
Tumorigenesis often arises from dysregulated cell-cycle
control or apoptosis. The ubiquitin and ubiquitin-
related families of proteins play instrumental roles in
various cellular processes including cell-cycle regulation
(Jentsch and Pyrowolakis, 2000) as well as cell death/
apoptosis (Jesenberger and Jentsch, 2002) through
modiﬁcation of target proteins.
Ubiquitin is a highly conserved 76 amino-acid
polypeptide that plays an important role in the
conjugation of target proteins, thereby ‘tagging’ these
proteins for degradation via the 26S proteasome path-
way (Hochstrasser, 1996a,b). The targeting of proteins
for degradation by ubiquitin occurs through a cascade
of events requiring participation of three enzymes, the
ubiquitin-activating enzyme (E1), the carrier protein
(E2) and the ubiquitin ligase (E3). The evolutionarily
conserved C-terminal glycine (Gly) residue of ubiquitin
is conjugated to the lysine (Lys) residue of target
proteins. Polyubiquitin chains can also be formed by
the attachment of a Lys residue from the preceding
ubiquitin molecule (Lys48) to the C-terminal Gly
residue of the next ubiquitin molecule, thus creating
proteosome targeting signals (Pickart, 1997).
The roles of ubiquitin-like family members are only
beginning to be elucidated. Two different families of
ubiquitin-like proteins have been reported (Jentsch and
Pyrowolakis, 2000). The ubiquitin-domain proteins
(UDPs), for example, RAD23, BAG1, Elongin B and
Gdx, do not form conjugates with other proteins,
although they contain embedded ubiquitin-like do-
mains. Residues outside these domains do not bear
similarities to each other or to ubiquitin. The second
family of ubiquitin-like proteins is known as the
ubiquitin-like modiﬁers (UBL), and they are related in
sequence to either a monomer or dimer of ubiquitin.
Several members of the UBL family, including SUMO/
Setrin and RUB1/NEDD8, function as modiﬁers in an
analogous manner to ubiquitin. Most of the UBL family
members have been reported to attach covalently to
*Correspondence: CG Lee, Division of Medical Sciences, National
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other proteins via their C-termini, which also contain
the conserved Gly–Gly motifs. The conjugation path-
ways of the studied UBL members are similar to that of
ubiquitin, although their E1, E2 and E3 proteins differ
(Jentsch and Pyrowolakis, 2000).
Several ubiquitin and ubiquitin-related proteins have
been associated with cell–cycle-related processes and
implicated in cancer. BRCA1, a breast and ovarian
cancer-speciﬁc tumor suppressor, contains a RING
domain typical of E3 and exhibits ligase activity
(Ruffner et al., 2001). Mutations within the RING
domain have been found to inactivate E3 activity and
predispose the patient to cancer (Ruffner et al., 2001).
The UBL protein, SUMO1, has been reported to
conjugate with the PML oncogene (Boddy et al., 1996;
Muller et al., 1998) and associate with the ‘death
domains’ of Fas/APO1 and tumor necrosis factor
(TNF) receptor 1 (Okura et al., 1996), while its
Saccharomyies cerevisiae analog Smt3 was found to be
required for chromosome segregation during mitosis
(Biggins et al., 2001). Another UBL protein NEDD8 has
been shown to be essential for cell-cycle progression in
mice (Tateishi et al., 2001). The UDP protein Elongin B
was found to be associated with the von Hippel Lindau
(VHL) tumor suppressor in a VHL-dependent E3
complex (Iwai et al., 1999), while the yeast UDP
protein, DSK2p, was reported to be involved in spindle
pole body duplication (Biggins et al., 1996).
FAT10 is an 18 kDa protein comprising 165 amino-
acid residues. It was originally discovered through the
identiﬁcation of expressed genes covering the HLA-F
genomic locus (Fan et al., 1996). A potential role of
FAT10 in antigen presentation was suggested by its
expression in mature B cells and dendritic cells (Bates
et al., 1997), and by its ability to be generally and
synergistically inducible with cytokines IFNg and TNFa,
but not IFNa (Raasi et al., 1999). FAT10 belongs to the
UBL family of proteins and contains two ubiquitin-like
moieties fused in tandem (Jentsch and Pyrowolakis,
2000). It is 29% identical to ubiquitin at its N-terminus
and 36% identical at the C-terminus. Like ubiquitin, it
has the C-terminal Gly–Gly residues. Furthermore,
there is a conserved Lys residue in each moiety of
FAT10 analogous to Lys48 of ubiquitin, each of which
may serve as a potential site for polyubiquitination of
FAT10. Interestingly, as has been found in some other
UBL members, FAT10 has been reported to have
potential involvement in cell-cycle regulation. FAT10
has been shown to bind noncovalently to the human
spindle assembly checkpoint protein, MAD2 (Liu et al.,
1999), a protein responsible for maintaining spindle
integrity during mitosis (Shah and Cleveland, 2000). The
inhibition of MAD2 function has been associated with
chromosomal instability, a characteristic of many
cancers (Wang et al., 2000; Gemma et al., 2001).
In the present study, we examined if there is an
association between the FAT10 expression and hepato-
cellular carcinoma (HCC). We report that FAT10, a
gene not previously reported to be associated with HCC
or other cancers, is consistently upregulated in the
tumors of approximately 90% of HCC patients
screened. Further analyses reveal that the strong
upregulation of FAT10 expression is not limited to
HCC, but is in fact a common feature of other cancers,
especially those of the gastrointestinal tract and female
reproductive system. We further demonstrate that
FAT10 is localized to the nucleus of HCC cells.
FAT10 has been implicated in cell-cycle regulation, a
key modulator of tumorigenesis (Liu et al., 1999), and
this report represents the ﬁrst demonstration of the
upregulation of FAT10 gene expression in gastrointest-
inal and gynecological tumors.
Materials and methods
Patients and tissue samples
All patient samples were obtained in accordance to the
Institutional Review Board (IRB) Guidelines of the Johns
Hopkins University, School of Medicine, USA and guidelines
of the National Cancer Center, Singapore.
Northern blot analysis
The upregulation of FAT10 expression in HCC tumors were
examined in 23 HCC patients by Northern blot analysis using
15 mg of total RNA as described previously (Hooi et al., 1997).
The FAT10 (GenBank Accession number: AF123050) cDNA
was ﬁrst prepared from RT–PCR of total RNA extracted from
liver tissue samples using FAT10-gene-speciﬁc primers. The
ampliﬁed cDNA was sequenced to conﬁrm its identity as
FAT10. cDNA probes were labeled with a-32P dCTP (Amer-
sham Pharmacia Biotech Inc., Piscataway, NJ, USA) using
Rediprime labeling kit (Amersham Pharmacia Biotech Inc.,
Piscataway, NJ, USA) according to the manufacturer’s
instructions.
The probed blot was then exposed to Biomax MS ﬁlm
(Kodak Inc., Rochester, NY, USA) or Fuji imaging plate
(Kanagawa, Japan) and quantitated using the FluorChemTM
v2.0 (Alpha Innotech Corporation, San Leandro, CA, USA)
or the phosphorimager, BAS-2500 (Fujiﬁlm, Kanagawa,
Japan).
In situ hybridization
Fresh HCC tissues and their adjacent nontumorous tissues
were immediately embedded in tissue freezing medium (Tissue-
Tek OCT compound, Sakura, Japan) in a cryomold (SIM-
PORT, Canada) in dry ice and stored at 701C. Sections
(5 mm) of the tissues were then mounted onto poly-l-lysine-
coated slides and ﬁxed immediately in 4% paraformaldehyde–
PBS for 15min at room temperature.
The unique sequence of the FAT10 cDNA was cloned into
pBluescript II KS+ vector (Stratagene, La Jolla, CA, USA).
Clones containing inserts in the forward and reverse orienta-
tion were selected for riboprobe generation (DIG RNA
labeling kit, Roche, Basel, Switzerland) as sense and antisense
probes.
In situ hybridization was then performed on the sectioned
tissues with the respective probes using DAKO mRNA in situ
hybridization solution (DAKO, Glostrup, Denmark) follow-
ing the method of Braissant and Wahli (1998), except that the
slides were treated with RNase (Komminoth et al., 1992) and
washed at higher stringency. Positive signals were visualized
using NBT/BCIP substrate (Roche, Basel, Switzerland).
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Generation of anti-FAT10 antibodies
The open reading frame of FAT10 was cloned downstream of
the N-terminal His-tag of the Gatewayt expression vector,
pEXPR17, using the Gatewayt Cloning Technology (Invitro-
gen, Carlsbad, CA, USA) to generate pEXPR17-FAT10,
which was then transformed into BL21-SI Escherichia coli cells
(Invitrogen, Carlsbad, CA, USA). Recombinant FAT10
protein expression in BL21-SI cells was induced by addition
of 0.3m NaCl for 5 h and puriﬁed using Ni-NTA resin (Qiagen,
Hilden, Germany) according to the manufacturer’s instruc-
tions. Fractions containing the highest amount of HisFAT10
protein were then pooled, dialyzed in water and freeze-dried.
Polyclonal antibodies against the recombinant FAT10 protein
were then generated in rabbits (BioGenes GmbH, Berlin,
Germany) and puriﬁed over a FAT10–Sepharose column.
Immunohistochemistry
Sections (5 mm) of frozen HCC tissue tissues were ﬁxed in
acetone for 10min at 41C, washed brieﬂy in water and treated
with freshly prepared 3% hydrogen peroxide for 10min to
block endogenous peroxidases. The slides are then incubated
with 2 mg/ml of anti-FAT10 primary antibody for 30min. A
polymer-linked anti-rabbit secondary antibody is then applied
using the DAKO EnvisionTM AP KIT (Code K4016) (DAKO,
Glostrup, Denmark) for another 30min. Freshly prepared
chromogen solution (fast red) is then applied and the slides are
counterstained with Harris Haematoxylin (Gill’s II Haema-
toxylin – Surgipath, Richmond, IL, USA).
Localization of FAT10–DsRed fusion protein in cells
To determine the subcellular localization of the FAT10
protein, a FAT10–DsRed fusion construct was generated.
The cytomegalovirus (CMV) promoter was introduced into
pDsRed (Clontech, Palo Alto, CA, USA) to produce
pCMVDsRed construct. The FAT10–DsRed fusion was
generated via a two-step polymerase chain reaction (PCR)
using primers as indicated in Figure 1a. In the ﬁrst step, FAT10
and DsRed genes were ampliﬁed separately. FAT10 was
ampliﬁed from human liver cDNA with primers C and D,
while DsRed was ampliﬁed from pCMVDsRed plasmid using
primers A and B (Figure 1a). The puriﬁed ampliﬁed FAT10
and DsRed PCR products were then mixed and another PCR
reaction was performed using primers B and D to generate the
fused FAT10–DsRed ampliﬁed product (Figure 1a). The fused
FAT10–DsRed ampliﬁed product was then cloned into
pCMVDsRed replacing the resident DsRed gene in the
construct to generate pCMVFATDsRed. Identity of the fusion
pCMVFATDsRed construct was conﬁrmed by sequencing.
pCMVFATDsRed or its parental pCMVDsRed constructs
were introduced into human embryonic liver cell line, WRL68
(European Collection of Cell Cultures, Salisbury, UK), plated
on sterilized coverslips in six-well plates via calcium phosphate
coprecipitation as described (Lee et al., 2000). At 48 h after
transfection, the cells were ﬁxed in 2% paraformaldehyde and
viewed under a ﬂuorescence microscope.
Generation of recombinant FAT10 adenoviruses
Recombinant human FAT10 adenoviruses (AdFAT10) (Figure
4c) were generated as described (He et al., 1998). The titer of
the viruses was assessed by monitoring the number of
ﬂuorescence 293 cells after infection with serially diluted viral
lysates and expressed as expression-forming units/ml.
Western blot analyses
Whole cell lysates 15–20mg were separated on a 12% SDS–
PAGE gel. The proteins on the gel were then transferred onto
a PVDF membrane (BioRad, CA, USA) and hybridized with
0.1mg/ml rabbit anti-FAT10 primary antibody and 1 : 10,000
HRP-conjugated goat anti-rabbit IgG (Pierce Biotechnology,
IL, USA). The blot was then visualized using SuperSignal
Duro Reagent (Pierce Biotechnology, IL, USA).
Localization of FAT10 protein in NIH3T3 cells
NIH3T3 cells (1 104) were seeded onto coverslips in 24-well
plates and grown in DMEM media containing 10% fetal bovine
serum at 371C, 5% CO2 for 2–3 days. AdControl or AdFAT10
adenoviruses were then added to the cells at a ratio of 20 : 1
(virus : cells) for 12h. Fresh media were then added to replace the
virus medium and the cells were incubated for another 36h before
being ﬁxed in 2% paraformaldehyde. The ﬁxed cells were
permealized with 0.2% Triton X-100 for 10min and stained with
anti-FAT10 antibodies (2mg/ml) for 1h at 371C. After three
washes in phosphate-buffered saline (PBS), the coverslip was
incubated with Alexa Fluors 647 chicken anti-rabbit IgG (H+L)
(molecular probes, Eugene, OR, USA) for 1h at room
temperature. The cells were then washed thrice in PBS and
mounted onto glass slides using FluorSave Reagent (Calbiochem,
San Diego, CA, USA). The slides were observed with Zeiss LSM
510, laser scanning microscope (Heidelberg, Germany).
Expression studies in various cancers and tissues
The expression levels of FAT10 in various other cancers were
determined with the use of the Cancer Proﬁling Array
(Clontech, Palo Alto, CA, USA) containing paired normal/
tumor tissues covering 12 different cancers from 241 patients.
In addition, FAT10 expression in various normal tissues and a
number of transformed cell lines were determined using the
Multiple Tissue Expression Array (Clontech, Palo Alto, CA,
USA) spotted with 76 different tissue types. Each spotted
tissue type was pooled from several individuals. Both arrays
were hybridized with either the FAT10 cDNA probe or
ubiquitin cDNA, the normalization probe provided by
Clontech. These probes were generated as described earlier
under conditions recommended by the manufacturer. Detailed
information of these two blots may be found at http://
www.clontech.com.
—————————————————————————————————————————————————————————c
Figure 1 (a) Strategy for amplifying FAT10–DsRed fusion gene. Upper panel is a schematic ﬁgure of the FAT10–DsRed fusion gene
and the primers utilized to amplify the fusion gene. Table in the lower panel contains sequences of the various primers utilized. DsRed
is ampliﬁed using A (containing the ﬁrst 20 bases of the DsRed gene) as the forward primer and B (containing the last 17 bases of the
DsRed gene with a NotI restriction enzyme site) as the reverse primer. FAT10 is ampliﬁed with reverse primer C (containing the last 21
bases of FAT10 gene excluding the stop codon and ﬁrst 20 bases of the DsRed gene including the AUG codon) and forward primer D
(containing ﬁrst 20 bases of the FAT10 gene with a BamHI restriction enzyme site). The FAT10–DsRed fusion construct was ampliﬁed
with primers D and B from the separately ampliﬁed FAT10 and DsRed genes. (b) FAT10–DsRed fusion protein is localized to nucleus
of cells. pCMVDsRed vector control construct or pCMVFATDsRed construct were transfected into WRL68 cells and observed 48 h
later using the ﬂuorescence microscope
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The probed blots were exposed to Biomax MS ﬁlm or Fuji
imaging plate. Samples with detectable signals in either the
tumor or normal samples were used for densitometric analysis
using FluorchemTM v2.0 or the phosphorimager, BAS-2500. For
the Cancer Proﬁling Array, FAT10 was considered differentially
expressed between nontumor and tumor tissue if the intensity
difference exceeded 1.5 times after normalization against signals
obtained using the ubiquitin control probe.
Results
FAT10 is overexpressed in HCC tissue
Northern blot analysis was performed on 23 tumor and
paired nontumorous samples from HCC patients to
examine the levels of FAT10 gene expression in HCC
(Figure 2). A 1 kb band representing FAT10 mRNA was
detected in 21 of the 23 HCC samples. In all, 19 of the 21
patients (90%) showed upregulation of FAT10 expres-
sion in tumor tissue (Figure 2).
FAT10 over-expression is localized to the nucleus of HCC
cells
To examine the cell-type speciﬁcity of FAT10 expression
in HCC liver tissue, in situ hybridization using antisense
FAT10 riboprobes as well as immunohistochemistry
utilizing anti-FAT10 antibodies that we generated were
performed on cryosections of liver tissue from HCC
patient #10 (see Figure 2). As evident in Figure 3d, high
levels of FAT10 transcript were detected primarily in
HCC cells, with low and scattered signals in other cell
types surrounding the HCC cells, including immune
cells. Similarly, FAT10 protein expression was localized
to the nuclei of HCC cells, and not other cell types
around the HCC cells (Figure 4a). In the paired adjacent
nontumorous liver tissue from the same patient, FAT10
transcripts and protein were undetectable.
FAT10 protein is localized to the nucleus of cell lines in
which the FAT10 gene is introduced
Two additional experiments were carried out to further
conﬁrm the intracellular localization of FAT10 protein.
In the ﬁrst experiment, a FAT10–DsRed fusion con-
struct (pCMVFATDsRed) or its parental construct
(pCMVDsRed) were introduced into human embryonic
liver cell line, WRL68. Cells transfected with
pCMVDsRed (negative control) exhibited uniform
ﬂuorescence in the nucleus and cytoplasm, whereas cells
transfected with pCMVFATDsRed fusion construct
showed intense red ﬂuorescence only in the nucleus,
indicating FAT10 protein localization to the nucleus
(Figure 1b). In the second experiment, control adeno-
viruses or recombinant adenoviruses expressing FAT10
were infected into NIH3T3 cells, and Western blot
analyses and immunoﬂuorescence analyses utilizing
anti-FAT10 antibodies were performed. Figure 4b con-
ﬁrms the expression of FAT10 protein in NIH3T3 cells
infected with AdFAT10 adenoviruses. As demonstrated
in Figure 4c, the FAT10 protein was localized to the
nucleus of cells infected with AdFAT10 adenoviruses.
FAT10 is also overexpressed in other cancers
To examine if FAT10 is also differentially expressed in
cancers other than HCC, FAT10 cDNA was labeled and
hybridized to an array blot containing representative
paired tumor/normal tissues from several different
cancers (Cancer Proﬁling Array, CPATM, Clontech).
1 2 3 4 5 6 7 8 9 10 11 12























Figure 2 FAT10 expression in paired liver samples from 23 HCC patients as analysed by northern hybridization. Upper panel of each
letter/number represents blots that were hybridized with FAT10 and lower panel of each letter/number represents the gel picture
showing the 28S ribosomal RNA to normalize for abnormal loading of the samples. T: tumor tissue, N: paired nontumorous tissue
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The expression levels of FAT10 were consistently low in
nontumorous tissues, but were upregulated in the
majority of paired tumor samples (Figure 5a). Notably,
FAT10 was consistently upregulated in the tumors of the
majority of patients with cancers of the gastrointestinal
and female reproductive system (Figure 5b). In addition,
FAT10 was also upregulated in the single cervical
cancer, single pancreatic cancer and two intestinal
cancer samples represented on the array (Figure 5a).
The other cancers represented on the array (e.g. kidney,
thyroid, etc.) did not show consistent up- or down-









Figure 3 In situ hybridization to localize FAT10 transcripts in HCC and adjacent nontumorous liver tissues. (a–d): HCC tissue
section from patient sample #10 with high FAT10 expression as demonstrated by Northern blot analysis; (e–h): adjacent nontumorous
liver tissue sections from the same patient with low FAT10 expression in the non-tumorous section of the liver as determined by
Northern blot analysis. Left column (a, c, e, g): Tissues were probed with the sense strand of the DIG-labeled FAT10 RNA probe
showing low background staining. Right column (b, d, f, h): tissues were probed with the antisense strand of the DIG-labeled FAT10
RNA probe. Only HCC tissues showed positive staining (b and d). Panel d – arrows: positive staining of FAT10 in cancer cell
cytoplasm, arrowheads: stroma cells show little FAT10 staining. Slides were counterstained with nuclear fast red. Original
magniﬁcation:  100 (a, b, e, f); x400 (c, d, g, h)
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In contrast to the FAT10 ﬁndings, expression of
ubiquitin was uniform across all normal and tumor
types represented on the array (Figure 5a).
Normal FAT10 expression is tissue specific
To study the tissue-speciﬁc distribution of FAT10 in
normal tissue, FAT10 cDNA was labeled and hybridized
to another array blot containing 76 different pooled
normal tissue types (Multiple Tissue Array, MTETM,
Clontech). FAT10 expression was detected in a number
of different tissues including the gastrointestinal system,
kidney, lung and prostate gland (Figure 6a). In contrast,
tissues from the brain and adrenal gland did not show
any detectable signals. Highest expression of FAT10
was observed in tissues of the reticuloendothelial system
(e.g. thymus, spleen) and the gastrointestinal system.
We further compared FAT10 expression levels in fetal
and adult tissues (Figure 6b). There was no difference
between fetal and adult tissues of the reticuloendothelial
system, and no detectable expression in both fetal and
adult brain and heart. Interestingly, higher expression
was observed in fetal compared to adult liver, while
adult kidney showed higher expression compared with
fetal kidney.
These results suggest that normal FAT10 expression is
both developmentally and tissue-speciﬁcally regulated.
Discussion
Upregulation of FAT10 gene expression in HCC
FAT10 belongs to a growing group of ubiquitin-related
proteins involved in a variety of fundamental cellular
processes including signal transduction, protein translo-
cation and cell-cycle regulation (for a review see, Jentsch
and Pyrowolakis, 2000). A well-characterized member
Tumor of HCC patient



































































Figure 4 FAT10 is expressed in nucleus of cells: (a) Immunohistochemistry using anti-FAT10 antibodies to localize FAT10 protein in
HCC and adjacent nontumorous cells. Top panel represents tissue section from the tumor of HCC patient #10 showing positive
staining (indicated by arrow) with anti-FAT10 antibodies. Lower panel represents tissue section from adjacent nontumorous liver of
HCC patient #10 showing negative staining with anti-FAT10 antibodies. (b) Western blot analyses of either uninfected NIH3T3 cells
(uninfected control) or NIH3T3 cells infected with either the control adenoviruses (AdVector infected) or FAT10-expressing
adenoviruses (AdFAT10 infected). Anti-FAT10 antibodies were used at concentration of 0.1 mg/ml. (c) Constructs used for the
generation of the recombinant adenoviruses (AdVector – vector control; AdFAT10 – FAT10-expressing adenoviral construct). (d)
Immunoﬂuorescence localization of FAT10 protein in NIH3T3 cells. NIH3T3 cells were infected with either AdVector (upper panels)
or AdFAT10 (lower panels) adenoviruses. Left panels represent phase contrast depiction of NIH3T3 cells, while right panels represent
either NIH3T3 infected with AdVector or AdFAT10 adenoviruses probed with anti-FAT10 antibodies
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of this family, SUMO1, has been shown to modify a
number of oncoproteins like p53 and c-jun, thus altering
their activity (Sampson et al., 2001). Also, the BRCA1
gene, a breast cancer susceptibility gene, has been shown
to encode an E3 ubiquitin ligase (Ruffner et al., 2001).
FAT10 has been reported to bind noncovalently to
MAD2 (Liu et al., 1999), a protein necessary for
maintaining spindle integrity during mitosis (Shah and
Cleveland, 2000), suggesting that it may play a role in
regulating genomic stability. Indeed, MAD2 dysregula-
tion has been associated with chromosomal instability
(Wang et al., 2000; Gemma et al., 2001) and has been
shown to cause increased tumor incidence in mice
(Michel et al., 2001).
Earlier reports have suggested that FAT10 protein is
localized to the cytoplasm of g-interferon-induced B
Figure 5 FAT10 expression in paired samples of 12 different types of cancers from 241 patients: 50 breast cancers, 42 uterine cancers,
53 colorectal cancers, 27 stomach cancers, 14 ovarian cancers, 21 lung cancers, 20 kidney cancers, six thyroid cancers, four prostate
cancers, one pancreatic cancer, two small intestinal cancer and one cervical cancer. (a) Commercially available blot (Cancer Proﬁling
Array, Clontech, CA, USA) containing SMARTt-ampliﬁed cDNA derived from RNA of tissues from different cancer patients was
probed with either 32P-labeled FAT10 (left panel), or 32P-labeled ubiquitin (right panel) as a normalization control. The intensity of the
FAT10 probe signal was quantitated using Fuji BAS2500 and normalized against ubiquitin, a housekeeping gene. FAT10 signals were
not detectable in either the tumor or paired nontumorous tissue of one breast cancer, eight uterine cancers, one stomach cancer, two
ovarian cancers, one lung cancer, one rectal cancer and two thyroid cancers. (b) Graphical representation of the differential expression
of FAT10 in seven different cancers. The dark shaded bar denotes the percentage (%) of patients in which the FAT10 gene is
overexpressed by at least 1.5 times in tumor tissue, the lightly shaded bar denotes the percentage (%) of patients in which FAT10 is
underexpress by at least 1.5 times in tumor tissue, while the unshaded bar represents the percentage (%) of patients in which the FAT10
gene expression remains unchanged (differential expression less than 1.5 times) or undetectable
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lymphoblastoid (JY) cells based on Western blot
analyses of fractionated cells (Liu et al., 1999), and to
the cytoplasm of murine ﬁbroblast cells via immuno-
ﬂuorescence of the HA in HA-tagged FAT10 protein
(Raasi et al., 2001). However, their results were not
conclusive as it is not possible to rule out HA directed
Figure 6 Tissue distribution of FAT10 expression. (a) Commercially available blot (Multiple Tissue Expression, MTEt, Clontech,
CA, USA) containing poly A+ RNA from 76 different human tissues pooled from several individuals and eight control RNA/DNA
samples was probed with either 32P-labeled FAT10 (middle panel) or 32P-labeled ubiquitin (bottom panel). The top panel represents a
grid describing the type of tissues that were spotted at the location indicated. (b) Graphical representation comparing the expression of
FAT10 in seven different tissues types between fetal (dark-colored bars) and adult (light-colored bars) tissues. Signal intensity was
determined using the FujiBAS2500 phosphorimager. Each bar represents pooled samples from several individuals
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localization from the data of Raasi et al. (2001), since
localization of HA-only negative (vector) control was
not shown. Similarly, in the FAT10 protein localization
study of Liu et al. (1999), no proper subcellular markers
were used as controls in their Western blots. In this
study, utilizing three different approaches, we demon-
strated that FAT10 protein is in fact localized to the
nuclei of HCC cells (Figures 1 and 4a and 4c). The
nuclear localization of FAT10 in HCC cells and its
reported binding to MAD2 protein is suggestive of a
role of FAT10 in the regulation of cell division.
In interphase cells, MAD2 is predominantly localized
to the cytoplasm, unless MAD1 is overexpressed and
translocates MAD2 to the nucleus (Iwanaga et al.,
2002). Curiously, we found that FAT10 protein was
localized to the nucleus in interphase cells, and hence are
in a different compartment from MAD2. It is possible
that overexpression of FAT10 induces the overexpres-
sion of MAD1 facilitating the translocation of MAD2
into the nucleus. However, we did not observe increased
MAD1 protein expression in two different cell lines
infected with AdFAT10 adenoviruses (data not shown).
Another possible hypothesis is that during interphase,
FAT10 and MAD2 remain in different cellular com-
partments and do not interact. When cells go into
mitosis and the nuclear membrane dissolves, FAT10 and
MAD2 are brought into close proximity facilitating
their interaction. Increased expression of FAT10 in the
nuclei of cancer cells may result in increased and
possibly abnormal interaction of FAT10 with MAD2
during mitosis, thus preventing MAD2 from functioning
appropriately as a ‘wait anaphase’ signal at the spindle
assembly checkpoint. Studies are in progress to further
examine the interaction between FAT10 and MAD2
during mitosis and to elucidate the molecular role of
FAT10 in carcinogenesis.
FAT10 was also reported to induce apoptosis in HeLa
and mouse ﬁbroblast cell lines (Raasi et al., 2001).
However, we have thus far found no evidence of
increased cell death or apoptosis in several cells lines
(NIH3T3, Hep3B and Hct116, etc.) in which the FAT10
gene was introduced. The survival and doubling times of
these cells are similar to their parental non-FAT10
overexpressing lines (data not shown).
Given a possible role of FAT10 in fundamental
cellular processes leading to tumorigenesis, we investi-
gated FAT10 expression in HCC using Northern blot
analyses. We found that, overall, B90% of HCC
tumors showed upregulation of the FAT10 gene expres-
sion (Figure 2). We also examined FAT10 expression in
other cancers using a cancer proﬁling array spotted with
cDNAs from 241 paired cancer/normal samples. Several
different types of cancers were found to exhibit
upregulation of FAT10 expression in the tumor tissues
compared to their paired nontumorous samples
(Figure 5a, b). Of note, FAT10 expression was
upregulated in a higher proportion of cancers of the
gastrointestinal tract (stomach, intestinal and colorectal)
and the female reproductive system (uterine, cervical
and ovarian). In other cancer types such as thyroid,
prostate and kidney, we did not detect any consistent
up- or downregulation.
Developmental and tissue-specific expression of FAT10
We further analysed the normal tissue distribution of
FAT10 expression using a multiple tissue array contain-
ing 76 different normal tissues. We found that FAT10 is
expressed at high levels in tissues of the gastrointestinal
and reticuloendothelial systems, at low levels in the
cardiovascular and reproductive tissues, but is strikingly
absent in the brain (Figure 6).
FAT10 appears to be expressed mostly in tissues
associated with the immunological system, such as the
reticuloendothelial and mucosal-associated lymphoid
tissues (MALT) systems (e.g. spleen, thymus and lungs).
This is consistent with previous reports that FAT10
expression is inducible by Epstein–Barr virus infection,
growth factors such as interferon-g and TNF-a (Raasi
et al., 1999) and is linked to the maturation state of B
cells and the antigen presentation of dendritic cells
(Bates et al., 1997). In contrast, FAT10 is conspicuously
absent in both fetal and adult brain, an immunologically
privileged organ. It is thus possible that the overexpres-
sion of FAT10 in the speciﬁc cancers is because of a
general immunological response during carcinogenesis.
This possibility is unlikely based on our microarray
analyses of tumor versus paired nontumorous liver
samples from four HCC patients. Although all four of
the HCC samples showed signiﬁcant overexpression of
the FAT10 gene in the tumor tissues compared to their
paired nontumorous tissues, we did not ﬁnd corrobor-
ating evidence of an immunological response through
the upregulation of immune response genes like b-2
microglobulin as well as TNF-stimulated genes like c-jun
and c-fos (data not shown). Also, none of the 22 key
genes in the inﬂammatory response represented on the
microarray (i.e. the arachidonates, prostaglandins and
phospholipase A2) were signiﬁcantly upregulated except
for phospholipase A2 group IIA, a gene linked to
arthritic inﬂammation, which saw marginal upregula-
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shown). Furthermore, our in situ hybridization and
immunohistochemistry analyses of HCC tissue sections
clearly show that FAT10 transcript and protein is
localized primarily to HCC hepatocytes and not to
immune cells in the liver (Figures 3 and 4a). These lines
of evidence strongly suggest that FAT10 overexpression
is unlikely to be the result of a general immunological or
inﬂammatory response in cancer.
Since FAT10 is homologous to ubiquitin, a molecule
responsible for protein degradation, FAT10 may also be
involved in protein metabolism. As such, FAT10 over-
expression may be merely the consequence of the general
overexpression of genes involved in increased protein
synthesis and degradation during carcinogenesis. Based
on our microarray analyses of tumor versus paired
nontumorous liver samples from four HCC patients,
however, this possibility is also unlikely. Although
FAT10 is signiﬁcantly overexpressed in all four HCC
tumors examined, there is no consistent evidence of a
general overexpression of proteins involved in protein
synthesis or degradation. Notably, ubiquitin, which
plays an important role in protein degradation, is not
signiﬁcantly differentially expressed in the tumors of any
of the four HCC patients or the tumors of different
cancers from 241 patients (Figure 5a). None of the
approximately 200 candidate genes classiﬁed to play (or
potentially play) a role in protein cleavage and
degradation were found to be signiﬁcantly differentially
expressed in all four HCC patients: only four of these
genes (transmembrane serine protease 2, plasma kallik-
rein B (Fletcher factor) 1, plasminogen, inter-a (globu-
lin) inhibitor H4) were found to be signiﬁcantly
underexpressed in three of four HCC tumors, while
two (cathepsin C, proteasome subunit, b 4) were found
to be signiﬁcantly overexpressed in two of the four HCC
tumors. Furthermore, none of the more than 400 genes
implicated to be involved in translation initiation,
elongation or post-translational modiﬁcation processes
were consistently signiﬁcantly differentially expressed in
all four HCC patients; only 20 genes, primarily
ribosomal proteins are overexpressed in two of the four
patients. Hence, these data strongly suggest that FAT10
overexpression is unlikely to be the result of a general
increase in protein metabolism or an immunological/
inﬂammatory response in cancer. Given FAT10’s
localization to nuclei of HCC cells, but not surrounding
non-HCC cells (Figures 1 and 4), it is possible that
FAT10 may play a role in cancer development through
the dysregulation of MAD2 (Liu et al., 1999).
In conclusion, we have demonstrated that FAT10
gene expression is highly upregulated in HCC and other
gastrointestinal and gynecological cancers. This study
represents the ﬁrst documentation of an association
between FAT10 overexpression and these cancers.
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FAT10 Plays a Role in the Regulation of
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Aneuploidy is a key process in tumorigenesis. Dysfunction of the
mitotic spindle checkpoint proteins has been implicated as a cause
of aneuploidy in cells. We have previously reported that FAT10, a
member of the ubiquitin-likemodifier family of proteins, is overex-
pressed in several gastrointestinal and gynecological cancers. Here
we show that FAT10 interacts with MAD2, a spindle checkpoint
protein, during mitosis. Notably, we show that localization of
MAD2 at the kinetochore during the prometaphase stage of the cell
cycle was greatly reduced in FAT10-overexpressing cells. Further-
more, compared with parental HCT116 cells, fewer mitotic cells
were observed after double thymidine-synchronized FAT10-over-
expressing cells were released into nocodazole for more than 4 h.
Nonetheless, when these double thymidine-treated cells were
released into media, a similar number of G1 parental and FAT10-
overexpressing HCT116 cells was observed throughout the 10-h
time course. Additionally, more nocodazole-treated FAT10-over-
expressing cells escapemitotic controls and aremultinucleate com-
paredwith parental cells. Significantly, we observed a higher degree
of variability in chromosome number in cells overexpressing
FAT10.Hence, our data suggest that high levels of FAT10protein in
cells lead to increased mitotic nondisjunction and chromosome
instability, and this effect is mediated by an abbreviated mitotic
phase and the reduction in the kinetochore localization of MAD2
during the prometaphase stage of the cell cycle.
Genetic instability is an important phenomenon that underlies
tumorigenesis. Chromosome instability (CIN)2 involving gains and loss
of chromosomes has been found to occur in most malignancies,
whereas microsatellite instability, which occurs at the nucleotide level,
is less commonly observed in cancers (1). Two forms of CIN, namely
structural instability and numerical instability (aneuploidy), can be
observed in various tumors. Genes responsible for CIN in human can-
cers include those involved in the condensation of chromosomes, cohe-
sion of sister chromatids, formation of microtubules, and kinetochore
structure and function as well as mitotic “checkpoint” genes that mon-
itor the proper progression through the cell cycle (1, 2).
MAD2 (mitotic arrest-deficient 2) is a keymitotic spindle checkpoint
protein whose primary role is to ensure that all of the chromosomes are
properly attached to the mitotic spindle before the onset of anaphase
(3). It is activated by associating with unattached kinetochores. Acti-
vated MAD2 binds to Cdc20 and prevents the anaphase-promoting
complex from ubiquitylating securin. As a result, anaphase is delayed
until all of the kinetochores are attached by microtubules and the chro-
mosomes are properly aligned along the metaphase plate (4–6).MAD2
is an essential gene, and MAD2/ mice die in utero (7). Loss of one
allele ofMAD2 has been reported to result in premature anaphase and
CIN in mammalian cells (8).
Dysregulation of MAD2 has been implicated in various cancers.
Reduced expression of MAD2 associated with loss of mitotic check-
point controlwas observed in ovarian cancer cells (9), breast cancer cells
(3), and nasopharyngeal carcinoma cells (10). Interestingly, MAD2 has
been reported to be overexpressed in colorectal (11) and gastric (12)
cancers. Nonetheless, mutations of MAD2 are infrequent in bladder
tumors, soft tissue carcinomas, hepatocellular carcinomas (13), lung
cancer, and breast cancer (14). Recently, it was demonstrated that the
deregulation of the Rb pathway leads to abberant overexpression of
MAD2, which then contributes to mitotic alterations and chromosome
instability (15). Aberrant interaction of MAD2 with other proteins may
also deregulate the checkpoint function of MAD2. For example, over-
expression of CMT2 (caught by MAD2), which is capable of binding to
MAD2, induces premature entry into anaphase without chromosome
segregation (16).
FAT10 is another protein that was identified using the yeast two-
hybrid system to noncovalently associate withMAD2 (17). Also known
as diubiquitin, FAT10 is an 18-kDa protein containing 165 amino acid
residues. It comprises two tandem ubiquitin-like domains and belongs
to the ubiquitin-like modifier (UBL) family of proteins (18). Its N and C
termini are 29 and 36% identical to the corresponding segments of ubiq-
uitin. Similar to ubiquitin, it contains the C terminus Gly-Gly residues
that are important for conjugating to other proteins as well as the con-
served Lys residue, which may serve as a potential site for polyubiquiti-
nation. Recently, it was reported that FAT10 degradation is accelerated
by its interaction with NEDD8 (neural precursor cell-expressed, devel-
opmentally down-regulated 8) ultimate buster-1L (19). Additionally,
the degradation of FAT10 and its conjugates were also found to be
ubiquitin-independent (20). FAT10 was observed to be up-regulated in
human fetal cells from pregnancies affected with Trisomy 21 (21). Its
role in tumorigenesis is suggested by its ability to be up-regulated by the
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inflammatory molecule, tumor necrosis factor  (22), a presumptive
tumor promoter (23, 24). We recently reported that FAT10 expression
is up-regulated in hepatocellular carcinoma and other gastrointestinal
and gynecological cancers (25).
In this study, we demonstrate that FAT10 interacts with MAD2, but
only duringmitosis.We also demonstrate that the kinetochore localiza-
tion of MAD2 is reduced in FAT10-overexpressing cells. Furthermore,
overexpression of FAT10 results in an abbreviated mitotic phase, as
evidenced by a delay of entry into mitosis but not G1. Additionally, a
greater number of FAT10-overexpressing cells escape mitotic controls
and are multinucleate upon prolonged nocodazole treatment. Notably,
we observed a higher degree of variability in chromosome number in
cells overexpressing FAT10, suggesting a more pronounced degree of
mitotic nondisjunction in these cells. This is the first report to identify
FAT10 as an important player in the regulation of mitosis and CIN.
MATERIALS ANDMETHODS
Generation of Plasmid Constructs and HCT116 Cell Lines Stably
Expressing FAT1—The Gateway Cloning Technology (Invitrogen) was
utilized to clone the FAT10 cDNA downstream of the N-terminal His6
tag peptide of the destination vectors pDEST26 (with CMV constitu-
tive promoter) and pT-REx-DEST31 (with tetracycline-inducible pro-
moter) to generate pEXPR26-HisFAT10 and pTREXPR31-HisFAT10,
respectively.
HCT116 colon carcinoma cells were transfected with pEXPR26-His-
FAT10 or co-transfected with pTREXPR31-HisFAT10 and pcDNA6/TR
FIGURE 1. Basic characterization of HCT116 cells that are stably expressing FAT10. A, Western blot of parental HCT116 and FAT10-expressing FAT116 cells hybridized with
anti-FAT10 antibody (1:3,000 dilution) or the control anti-actin antibody (1:5,000 dilution) and 1:10,000 diluted horseradish peroxidase-goat anti-rabbit secondary antibody. Super-
signal West Dura reagent (Pierce) was used to visualize the blot, and the film was exposed for about 3min. B, immunofluorescence pictures of HCT116 cells and FAT116 cells as well
as an equal mixture of HCT116 and FAT116 cells hybridized with anti-FAT10 antibodies (left) and DAPI (middle). The rightmost panel shows a composite picture of cells stained with
both anti-FAT10 antibody and DAPI. The arrow denotes FAT116 cells, whereas the arrowhead denotes HCT116 cells. C, brightfield images of HCT116 (left) and FAT116 (right) cells.D,
growth profile of HCT116 and FAT116 cells. Cells were grown on 24-well plates, and viable cells were counted at the indicated time points. E, cell cycle (top two panels) and apoptotic
(bottom two panels) profile of HCT116 (left two panels) and FAT116 (right two panels) cells.
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(containing the tetracycline repressor gene) using SuperfectTM trans-
fection reagent (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions to generate cells expressing FAT10 constitutively or
under tetracycline induction. Forty-eight hours post-transfection, a
1:100 dilution of cells was seeded into McCoy’s 5A medium (Sigma)
containing 10% fetal calf serum and 0.7 mg/ml G418-sulfate (Promega).
Additionally, 1 g/ml Blasticidin (Invitrogen) was added to cells
cotransfected with pTREXPR31-HisFAT10 and pcDNA6/TR. Cells
were then incubated at 37 °C in 5% CO2 for 10 days, and several
colonies were selected and analyzed for FAT10 expression by Western
blot analyses using anti-FAT10 antibody (25). For cells transfected with
pTREXPR31-HisFAT10 andpcDNA6/TR, expression ofHisFAT10was
induced for 24 hwith 2g/ml tetracycline (Invitrogen) prior to harvest-
ing for Western analysis. One clone stably expressing FAT10 constitu-
tively (FAT116) and three clones stably expressing FAT10 under tetra-
cycline induction (TetFAT116a, TetFAT116b, and TetFAT116c) were
selected for further analyses.
Characterization of HCT116 Cells Stably Expressing FAT1—Mor-
phology of cells was examined under an Olympus Research inverted
microscope (IX51), and images were captured with a Qimaging Retiga
1300R digital imager (Qimaging). The growth profile of these cells was
determined by seeding these cells in 24-well plates. At various time
points as indicated, cells were harvested, and only viable cells were
counted using trypan blue exclusion and a hemocytometer. Cell cycle
profile was examined by fixing the cells in 2% paraformaldehyde, stain-
ing themwith propidium iodide solution, and analyzing the stained cells
using the FACScaliburTM instrument (BD Biosciences). Apoptotic pro-
file was examined using the Annexin V-phycoerythrin kit (BD Bio-
sciences) according to the manufacturer’s protocol and analyzed using
the FACScaliburTM instrument.
Immunofluorescence Analysis—HCT116 or FAT116 cells were grown
on coverslips and fixed in 4% paraformaldehyde solution. These cells were
thenpermeabilized in 0.2%Triton solution and co-stainedwith rabbit anti-
FAT10 polyclonal antibody (25) and mouse anti-MAD2 monoclonal IgG
(BD Biosciences). Alexa Fluor 647 chicken anti-mouse or Alexa Fluor
488 anti-rabbit IgG (Molecular Probes, Inc., Eugene, OR) were used as
secondary antibodies. Cells were also incubated with DAPI to distinguish
the cell cycle stages. Cellular localization and cell cycle stage observa-
tions were performed on the LSM510 confocal microscope (Carl Zeiss,
Oberkochen, Germany).
Immunoprecipitation—HCT 116 cells were infected with either con-
trol vector adenoviruses (control) or adenoviruses expressing the
FAT10 gene (25). Forty-eight hours later, these cells were incubated in
300 ng/ml nocodazole-containing media or left untreated. Twenty
hours later, the cells were pelleted and lysed. Cell debris was removed
through centrifugation, and the protein concentration of the protein
lysate was adjusted to 3 mg/ml. Immunoprecipitation was carried out
using the protein G-immunoprecipitation kit (Roche Applied Science)
on 600 g of the lysate with 2 g of either of the following antibodies:
p16 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), which
served as a nonspecific rabbit IgG control; p53 antibody (Santa Cruz
Biotechnology), which served as a nonspecific mouse IgG control;
monoclonal MAD2 antibody (BD Biosciences); and FAT10 antibodies
generated by our laboratory in rabbits. The immunoprecipitated pro-
teins were electrophoresed in 18% SDS-polyacrylamide gel, and West-
ern blot analyses was performed as described previously (25) using
either FAT10 or MAD2 antibodies.
Generation of MAD2-EGFP Fusion Construct—To determine the
subcellular localization of the MAD2 protein, aMAD2-EGFP fusion
construct was generated via a two-step PCR as described previously
(25) using the following primers: primer A, 5-tataggatccaatggcgct-
gcagctctcc-3; primer B, 5-ctcgcccttgctcaccatgtcattgacaggaattttgt-
3; primer C, 5-atggtgagcaagggcgag-3; primer D, 5-ttgcggccgct-
tacttgtacagctcgtcca-3. In the first step,MAD2 and EGFP genes were
amplified separately. MAD2 was amplified from human liver cDNA
with primers A and B, whereas EGFP was amplified from pEGFP-1
(Clontech, Palo Alto, CA) using primers C and D. The purified
amplified MAD2 and EGFP PCR products were then mixed, and
another PCR was performed using primers A and D to generate the
fused MAD2-EGFP-amplified product. The fused MAD2-EGFP-
amplified product was then cloned into the BamHI/NotI site of the
pCMVDsRed plasmid, replacing the resident DsRed (Discosoma red
fluorescent protein) gene in the construct to generate pCMVMAD-
2EGFP. The identity of the fusion pCMVMAD2EGFP construct was
confirmed by sequencing.
MAD2 aggregation at the kinetochores was quantitated by determin-
ing the intensity of the bright fluorescent signals normalized against
similarly sized diffused fluorescent signals in other regions of the cells.
The region outside the cell serves as the “blank” signals. A paired two-
tailed t test was utilized to evaluate the significance of the difference
between HCT116 and FAT116 cells.
DNA Content, Mitotic Index, and Apoptosis Determination—HCT116,
FAT116, uninduced TetFAT116c, and tetracycline-induced TetFAT116c
were synchronized to G1/S phase using double thymidine treatment.
Briefly, cells were incubated in media containing 3 mM thymidine (Sigma)
for 17 h, followed by 12 h in media without thymidine and finally another
15 h inmedia containing 3mM thymidine. To determine themitotic index,
synchronizedcellswere released into300ng/mlnocodazole-supplemented
media toarrest cells atmitosis, harvestedat the indicated timepoints inPBS
containing 4 mM EDTA, and fixed in 2% paraformaldehyde. Fixed cells
were permeabilized with 0.2% Triton X-100 solution and probed with
MPM2 antibody (Upstate Biotechnology, Inc., Lake Placid, NY) as the pri-
mary antibody and Alexa Fluor 488 chicken anti-mouse IgG (Molecular
Probes, Inc., Eugene, OR) as the secondary antibody. Stained cells were
analyzed using the FACScaliburTM flow sorter (BDBiosciences). To deter-
mine DNA content, synchronized cells were released into fresh working
mediawithoutnocodazole,harvestedat the indicated timepoints, and fixed
in 2% paraformaldehyde. These cells were then stained with propidium
iodide solution and analyzed using the FACScaliburTM instrument.
FIGURE 2. FAT10 interactswithMAD2duringmitosis.Untreated (upper two panels) or
nocodazole-treated (lower two panels) HCT116 (Control) or FAT10-expressing HCT116
(FAT10) cells are immunoprecipitatedwithanti-FAT10, anti-MAD2, ornonspecific control
antibodies (anti-p16 was used as a nonspecific rabbit IgG control, whereas anti-p53 was
used as a nonspecific mouse IgG control) and probed with anti-MAD2 or anti-FAT10
antibodies on Western blots. The leftmost panel shows blots before immunoprecipita-
tion (IP), whereas themiddle and right panels showblots after immunoprecipitation. The
topmost panel and third panel from the top show proteins probed with the anti-FAT10
antibody, whereas the second panel from the top and the bottom panel represent West-
ern blot of the same proteins probed with anti-MAD2 antibody.
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FIGURE 3. MAD2 localization during prometaphase is altered in FAT10-overexpressing cells. A–C, pCMVEGFP or pCMVMAD2EGFP constructs were transfected into either
HCT116 or FAT116 cells. A, Western blot of these cells probed with a 1:5,000 dilution of either anti-EGFP, anti-MAD2, anti-FAT10, or anti-actin primary antibodies (Ab) and a 1:30,000
dilution of horseradish peroxidase-goat anti-rabbit secondary antibody. Advanced ECL reagent (Amersham Biosciences) was used to visualize the blot, and the filmwas exposed for
FAT10 Overexpression Induces CIN
















A paired two-tailed t test was utilized to evaluate the significance of
the difference between control/uninduced and FAT10/induced cells.
Analysis of Chromosomal Numbers—G-banded chromosome analysis
was performed onHCT116 parental cells, FAT116 cells, uninduced paren-
tal HCT116, TetFAT116a, TetFAT116b, and TetFAT116c cells, and
tetracycline-induced parental HCT116, TetFAT116a, TetFAT116b, and
TetFAT116c cells. The parental HCT116 and FAT116 cells had been in
continuous culture for11 months with80 subcultures (i.e. these cells
had undergone250 cell doublings). Tetracycline-inducible TetFAT116a,
TetFAT116b, and TetFAT116c cells and parental HCT116 cells were
grown in media with or without 3 g/ml tetracycline supplementation
(Sigma) for 33 subcultures (or100doublings).These cellswere reselected
in5g/mlBlasticidinand0.7mg/mlG418beforekaryotypedetermination.
Briefly, cells were first synchronized for 17 h in media containing 3
mM thymidine, replacedwith freshmediumwithout thymidine for 7 h, and
then treated with 0.1 g/ml colcemid (Invitrogen) for 1.5 h. Cells were
detached in phosphate-buffered saline containing 4 mM EDTA and rinsed
with phosphate-buffered salinewithout EDTA, swelled in 0.06MKCl solu-
tion, and fixed in a 3:1 methanol/glacial acetate acid mix. Fixed cells were
droppedontomicroscope slides, partially digestedwith trypsin, and stained
with Giemsa solution (Invitrogen). Chromosome numbers were counted
usingBandView(AppliedSpectral ImagingGmbH,Mannheim,Germany).
RESULTS
Cells Stably Overexpressing FAT10 Have Growth, Cell Cycle, and
Apoptotic Profiles Similar to Those of Parental Cells—Wegenerated and
characterized theHCT116 cell line stably overexpressing FAT10 named
FAT116. FAT116 cells were found to express high levels of the FAT10
protein, as shown by Western blot analyses (Fig. 1A). The FAT10 pro-
tein was found to be expressed in the nucleus of these FAT116 cells (Fig.
1B) through confocal microscopy.
Morphology (Fig. 1C) and growth properties (Fig. 1D) of FAT116
cells were found to be similar to their parental HCT116 cells. Addition-
ally, expression of FAT10 in FAT116 cells also did not alter the general
cell cycle (Fig. 1E, top two panels) or apoptotic profiles (Fig. 1E, bottom
two panels) significantly.
FAT10 Interacts with MAD2 during Mitosis—As FAT10 was
reported to interact with MAD2 (17), it may play a role in the regu-
lation of mitosis. We thus evaluated if this interaction between
FAT10 and MAD2 occurs during the mitotic phase of the cell cycle
using co-immunoprecipitation assays. We were unable to detect the
FAT10 protein in the anti-MAD2 immunoprecipitate or vice versa in
unsynchronized cells, where a majority of the cells are in the G1
phase (Fig. 2, untreated). Notably, when these cells were arrested at
mitosis with nocodazole, MAD2 was detected in the anti-FAT10 or
anti-MAD2 immunoprecipitate in FAT10-expressing HCT116 cells
and only in anti-MAD2 immunoprecipitate in control cells (Fig. 2,
Nocodazole treated). FAT10 was detected in anti-MAD2 or anti-
FAT10 immunoprecipitate of only nocodazole-treated FAT10-ex-
pressing HCT116 cells (Fig. 2). Neither FAT10 nor MAD2 was
detected when cells were co-immunoprecipitated with nonspecific
control antibodies (Fig. 2). These results confirm the previous obser-
vations (17) that MAD2 and FAT10 are capable of interaction, and
we demonstrate that the interaction occurs during mitosis.
Localization of MAD2 at the Kinetochore Is Greatly Reduced in FAT10-
overexpressing Cells—To determine the fate of MAD2 in FAT10-overex-
pressing cells, we generated a construct, pCMVMAD2EGFP, whereby the
MAD2 gene was fused with the EGFP gene.We then transfected this con-
struct as well as the vector control construct not containingMAD2, pCM-
VEGFP, into either the parental HCT116 or the FAT116 cells and demon-
strated throughWestern analyses that the EGFP andMAD2-EGFP fusion
proteins could be expressed (Fig. 3A). As shown in Fig. 3B, when pCM-
VEGFP, the vector control plasmid,was introduced into either the parental
HCT116 or FAT116 cells, the EGFP fluorescence signal was diffused
throughout the cell (Fig. 3B, top two panels). When the construct,
pCMVMAD2EGFP, was transfected into the parental HCT116 cells, the
MAD2-EGFP fusion protein seemed to accumulate as strong punctate sig-
nals at the kinetochores (Fig. 3B, bottom left panels) during the promet-
aphase but not the metaphase stage of the cell cycle. This observation is
consistent with the reported localization of MAD2 during mitosis (26).
Interestingly, in FAT10-overexpressing FAT116 cells, the MAD2-EGFP
fusionprotein appeareddiffusewhether the cellswere in theprometaphase
or metaphase stage of the cell cycle (Fig. 3B, bottom right panels). Statisti-
cally significant (p 0.01) reductions in the punctuate signals at the kin-
etochores was observed in the prometaphase stage in FAT10-expressing
cells compared with parental HCT116 cells (Fig. 3C). In cells that did not
receive the pCMVEGFPor pCMVMAD2EGFP construct, no fluorescence
was observed (Fig. 3B, top row of each panel). Taken together, these results
suggest that MAD2 localization at the kinetochore is greatly reduced in
FAT10-overexpressing cells during the critical prometaphase stage of the
cell cycle.
These observations are consistent with the results obtained when
HCT116 and FAT116 cells were stained with anti-FAT10, anti-MAD2
antibodies, and DAPI (Fig. 3, D and E). As shown in Fig. 3D, in parental
HCT116 cells where FAT10 expression is negligible, MAD2 aggregated at
the kinetochores during the prometaphase stage of the cell cycle. However,
when the FAT10 genewas overexpressed in FAT116 cells,MAD2 aggrega-
tion at the kinetochores was significantly reduced (p 0.01).
Hence, FAT10 interaction with MAD2 during mitosis may decrease
the efficiency of binding of MAD2 to the unattached kinetochore,
although it does not seem to completely block the function of MAD2.
These results are consistent with the previous observation that MAD2
haploinsufficiency is sufficient to cause premature anaphase and chro-
mosome instability (8).
FAT10 Overexpression Results in an Abbreviated Mitotic Phase—Since
FAT10 interacts and reduces the kinetochore localization of MAD2
during mitosis and since MAD2 is a mitotic checkpoint protein (5), we
examined the effect of overexpression of FAT10 on cell cycle regulation
and especially on mitosis. HCT116 parental cells, HCT116 cells stably
expressing FAT10 constitutively (FAT116), and uninduced and induced
HCT116 cells stably expressing FAT10 under the tetracycline-inducible
promoter (TetFAT116c) were synchronized at G1/S phase using double
thymidine treatment (Fig. 4,A andC, 0 h). These cells were released into
either media containing nocodazole or freshmedia without nocodazole
and at various time points were stained with the mitosis-specific anti-
body, MPM2 (Fig. 4B) or propidium iodide to monitor their progress
intomitosis (Fig. 4,A,D, and E) or the nextG1 phase (Fig. 4,C, F, andG),
respectively.
10–15 s. The blots were probed initially with anti-MAD2 antibody, stripped and then reprobed with anti-EGFP antibody, stripped and then reprobed with anti-FAT10 antibody, and
then stripped and finally reprobed with anti-actin antibody. B, EGFP or MAD2-EGFP fluorescence (column 1 of each panel) or fluorescence from cells stained with DAPI (column 2 of
each panel) or composite of EGFP orMAD2-EGFP andDAPI fluorescence (column 3of each panel). The top rowof each panel shows the lowmagnification view,where transfected and
untransfected cells are present. Untransfected cells were found not to be fluorescent. C, quantitation of punctuate signals in prometaphase I and II in HCT116 and FAT116 cells. n, the
number of bright spots quantitated. **, statistical significance at p  0.01. D and E, immunofluorescence staining of HCT116 or FAT116 cells with anti-FAT10 and anti-MAD2
antibodies. D, prometaphase HCT116 (top panels) and FAT116 (bottom panels) cells stained with DAPI (blue), anti-FAT10 (red), and anti-MAD2 (green) antibodies. E, quantitation of
punctuate signals in prometaphase HCT116 and FAT116 cells stained with anti-MAD2 antibodies. n, the number of bright spots quantitated. **, statistical significance at p 0.01.
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As shown in Fig. 4D,5% of bothHCT116 and FAT116 cells entered
mitosis at 4 h after release fromG1/S. However, at each time point after
4 h, 10% more parental cells entered mitosis than FAT10-overex-
pressing cells. Similar observations were made when uninduced and
tetracycline-induced TetFAT116 cells were compared (Fig. 4E). When
these experiments were repeated on different occasions, similar trends
were observed. These results suggest that there may be a delay in
entrance intomitosis in FAT10-overexpressing cells. However, it is also
possible that the observed reduction in mitotic FAT10-expressing cells
may be a consequence of these cells escaping M-phase and reverting to
interphase with a tetraploid G1 DNA content.
Interestingly, reentry of cells into G1 phase from their arrest at G1/S
was similar between HCT116 and FAT116 cells (Fig. 4F) as well as
between uninduced and tetracycline-induced TetFAT116 cells, despite
the delayed entry intomitosis of FAT116 and tetracycline-induced Tet-
FAT116 cells (Fig. 4G). Similar trends were observed when these exper-
iments were repeated.
When data from the different experiments were combined and ana-
lyzed together, we found that the difference between the HCT116 and
FAT116 cells (Fig. 4H) or uninduced and induced TetFAT116 cells (Fig.
4I) in time of entry into mitosis was significantly greater (p 0.05) than
their corresponding difference in time of reentry into G1. Taken
together, these data suggest both a delayed and an abbreviated mitotic
phase in cells overexpressing FAT10. An alternative explanation is that
FAT10 overexpression results in shortened mitotic arrest in cells with
spindle damage.
FAT10 Overexpression Results in Greater Escape fromMitotic Arrest,
More Multinucleate Cells upon Prolonged Mitotic Arrest, and Chromo-
some Instability—To address the effect of FAT10 overexpression on
mitosis, parental HCT116 and FAT116 cells were treated with 200
ng/ml nocodazole for 8 h. Mitotic cells were then shaken off and
replated in media containing 200 ng/ml nocodazole for another 15 h.
The doubling time for both HCT116 and FAT116 cells is 15 h. We
foundmore adherent FAT116 (20%) thanHCT116 (6.5%) cells (Fig. 5,
A and B), suggesting that more FAT116 cells either failed to arrest or
escapedmitotic arrest and continued to cycle. To rule out the possibility
that the observed increase in adherent FAT116 cells was due to
increased contamination of interphase FAT116 cells, the mitotic index
of the reattached HCT116 and FAT116 cells after shake-off was deter-
mined. As shown in Fig. 5C, greater than 95% of the reattached cells
were mitotic cells, and the percentage of interphase cells was small and
similar between the HCT116 and FAT116 cells. Upon prolonged expo-
sure to nocodazole (54 h), most of the HCT116 and FAT116 cells died.
Of the cells that reattached, more FAT116 cells (40%) showed abnor-
mal nuclear morphology and were multinucleated (Fig. 5D) compared
with the attached parental HCT116 cells (5%). Hence, overexpression
of FAT10 directly affects mitosis in cells.
FIGURE 4. FAT10 overexpression results in abbreviatedmitosis. Cells were arrested at G1/S phase by double thymidine treatment and then released tomediumwith (A,D, and E)
orwithout (C, F, andG) 300ng/ml nocodazole. These cellswere thenharvested at the indicated timepoints formitotic index (MPM2 staining;A,D, and E) or cell cycle stage (propidium
iodide staining; C, F, and G) determination, respectively. A, representative fluorescence-activated cell sorting profile of mitotic index analyses showing HCT116 cells probed with
MPM2 antibody. Control denotes unsynchronized cells. B, confocal images showing mitotic cells giving positive signals when probed with MPM2 antibody. C, representative
fluorescence-activated cell sortingprofile of cell cycle stagedetermination showingDNAofHCT116cells stainedbypropidium iodide. Control denotesunsynchronized cells.D, F, and
H, HCT116 cells compared with FAT116 cells. E, G, and I, HCT116 cells stably expressing FAT10 under tetracycline-inducible promoter (TetFAT116c). These cells were grown without
(uninduced TetFAT116) orwith (induced TetFAT116) 3g/ml tetracycline.H and I, difference in percentage ofmitotic cells (open squares) andG1 phase cells (closed squares) between
HCT116 cells and FAT10-expressing HCT116 cells. The values are shown as means S.E. of three independent experiments. *, significant difference at p 0.05.
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We next examined if overexpression of FAT10 affects chromosome
stability. Parental HCT116 cells were reported to have a relatively stable
karyotype (45,X), with aneuploid cells occurring at only6.8% (ATCC,
Manassas, VA) (8). HCT116 and FAT116 cells were grown in culture for
11 months (80 passages), which is equivalent to 250 cell dou-
blings, before they were harvested for chromosome analyses (Fig. 6A).
As shown in the table in Fig. 6C, the parental HCT116 cell line was itself
aneuploid, with a modal chromosome number of 45 and the over-
whelming majority of cells (82%) having 40–49 chromosomes/cell.
None of the parental HCT116 cells contained more than 100 chromo-
somes. On the other hand, a majority of FAT116 cells (70%) carried
80–89 chromosomes, with 5% of these cells having more than 100
chromosomes. Thus, constitutive FAT10 overexpression increases ane-
uploidy in HCT116 cells. It is possible that the increased chromosome
numbers observed in the FAT116 cell line were due to a clonal artifact,
whereby in that particular clone, the pEXPR26-HisFAT10 plasmid was
introduced into a HCT116 cell already containing 80–89 chromo-
somes, which was the case in4.2% of parental cells.
To rule out the clonal artifact, we also analyzed the parental HCT116
as well as three different clones of HCT116 cells expressing FAT10
under a tetracycline-inducible promoter (TetFAT116a, TetFAT116b,
and TetFAT116c). Upon tetracycline induction, FAT10 expression was
greatly increased (Fig. 6B). Uninduced and tetracycline-induced paren-
tal HCT116 and TetFAT116a–TetFAT116c cells were grown for100
population doublings (33 passages) with medium changes every 3 days,
after which chromosomal analysis was performed. Approximately 84%
of parental HCT116 cells contained relatively normal chromosome
numbers of 40–49 whether they were treated with tetracycline or not.
In contrast, when uninduced, 87–96% of Tet116a–Tet116c cells were
shown to contain relatively normal chromosome numbers of 40–49 in
all three clones (Fig. 6, C and D). However, in the same three clones
induced with tetracycline, only between 43 and 56% of cells carried
40–49 chromosomes, with the remaining cells carrying either more or
fewer chromosomes (Fig. 6, C and D). Notably, for all three clones,
between 2.5 and 4% of tetracycline-induced cells were observed to con-
tain more than 100 chromosomes (Fig. 6, C and D). This was not
observed in uninduced TetFAT116 cells or uninduced or tetracycline-
induced parental HCT116 cells.
DISCUSSION
FAT10 belongs to the UBL family of proteins that have been impli-
cated in the regulation of diverse processes including cell cycle and the
maintenance of genome integrity (18, 27). In this report, we present
evidence to show that, like its other family members (e.g. SUMO (small
ubiquitin-like modifier) (28)), FAT10 plays a role in the regulation of
mitosis and chromosome stability.
FIGURE5.MoreFAT10-overexpressingcells escapemitotic arrest andaremultinucleatewhenexposed toprolongednocodazole treatment.A,microscope imagesofHCT116
and FAT116 cells that were treated with nocodazole for 8 h and resultant nonadherent cells collected and reseeded onto nocodazole-containingmedia for another 15 h. The arrow
indicates adherent cells that either failed to arrest or escapedmitotic arrest and continued to cycle through. B, table shows the percentage of adherent HCT116 or FAT116 cells after
replating. C, flow cytometry diagram showing cells stainedwithMPM2 to determine themitotic index. Left panel, HCT116 cells; right panel, FAT116 cells.D, HCT116 and FAT116 cells
were grown in media with or without nocodazole for 54 h and analyzed by DAPI staining and fluorescence microscopy. The arrow indicates multinucleate cells.
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Wegenerated anHCT116 cell line stably expressing FAT10 and showed
that theoverexpressionofFAT10didnot affect themorphologyof the cells,
growth properties, general cell cycle, or apoptotic profiles (Fig. 1). Curi-
ously,whereaswewereable togenerate stableHCT116cell lines expressing
FAT10, earlier attempts by Raasi et al. (22, 29) to generate stable HeLa cell
lines expressing FAT10 failed. A possible explanation could be that the
HCT116 cell line may be better able to tolerate aneuploidy than the HeLa
cell line. Additionally, our observation that FAT10 expression did not sen-
sitize HCT116 cells to apoptosis seems to contradict the same report that
found that FAT10 induces apoptosis in mouse fibroblast cells (29). It is
possible that species-specificdifferencescouldaccount for thisdifference in
the property of cells expressing FAT10, since we examined human FAT10
expression in a human cell line (HCT116), whereas the other report exam-
inedmurine FAT10 expression in a mouse cell line.
Using FAT10-specific antibodies that we generated (25), we found
that during interphase, FAT10 expression is primarily nuclear in
HCT116 cells stably expressing FAT10 (Fig. 1B). These observations are
consistent with our earlier report, where we found that FAT10 was
localized in the nucleus of WRL68 cells and the tumor of a hepatocel-
lular carcinoma patient (25), but contradicts other reports (17, 19, 29). A
possible reason for this seeming discrepancy is that whereas we directly
observed FAT10 expression in the cells using FAT10-specific antibodies
and fluorescence microscopy, the other reports primarily detected
FAT10 expression through indirect approaches including subcellular
fractionation andWestern blot analyses using FAT10-specific antibod-
ies (17) or immunofluorescence microscopy using either anti-HA (29)
or anti-X-pressTM antibodies (19) of HA- or His-tagged FAT10.
FAT10 Interacts with MAD2 and Reduces the Kinetochore Localiza-
tion of MAD2 during the Prometaphase of the Cell Cycle—Since FAT10
was reported to interact withMAD2 (17), we proceeded to elucidate the
relationship between FAT10 and MAD2. Using co-immunoprecipita-
tion assays, we found that the reported interaction of FAT10 with
MAD2occurred only during themitotic phase of the cell cycle.Wewere
unable to immunoprecipitate FAT10 with anti-MAD2 antibodies or
vice versa using unsynchronized cells that were primarily G1 phase cells
(Fig. 2). Nonetheless, we found that in mitotic cells, FAT10 can be
immunoprecipitated with anti-MAD2 antibodies and vice versa (Fig. 2).
Interestingly, using MAD2-EGFP fusion constructs, we found that
whereas MAD2 localizes at the kinetochores in the parental HCT116
cells, in FAT10-expressing HCT116 cells, MAD2 localization at the
kinetochores is greatly reduced (Fig. 3, B and C). Similar observations
were made when HCT116 and FAT116 cells were stained with DAPI,
anti-MAD2, and anti-FAT10 antibodies. In the prometaphase stage of
the cell cycle, MAD2 was found to aggregate at the kinetochores. How-
ever, localization of MAD2 at the kinetochores was significantly
reduced in prometaphase FAT116 cells (Fig. 3, D and E). This has
important implications, since MAD2 is a spindle checkpoint protein
that helps to ensure the fidelity of the mitotic process by delaying the
FIGURE 6.More FAT10-overexpressing cells have abnormal chromosome numbers. HCT116 and FAT116 cells, grown for250 population doublings as well as three clones of
TetFAT116 cells and parental HCT116 cells culturedwith or without tetracycline for100 population doublings were karyotyped. A, representative images showing cells having the
indicated number of chromosomes per cell. B, Western blot result showing FAT10 protein expression in TetFAT116 cells in the presence or absence of tetracycline induction. The
bottompanel shows the sameblot probedwith anti-actin antibodies as normalization control.C, table showing thepercentage of cells having the indicatednumber of chromosomes
per cell. D, graphical representation of the three clones of TetFAT116 cells in the absence or presence of tetracycline (see table in C) in which the mean and S.D. (n  3) of the
percentage of uninduced versus tetracycline-induced cells containing indicated number of chromosomes per cell are presented. *, statistical difference (p  0.05) between
uninduced and tetracycline-induced cells.
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onset of anaphase until all of the chromosomes are properly aligned at
the spindle (see Ref. 30). Normally, MAD2 localizes to unattached kin-
etochores during the prometaphase stage ofmitosis (Fig. 3B) (3, 31).We
thus hypothesized that the interaction of FAT10 with MAD2 decreases
the ability ofMAD2 to localize to unattached kinetochores. This is likely
to disrupt the role of MAD2 as a checkpoint protein, resulting in dys-
regulated mitosis and aneuploidy.
FAT10 Overexpression Results in Dysregulated Mitosis and Chromo-
some Instability—We proceeded to explore the effect that FAT10 over-
expression has on HCT116 cells. As shown in Fig. 4,D and E, compared
with parental or uninduced HCT116 cells, fewer mitotic cells were
observed after double thymidine-synchronized FAT10-overexpressing
cells were released into nocodazole for more than 4 h. This may be due
to a delay in the entrance into mitosis or an escape from mitotic arrest.
Nonetheless, when these double thymidine-treated cells were released
into media, similar numbers of G1 parental and FAT10-overexpressing
HCT116 cells were observed throughout the 10-h time course (Fig. 4, F
and G). Taken together, these results suggested that FAT10-overex-
pressing cells experienced a delayed and abbreviatedmitotic phase or an
abbreviated mitotic arrest phase upon spindle damage.
An abbreviated mitotic phase in FAT10-overexpressing cells could
potentially have adverse consequences. For example, there may be
insufficient time for proper alignment of the sister chromatids at the
equator, leading to premature separation of these sister chromatids and
an increased rate of chromosome missegregation. This possibility is
pertinent, given the observation that dysfunctional MAD2 also causes
premature sister chromatid separation and chromosome instability (8).
We therefore examined the effect of FAT10 overexpression on mitosis
and chromosomal instability.
Upon treatment with nocodazole, more FAT10-overexpressing cells
either failed to arrest or escaped mitotic arrest (Fig. 5, A and B). Pro-
longed exposure to nocodazole resulted inmore FAT10-overexpressing
cells exhibiting abnormal andmultinuclearmorphology than the paren-
tal controls (Fig. 5D). These results suggest dysregulation of mitosis in
FAT10-overexpressing cells.
Significantly, we demonstrate using HCT116 cells stably expressing
FAT10 either constitutively or under a tetracycline-inducible promoter
that more FAT10-expressing cells have an abnormal chromosome
number compared with the parental or uninduced counterpart (Fig. 6).
These results strongly suggest that FAT10 overexpression adversely
affects proper mitotic disjunction, resulting in aneuploidy and CIN.
Aneuploidy and CIN are commonly observed in most cancers,
including leukemia (32, 33), colon cancer (34), and hepatocellular car-
cinoma (35). CIN has been proposed as a key initiator of tumor devel-
opment (2). The checkpoint protein, MAD2, has been shown to play an
important role in maintaining chromosome stability, since haploinsuf-
ficiency of this protein results in enhancedCIN (8). Interestingly, abber-
ant overexpression of the MAD2 gene was recently reported to also
result in enhanced CIN (15). We have shown that FAT10 not only
colocalizes withMAD2 duringmitosis; its overexpression also results in
the reduced localization of MAD2 at the kinetochore during the pro-
metaphase stage of the cell cycle. Significantly, we demonstrate that
overexpression of FAT10 in HCT116 cells results in an abbreviated
mitotic phase, greater escape frommitotic controls,moremultinucleate
cells upon prolonged mitotic arrest, and CIN, suggesting that proper
FAT10 andMAD2 stoichiometrymay be essential in maintaining chro-
mosome stability in HCT116 cells. This result is consistent with the
recent reports that abberant overexpression (15) or underexpression (8)
of theMAD2 gene can also lead to mitotic defects and CIN. The mech-
anism by which FAT10 reduced the kinetochore localization of MAD2
during the prometaphase stage of the cell cycle remains unclear and
awaits further investigation. Nonetheless, our observations suggest that
FAT10, like other members of the UBL family (e.g. SUMO) (28), plays a
role in the maintenance of genomic stability.
Since FAT10 has been found to be overexpressed in several cancers
(25), we propose that dysregulation of FAT10 expression may contrib-
ute to tumorigenesis through its interaction with MAD2 to cause CIN
by deregulating mitosis.
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